Document:

Exhibits 10.22

 

May 25, 2020

 

AdaptHealth LLC

220 West Germantown Pike Suite 250

Plymouth Meeting, PA

Attention: Luke McGee, Chief Executive
Officer

 

Joint Commitment Letter

$240,600,000 Incremental Term Facility

 

Ladies and Gentlemen:

 

AdaptHealth LLC, a
Delaware limited liability company (“you” or the “Borrower”) has advised Regions Bank (“Regions
Bank”), Regions Capital Markets, a division of Regions Bank (“RCM” and, together with Regions Bank,
 “Regions”), Citizens Bank, N.A. (“Citizens”), Deutsche Bank AG New York Branch (“DBNY”),
Deutsche Bank Securities Inc. (“DBSI” and, together with DBNY, “DB”), Royal Bank of Canada
(“Royal Bank”) and RBC Capital Markets, LLC (“RBCCM” and, together with Royal Bank,
DB, Citizens and Regions, “we”, “us” or the “Commitment Parties”) that
you intend to acquire (the “Acquisition”), directly or indirectly, the equity interests of an entity previously
identified to us by you as “Eleanor” (the “Target”) pursuant to a Stock Purchase Agreement, dated
as of the date hereof, among, inter alios, the Borrower, the Target and the “Representative” identified therein
(together with all exhibits, schedules, and disclosure letters thereto, collectively, the “Acquisition Agreement”).
You have further advised the Commitment Parties that you intend to finance the Acquisition and the costs and expenses related to
the Transactions (as defined below) with a new $240,600,000 senior secured incremental term loan facility (the “Incremental
Term Facility”), which will be issued under that certain Third Amended and Restated Credit and Guaranty Agreement, dated
as of March 20, 2019 (as amended prior to the date hereof, the “Existing Credit Agreement”) among the Borrower,
the guarantors party thereto, the lenders from time to time party thereto and CIT Finance LLC, as administrative agent (the “Agent”).
The Acquisition, the entering into and funding of the Incremental Term Facility, and all related transactions are hereinafter referred
to, collectively, as the “Transactions”. The date of the initial borrowing under the Incremental Term Facility
is referred to herein as the “Closing Date”.

 

In connection with
the foregoing, (a) Regions Bank is pleased to advise you of its commitment to provide up to $85,300,000 of the Incremental Term
Facility and to act as a co-syndication agent for the Incremental Term Facility, (b) Citizens is pleased to advise you of its commitment
to provide up to $55,300,000 of the Incremental Term Facility and to act as a co-syndication agent for the Incremental Term Facility,
(c) DBNY is pleased to advise you of its commitment to provide up to $50,000,000 of the Incremental Term Facility and to act (directly
or through a designated affiliate thereof) as a co-syndication agent for the Incremental Term Facility, and (d) Royal Bank is pleased
to advise you of its commitment to provide up to $50,000,000 of the Incremental Term Facility and to act as a co-syndication agent
for the Incremental Term Facility, in each case, all upon and subject to the terms and conditions set forth herein and in the Summary
of Principal Terms and Conditions attached hereto as Annex I (the “Term Sheet” and together with this letter,
the “Commitment Letter”). The foregoing commitments of Regions Bank, Citizens, Royal Bank and DBNY (collectively,
in their capacities as lenders, the “Lead Banks”) are several and not joint. RCM, Citizens, DBSI and RBCCM will
serve as joint lead arrangers and joint book runners for the Incremental Term Facility (RCM, Citizens, DBSI and RBCCM, in such
capacities, are collectively referred to herein as the “Lead Arrangers”), and each of the Lead Arrangers is
pleased to advise you of its willingness, in connection with the foregoing commitments of the Lead Banks, to use commercially reasonable
efforts to form a syndicate of financial institutions (together with the Lead Banks, the “Incremental Lenders”)
in consultation with you, for the Incremental Term Facility. It is agreed that in any Information Materials (as defined below)
and all other offering or marketing materials in respect of the Incremental Term Facility, RCM shall have “left side”
designation and shall appear on the top left and shall hold the leading role and responsibility customarily associated with such
 “top left” placement.

 

A.            Terms
and Conditions of the Incremental Term Facility

 

The principal terms
and conditions of the Incremental Term Facility shall include those set forth in the Term Sheet. In addition, the Lead Arrangers,
on behalf of the Incremental Lenders, may require certain other customary terms and conditions found in a credit facility of this
type, which may not be specifically listed in the Term Sheet; provided, however, that all such terms and conditions
shall comply with all the requirements of an “Incremental Term Loan” under, and as defined in, the Existing Credit
Agreement and none of such terms and conditions shall require any consent of the lenders party to the Existing Credit Agreement
other than the Incremental Lenders or require, or result in, any change in the terms and conditions of the Existing Credit Agreement
other than any “Incremental Facility Amendment” as defined therein and amendments, if any, required to add the Incremental
Term Facility as a “Term Loan’ thereunder. Without limiting the foregoing, the terms and conditions of the Incremental
Term Loan Facility shall be no more restrictive, taken as a whole, than those set forth in the Existing Credit Agreement.

 

     

     

    

 

AdaptHealth LLC

Page 2

 

B.            Syndication

 

The Lead Arrangers
agree to syndicate the Incremental Term Facility. RCM will manage and control all aspects of the syndication of the Incremental
Term Facility in consultation with the Borrower, including the timing of all offers to potential Incremental Lenders, the allocation
of commitments, and the determination of compensation and titles (such as co-agent, managing agent, etc.), if any, given to such
Incremental Lenders (other than the Commitment Parties to the extent set forth in this Commitment Letter). The Borrower agrees
that no additional agents, co-agents, underwriters or arrangers will be appointed, or other titles conferred, without the prior
written consent of RCM and that no Incremental Lender will receive any compensation for its commitment to, or participation in,
the Incremental Term Facility except as expressly set forth in the Term Sheet or the Joint Fee Letter (as defined below), or as
otherwise agreed to and offered by RCM. It is also understood and agreed that the amount and distribution of the fees among the
Incremental Lenders will be at the sole and absolute discretion of Regions.

 

Notwithstanding anything
herein to the contrary, the Lead Arrangers will not syndicate, assign or participate to any Disqualified Institution (as defined
in the Existing Credit Agreement).

 

As consideration for
the undertakings and the obligations of the Commitment Parties hereunder, the Borrower agrees to cooperate in such syndication
process and to take all action as the Lead Arrangers may reasonably request to assist, and to use commercially reasonable efforts
to cause the Target to assist, the Lead Arrangers in forming a syndicate of Incremental Lenders acceptable to the Borrower and
the commitment of the Lead Banks hereunder shall be reduced dollar-for-dollar pro rata as and when corresponding commitments are
received from other Incremental Lenders; provided that, notwithstanding the Lead Arrangers’ right to syndicate the
Incremental Term Facility and receive commitments with respect thereto, (i) the Lead Banks shall not be relieved, released or novated
from their obligations hereunder (including, subject to the satisfaction of the conditions set forth herein, their obligation to
fund the Incremental Term Facility on the Closing Date) in connection with any syndication, assignment or participation of the
Incremental Term Facility, including their commitments in respect thereof, until after the Closing Date has occurred and (ii) unless
you otherwise agree in writing, the Lead Banks shall retain exclusive control over all rights and obligations with respect to their
respective commitments in respect of the Incremental Term Facility, including all rights with respect to consents, modifications,
supplements, waivers and amendments, until after the Closing Date has occurred. The Borrower’s and the Target’s assistance
may include, but not be limited to: (i) providing and causing its advisors to provide the Lead Banks and the other Incremental
Lenders upon request with all information reasonably necessary to complete the syndication, including, but not limited to, information
and evaluations prepared by you, the Target and your and its respective advisors, or on your or its behalf, relating to the transactions
contemplated hereby (including the Projections (as defined below), the “Information”), (ii) assisting in the
preparation of an Information Memorandum (the “Information Memorandum”) and other materials reasonably acceptable
to you to be used in connection with the syndication of the Incremental Term Facility (collectively with the Term Sheet, the “Information
Materials”), (iii) using your commercially reasonable efforts to ensure that the syndication efforts of the Lead Arrangers
benefit materially from your and the Target’s existing banking relationships, and (iv) otherwise assisting the Commitment
Parties in their syndication efforts, including by making your officers and advisors, and using commercially reasonable efforts
to make the officers and advisors of the Target and its subsidiaries, available from time to time to attend and make presentations
regarding the business and prospects of the Borrower, the Target and their respective subsidiaries, as appropriate, at one meeting
of prospective Incremental Lenders.

 

     

     

    

 

AdaptHealth LLC

Page 3

 

C.            Fees

 

The fees payable to
the Commitment Parties in connection with their obligations hereunder are set forth in that certain letter agreement dated the
date hereof, executed by the Commitment Parties and acknowledged and agreed to by the Borrower (the “Joint Fee Letter”).
The obligations of the Commitment Parties pursuant to this Commitment Letter are subject to the execution and delivery of the Joint
Fee Letter by the Borrower, which Joint Fee Letter constitutes an integral part of this Commitment Letter.

 

D.            Conditions
Precedent

 

The undertakings and
obligations of the Commitment Parties under this Commitment Letter are subject solely to satisfaction of the conditions precedent
set forth in the Term Sheet under the heading “Conditions Precedent to Closing” and on Addendum II thereto.

 

E.            Information.

 

The Borrower represents
and warrants (to your knowledge to the extent it relates to the Target) and covenants to the Commitment Parties that (i) all Information,
other than Projections, that has been or will be made available to the Commitment Parties by the Borrower or any of its representatives
(or on your or their behalf), or by the Target or any of its representatives (or on any of their behalf), in connection with any
aspect the transactions contemplated by this Commitment Letter (other than the Projections) is or will be, when furnished, when
taken as a whole, complete and correct in all material respects and does not or will not, when furnished, when taken as a whole,
contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained
therein not materially misleading (after giving effect to all supplements and updates thereto from time to time); (ii) all financial
projections concerning the Borrower, the Target or any of their respective subsidiaries that have been or are hereafter made available
to the Commitment Parties or the other Incremental Lenders by you or any of your representatives (or on your or their behalf) or
by the Target or any of its representatives (or on any of their behalf) (the “Projections”) have been or will
be prepared in good faith based upon reasonable assumptions at the time made, it being understood that such Projections are subject
to significant uncertainties and contingencies, many of which are beyond your control, that no assurance can be given that any
particular Projection will be realized, actual results may differ and that such differences may be material. The Borrower agrees
to supplement the Information and the Projections from time to time until the Closing Date so that the representations and warranties
contained in this Section E remain correct in all material respects (or as to information concerning the Target and its
subsidiaries and its business, correct in all material respects to your knowledge). In issuing the commitments and undertakings
hereunder and in arranging and syndicating the Incremental Term Facility, the Commitment Parties shall be entitled to use and rely
on the accuracy of the Information and the Projections without responsibility for independent verification thereof. The Borrower
further represents and warrants that this Commitment Letter has been duly authorized by, and validly executed and delivered by,
the Borrower.

 

The Borrower acknowledges
that the Lead Arrangers on behalf of the Borrower will make available Information Materials to the proposed syndicate of Incremental
Lenders by posting the Information Materials on SyndTrak or another similar electronic system. In connection with the syndication
of the Incremental Term Facility, unless the parties hereto otherwise agree in writing, the Borrower shall be under no obligation
to provide Information Materials suitable for distribution to any prospective Incremental Lender (each, a “Public Lender”)
that has personnel who do not wish to receive material non-public information (within the meaning of the United States federal
securities laws, “MNPI”) with respect to the Borrower, the Target or any of their respective affiliates, or
the respective securities of any of the foregoing. The Borrower agrees, however, that the definitive credit documentation will
contain provisions concerning Information Materials to be provided to Public Lenders and the absence of MNPI therefrom. Prior to
distribution of Information Materials to prospective Incremental Lenders, the Borrower shall provide the Lead Arrangers with a
customary letter authorizing the dissemination thereof.

 

The Borrower authorizes
the Lead Arrangers and their affiliates, including the Lead Banks, to share with each other, and to use, credit and other confidential
or non-public information regarding the Borrower, the Target and their respective subsidiaries to the extent permitted by applicable
laws and regulations and for the purpose of performing their obligations under this Commitment Letter and the Incremental Term
Facility.

 

     

     

    

 

AdaptHealth LLC

Page 4

 

F.            Indemnities,
Expenses, Etc.

 

1.           Indemnification.
The Borrower agrees to indemnify and hold harmless each Commitment Party, each Incremental Lender, each of their respective affiliates
and the respective directors, officers, employees, agents, representatives, legal counsel, and consultants of each of the foregoing
(each, an “Indemnified Person”) against, and to reimburse each Indemnified Person upon its demand for, any losses,
claims, damages, liabilities or reasonable and documented expenses (including, without limitation, the legal expenses of one firm
of counsel for all Indemnified Persons, taken as a whole, and if necessary, of a single local counsel in each appropriate jurisdiction
(which may include a single special counsel acting in multiple jurisdictions (and, in the case of an actual or reasonably perceived
conflict of interest where the Indemnified Person affected by such conflict notifies you of the existence of such conflict and
thereafter retains its own counsel, of another firm of counsel for each group of similarly affected Indemnified Persons in each
relevant jurisdiction)) of any kind or nature (“Losses”) incurred by such Indemnified Person or asserted against
such Indemnified Person by any third party or by the Borrower or any of its subsidiaries, insofar as such Losses arise out of or
in any way relate to or result from this Commitment Letter, the Joint Fee Letter, the financings and other transactions contemplated
by this Commitment Letter (including, without limitation, the performance by any Indemnified Person of its obligations hereunder)
or the use of the proceeds of the Incremental Term Facility, including, without limitation, (i) all Losses arising out of any legal
proceeding relating to any of the foregoing (whether or not such Indemnified Person is a party thereto, and whether or not such
proceeding is brought by or on behalf of you, any of your affiliates or equity holders) and (ii) Losses that arise out of untrue
statements made or statements omitted to be made by the Borrower, or with the Borrower’s consent or in conformity with the
Borrower’s actions or omissions, in each case whether or not such Indemnified Person is a party to any such proceeding and
whether or not such proceeding is brought by or on behalf of you, any of your affiliates or equity holders; provided that
the Borrower shall not be liable to an Indemnified Person pursuant to this indemnity for any Losses to the extent that a court
having competent jurisdiction shall have determined by a final judgment (not subject to further appeal) that such Loss resulted
from the gross negligence or willful misconduct of such Indemnified Person, or the material breach by such Indemnified Person of
its obligations under this Commitment Letter or the Term Sheet. The Borrower also agrees that no Indemnified Person shall have
any liability (whether direct or indirect, in contract or tort or otherwise) to the Borrower or its subsidiaries or affiliates
or to its respective equity holders or creditors arising out of, related to or in connection with any aspect of the transactions
contemplated hereby, except solely to you, and then solely to the extent of your direct, as opposed to special, indirect, consequential
or punitive, damages determined in a final, nonappealable judgment by a court of competent jurisdiction to have resulted from such
Indemnified Person’s gross negligence or willful misconduct, or the material breach by such Indemnified Person of its obligations
under this Commitment Letter or the Term Sheet. Notwithstanding any other provision of this Commitment Letter, no Indemnified Person
shall be liable for any damages arising from the use by others of information or other materials obtained through electronic telecommunications
or other information transmission systems, other than for direct or actual damages resulting from the gross negligence or willful
misconduct of such Indemnified Person, or the material breach by such Indemnified Person of its obligations under this Commitment
Letter or the Term Sheet, in each case, as determined by a final and nonappealable judgment of a court of competent jurisdiction.
The Borrower shall not, without the prior written consent of any Indemnified Person (which consent shall not be unreasonably withheld,
conditioned or delayed), effect any settlement of any pending or threatened proceeding in respect of which such Indemnified Person
is a party and indemnity has been sought hereunder by such Indemnified Person, unless such settlement includes an unconditional
release of such Indemnified Person from all liability on claims that are the subject matter of such indemnity.

 

2.           Expenses.
In further consideration of the commitments and undertakings of the Commitment Parties hereunder, and recognizing that in connection
herewith the Commitment Parties will be incurring certain costs and expenses (including, without limitation, fees and disbursements
of counsel, and costs and expenses for due diligence, syndication, transportation, duplication, mailings, messenger services, dedicated
web page on the internet for the transactions contemplated by this Commitment Letter, appraisal, audit, and insurance), the Borrower
hereby agrees to pay, or to reimburse the Commitment Parties on demand for, all such reasonable, documented, out-of-pocket costs
and expenses (whether incurred before or after the date hereof), regardless of whether any of the transactions contemplated hereby
are consummated. The Borrower also agrees to pay all costs and expenses of the Commitment Parties (including, without limitation,
fees and disbursements of counsel) incurred in connection with the enforcement of any of its rights and remedies hereunder.

 

     

     

    

 

AdaptHealth LLC

Page 5

 

G.           Miscellaneous

 

1.            Effectiveness.
This Commitment Letter shall constitute a binding obligation of the Commitment Parties for all purposes immediately upon the acceptance
hereof by the Borrower in the manner specified below. Notwithstanding any other provision of this Commitment Letter, the commitments
and undertakings of the Commitment Parties set forth herein shall not be or become effective for any purpose unless and until this
Commitment Letter and the Joint Fee Letter shall have been accepted by the Borrower in the manner specified below.

 

2.           Termination.
Unless this Commitment Letter and the Joint Fee Letter have been executed by the Borrower and delivered to the Lead Arrangers,
prior to 5:00 p.m., Eastern time, on May 25, 2020, the commitments and obligations of the Commitment Parties under this Commitment
Letter shall terminate on such date. If this Commitment Letter and the Joint Fee Letter are executed and delivered by the Borrower
to the Lead Arrangers, in accordance with the preceding sentence, all commitments and undertakings of the Commitment Parties hereunder
shall terminate on the earliest of: (a) September 22, 2020 (as such date may be extended for a period not to exceed 30 days pursuant
to the second proviso to Section 13.01(b)(iii) of the Acquisition Agreement as in effect on the date hereof), unless the definitive
legal documents related to the Incremental Term Facility have been executed and delivered on or prior to such date (it being agreed
that the parties hereto will work diligently to achieve this schedule); (b) the closing of the Acquisition without the use of the
Incremental Term Facility; (c) the acceptance by the Target or any of its affiliates of an offer for all, or any substantial part,
of the capital stock or property and assets of the Target and its subsidiaries, other than as part of the Transactions; and (d) the
termination of the Acquisition Agreement prior to the consummation of the Transactions. In consideration of the time and resources
that the Commitment Parties will devote to the Incremental Term Facility, you agree that, until such expiration, you will not,
and will cause the Target not to, solicit, initiate, entertain or permit, or enter into any discussions in respect of, any offering,
placement or arrangement of any competing senior credit facility or facilities for the Borrower and its subsidiaries with respect
to the matters addressed in this Commitment Letter (other than any bank financing with respect to which RCM shall act as the “left”
lead arranger and bookrunner). Furthermore, by acceptance of this Commitment Letter, any other commitments outstanding with respect
to the Incremental Term Facility by any Commitment Party will be terminated.

 

3.            No
Third-Party Beneficiaries. This Commitment Letter is solely for the benefit of the Borrower, the Commitment Parties and the
Indemnified Persons; no provision hereof shall be deemed to confer rights on any other person or entity.

 

4.            No
Assignment; Amendment. This Commitment Letter and the Joint Fee Letter may not be assigned by the Borrower or any Commitment
Party to any other person or entity; provided that, without limiting the foregoing restriction, all of the obligations of
the Borrower hereunder and under the Joint Fee Letter shall be binding upon the successors and assigns of the Borrower and the
Commitment Parties, respectively. No amendment, waiver or modification of any provision hereof shall in any event be effective
unless in writing and signed by the parties hereto and then only in the specific instance and for the specific purpose for which
given. The section headings contained herein have been inserted as a matter of convenience of reference and are not part of this
Commitment Letter.

 

5.            Use
of Name and Information. The Borrower agrees that any references to any Commitment Party or any of their respective affiliates
made in connection with the Incremental Term Facility are subject to the prior approval of such Commitment Party. With your prior
consent (which consent shall not be unreasonably withheld, conditioned or delayed) each Commitment Party shall be permitted to
use information related to the syndication and arrangement of the Incremental Term Facility in connection with marketing, press
releases or other transactional announcements or updates provided to investor or trade publications; including, but not limited
to, the placement of “tombstone” advertisements in publications of its choice at its own expense. Notwithstanding the
foregoing, you hereby authorize the Commitment Parties to download copies of the Borrower’s, the Target’s and their
respective subsidiaries’ logos from their respective websites, use copies thereof in IntraLinks, SyndTrak or similar workspaces
established by the Lead Arrangers to syndicate the Incremental Term Facility and use such logos on any confidential information
memoranda, presentations and other marketing materials prepared in connection with the syndication of the Incremental Term Facility
as provided in Section E of this Commitment Letter. You also agree that we may use such logos and other publicly available
information in customary marketing materials, including pitch books, describing our services to the Borrower, the Target and their
respective subsidiaries.

 

     

     

    

 

AdaptHealth LLC

Page 6

 

6.           GOVERNING
LAW. THIS COMMITMENT LETTER AND THE JOINT FEE LETTER WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE
OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS THEREOF; provided, however, that the laws of the
State of Delaware shall govern in determining the interpretation of the definition of “Material Adverse Effect” (as
defined in the Purchase Agreement) and whether or not a “Material Adverse Effect” has occurred.

 

7.            WAIVER
OF TRIAL BY JURY. TO THE EXTENT PERMITTED BY APPLICABLE LAW, EACH OF THE BORROWER AND EACH COMMITMENT PARTY WAIVES TRIAL BY
JURY IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATED TO THIS COMMITMENT LETTER, THE JOINT FEE LETTER OR ANY OTHER DOCUMENTS
CONTEMPLATED HEREBY. The Borrower irrevocably and unconditionally submits to the exclusive jurisdiction of any state court
in the State of New York or the United States District Court for the Southern District of New York for the purpose of any suit,
action or proceeding arising out of or relating to this Commitment Letter or the Joint Fee Letter. Each of the Borrower and each
Commitment Party irrevocably and unconditionally waive any objection to the laying of venue of any such suit, action or proceeding
brought in any such court and any claim that any such suit, action or proceeding has been brought in any such court and any claim
that any such suit, action or proceeding has been brought in an inconvenient forum. A final judgment in any such suit, action or
proceeding brought in any such court may be enforced in any other courts to whose jurisdiction the Borrower or the Commitment Parties
are or may be subject, by suit upon judgment.

 

8.            Survival.
The obligations and agreements of the Borrower and the Commitment Parties contained in the last paragraph of Section E,
Section F, and paragraphs 2, 6, 7, and 9 of this Section G shall survive the expiration and termination of this Commitment
Letter.

 

9.            Confidentiality.
The Borrower will not disclose or permit disclosure of this Commitment Letter, the Joint Fee Letter nor the contents of the foregoing
to any person or entity (including, without limitation, any Incremental Lender other than any Lead Bank), either directly or indirectly,
orally or in writing, except (i) to the Borrower’s officers, directors, agents and legal counsel who are directly involved
in the transactions contemplated hereby, in each case on a confidential basis or (ii) as required by law (in which case the Borrower
agrees to inform the Commitment Parties promptly thereof); provided, however, it is understood and agreed that the
Borrower may disclose this Commitment Letter (including the Term Sheet) but not the Joint Fee Letter after your acceptance of this
Commitment Letter and the Joint Fee Letter, (a) to the Target (including any shareholder representative), its subsidiaries and
their respective officers, directors, agents, employees, attorneys, accountants, advisors, or controlling persons or equity holders,
on a confidential and need-to-know basis, (b) to the Agent and its officers, directors, agents, employees, attorneys, accountants
and advisors, and (c) in filings with the Securities and Exchange Commission and other applicable regulatory authorities and stock
exchanges; provided, further that, to the extent portions thereof have been redacted in a customary manner (including
the portions thereof addressing fees payable to the Commitments Parties and/or the Incremental Lenders and any economic flex terms)
reasonably satisfactory to the Lead Arrangers, you may disclose the Joint Fee Letter and the contents thereof to the Target (including
any shareholder representative), its subsidiaries and its and their respective officers, directors, agents, employees, attorneys,
accountants, advisors, or controlling persons or equity holders, on a confidential and need-to-know basis. The Commitment Parties
hereby notify the Borrower that pursuant to the requirements of the USA Patriot Act, Title III of Pub. L. 107-56 (signed into law
October 26, 2001) (the “Patriot Act”) and 31 C.F.R. § 1010.230 (the “Beneficial Ownership Regulation”),
the Commitment Parties and their affiliates are required to obtain, verify and record information that identifies the Borrower,
the Target and its and their respective subsidiaries, which information includes the name, address, tax identification number and
other information regarding the Borrower, the Target and its and their respective subsidiaries that will allow the Commitment Parties
to identify the Borrower, the Target and its and their respective subsidiaries in accordance with the Patriot Act. This notice
is given in accordance with the requirements of the Patriot Act and the Beneficial Ownership Regulation and is effective for the
Commitment Parties and their affiliates.

 

     

     

    

 

AdaptHealth LLC

Page 7

 

The Commitment Parties
shall use all nonpublic information provided to them by or on behalf of you hereunder solely for the purpose of providing the services
which are the subject of this Commitment Letter and otherwise in connection with the Transactions and shall treat confidentially
all such information; provided, however, that nothing herein shall prevent the Commitment Parties from disclosing
any such information (i) pursuant to the order of any court or administrative agency or in any pending legal or administrative
proceeding, or otherwise as required by applicable law or compulsory legal process (in which case the Commitment Parties agree
to inform you promptly thereof prior to such disclosure to the extent not prohibited by law, rule or regulation), (ii) upon the
request or demand of any regulatory authority having jurisdiction over the Commitment Parties or any of their respective affiliates
(in which case the Commitment Parties shall, except with respect to any audit or examination conducted by bank accountants or any
governmental, regulatory or self-regulatory authority exercising examination or regulatory authority, inform you promptly thereof
prior to such disclosure to the extent not prohibited by law, rule or regulation), (iii) to the extent that such information becomes
publicly available other than by reason of disclosure in violation of this Commitment Letter by the Commitment Parties or any of
its affiliates or any related parties thereto, (iv) to the Commitment Parties’ affiliates and the Commitment Parties’
and such affiliates’ directors, officers, employees, legal counsel, independent auditors and other experts or agents who
need to know such information in connection with the Transactions and are informed of the confidential nature of such information,
(v) for purposes of establishing a “due diligence” defense, (vi) to the extent that such information is received by
the Commitment Parties from a third party that is not to the Commitment Parties’ knowledge subject to confidentiality obligations
to you, (vii) to the extent that such information is independently developed by the Commitment Parties, (viii) to potential Lenders,
participants or assignees or any hedge provider or prospective hedge provider (or their advisors); provided that the disclosure
of any such information to any such parties shall be made subject to the acknowledgment and acceptance by such counterparty (and
their advisors, as applicable) that such information is being disseminated on a confidential basis (on substantially the terms
set forth in this paragraph or as is otherwise reasonably acceptable to you and each Commitment Party) in accordance with customary
market standards for dissemination of such type of information and (ix) to market data collectors, similar services providers to
the lending industry, and service providers to the Commitment Parties and the Lenders in connection with the administration and
management of the Incremental Term Facility; provided that such information referred to in this clause (ix) is limited to
the existence of this Commitment Letter and information about the Incremental Term Facility. This paragraph shall terminate on
the earlier of the second anniversary of the date hereof and the Closing Date.

 

10.         Counterparts.
This Commitment Letter and the Joint Fee Letter may be executed in any number of separate counterparts, each of which shall collectively
and separately constitute one agreement. Delivery of a counterpart hereof via facsimile, email or other electronic transmission
shall be as effective as delivery of a manually executed counterpart hereof.

 

11.         No
Fiduciary Duty. The Borrower acknowledges and agrees that (i) the commitment to and syndication of the Incremental Term Facility
pursuant to this Commitment Letter are an arm’s-length commercial transaction between the Borrower, on the one hand, and
the Commitment Parties and, if applicable, their affiliates, on the other, and you are capable of evaluating and understanding,
and do understand and accept, the terms, risks and conditions of the transactions contemplated by this Commitment Letter, (ii)
in connection with the transactions contemplated hereby and the process leading to such transactions, each Commitment Party and
its applicable affiliates (as the case may be) is acting and has been acting solely as a principal and is not the agent or fiduciary
of the Borrower, the Target or their respective affiliates, stockholders, creditors, employees or any other party, (iii) the Commitment
Parties and their applicable affiliates (as the case may be) have not assumed an advisory responsibility or fiduciary duty in favor
of the Borrower with respect to the transactions contemplated hereby or the process leading thereto (irrespective of whether any
Commitment Party or any of their respective affiliates has advised or are currently advising the Borrower on other matters) and
no Commitment Party has any obligation to the Borrower except those expressly set forth in this Commitment Letter, (iv) each Commitment
Party and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those
of the Borrower, the Target and their respective affiliates, and no Commitment Party shall have any obligation to disclose any
of such interests by virtue of any fiduciary or advisory relationship as a consequence of this Commitment Letter, (v) no Commitment
Party has provided any legal, accounting, regulatory or tax advice with respect to any of the transactions contemplated hereby
and the Borrower has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. The
Borrower waives and releases, to the fullest extent permitted by law, any claims that it may have against each Commitment Party
with respect to any breach or alleged breach of fiduciary duty as a consequence of this Commitment Letter.

 

     

     

    

 

AdaptHealth LLC

Page 8

 

12.          Entire
Agreement. Upon acceptance by the Borrower as provided herein, this Commitment Letter and the Joint Fee Letter referenced herein
shall supersede all understandings and agreements between the parties to this Commitment Letter in respect of the transactions
contemplated hereby. Those matters that are not covered or made clear herein or in the Term Sheet or the Joint Fee Letter are subject
to mutual agreement of the parties hereto and thereto. Each of the parties hereto agrees that this Commitment Letter and the Joint
Fee Letter referenced herein are binding and enforceable agreements with respect to the subject matter contained herein, including
an agreement to negotiate in good faith the documentation with respect to the Incremental Term Facility by the parties hereto in
a manner consistent with this Commitment Letter.

 

[Signatures on Following Page]

 

     

     

    

 

We look forward to working with you on
this important transaction.

 

	 	Very truly yours,
	 	 	 
	 	REGIONS BANK
	 	 	 
	 	By:	/s/ Ned Spitzer
	 	Name: Ned Spitzer
	 	Title: Managing Director
	 	 	 
	 	REGIONS CAPITAL MARKETS, A DIVISION OF REGIONS BANK
	 	 	 
	 	By: 	/s/ D. Clay Hall
	 	Name: D. Clay Hall
	 	Title: Managing Director
	 	 	 
	 	CITIZENS BANK, N.A.
	 	 	 
	 	By: 	/s/ Jamie Harbeson
	 	Name: Jamie Harbeson
	 	Title: Director
	 	 	 
	 	By: 	/s/ Tricia E. Lebo
	 	Name: Tricia E. Lebo
	 	Title: Managing Director
	 	 	 
	 	DEUTSCHE BANK AG NEW YORK BRANCH
	 	 	 
	 	By:	/s/ Yumi Okabe
	 	Name: Yumi Okabe
	 	Title: Vice President
	 	 	 
	 	By:	/s/ Suzan Onal
	 	Name: Suzan Onal
	 	Title: Vice President
	 	 	 
	 	DEUTSCHE BANK SECURITIES INC.
	 	 	 
	 	By:	/s/ Yumi Okabe
	 	Name: Yumi Okabe
	 	Title: Vice President
	 	 	 
	 	By:	/s/ Suzan Onal
	 	Name: Suzan Onal
	 	Title: Vice President
	 	 	 
	 	ROYAL BANK OF CANADA
	 	 	 
	 	By:	/s/ Charles D. Smith
	 	Name: Charles D. Smith
	 	Title: Co-Head, U.S. Leveraged Finance

 

JOINT COMMITMENT LETTER

ADAPTHEALTH LLC

 

     

     

    

 

		RBC CAPITAL MARKETS, LLC
	 	 	 
	 	By:	/s/ Charles D. Smith
	 	Name: Charles D. Smith
	 	Title: Co-Head, U.S. Leveraged Finance

 

JOINT COMMITMENT LETTER

ADAPTHEALTH LLC

 

     

     

    

 

	ACCEPTED AND AGREED AS OF THE DATE FIRST ABOVE WRITTEN:	 
	 	 
	ADAPTHEALTH LLC,	 
	a Delaware limited liability company	 
	 	 
	By:	/s/ Luke McGee	 
	Name: Luke McGee	 
	Title: Chief Executive Officer	 

 

JOINT COMMITMENT LETTER

ADAPTHEALTH LLC

 

     

     

    

 

ANNEX I

Summary of Principal Terms and Conditions
of

AdaptHealth LLC 

$240,600,000 Incremental Term Facility

 

Capitalized terms
not otherwise defined herein have the same meanings as specified therefor in the Existing Credit Agreement. 

 

	Borrower:	AdaptHealth LLC, a Delaware limited liability company (the “Borrower”).
	 	 
	Guarantors:	The Guarantors identified in Existing Credit Agreement shall guaranty the Incremental Term Facility (together with the Borrower, the “Loan Parties”).  
	 	 
	Administrative 	 
	Agent:	CIT Finance LLC acts as sole administrative agent for the Existing Credit Agreement (the “Agent”).
	 	 
	Co-Syndication Agents:	Regions Bank (“Regions”), Citizens Bank, N.A. (“Citizens”), Deutsche Bank Securities Inc. (“DBSI”) and Royal Bank of Canada (“Royal Bank”) will act as co-syndication agents for the Incremental Term Facility. 
	 	 
	Joint Lead Arrangers 	 
	and Joint Bookrunners:	Regions Capital Markets, a division of Regions Bank, Citizens, DBSI and RBC Capital Markets, LLC will act as joint lead arrangers and joint bookrunners (the “Lead Arrangers”) for the Incremental Term Facility.
	 	 
	Incremental Lenders:	Regions, Citizens, Deutsche Bank AG New York Branch and Royal Bank and a syndicate of financial institutions acceptable to the Lead Arrangers and the Agent, in consultation with the Borrower (together, the “Incremental Lenders”).
	 	 
	Incremental Term 	 
	Facility:	An Incremental Term Facility in an aggregate principal amount of $240,600,000 will be issued under the Existing Credit Agreement.  The Existing Credit Agreement shall be amended to add the Incremental Term Facility as an additional term loan tranche having the terms set forth herein.  The Incremental Term Facility shall share ratably in the benefits of the Existing Credit Agreement and the other Loan Documents with the other outstanding Obligations.   
	 	 
	Existing Facilities:	Senior secured credit facilities (the “Existing Facilities”) in the initial aggregate principal amount of $425,000,000, consisting of the following: 
	 	 
	 	(a) a revolving credit facility in an initial aggregate principal amount of $75,000,000, which includes a $6,000,000 sublimit for the issuance of letters of credit and a $5,000,000 sublimit for swingline loans; 
	 	 
	 	(b) a term loan facility in an initial aggregate principal amount of $300,000,000 (the “Initial Term Loan”); and 

 

    	Confidential	1	 

     

    

 

	 	(c) a delayed draw term loan in an initial aggregate principal amount of $100,000,000 (the “Existing DDTL”, and, together with the Initial Term Loan, the “Existing Term Facility”). 
	 	 
	 	The Incremental Term Facility and the Existing Facilities are collectively referred to herein as the “Senior Credit Facility”. 
	 	 
	Purpose:	Proceeds of the Incremental Term Facility shall be used (i) to finance in part the Acquisition and (ii) to pay transaction fees, costs and expenses related to the Transactions.
	 	 
	Closing Date:	The date of execution of definitive documentation for the Incremental Term Facility (the “Closing Date”).
	 	 
	Interest Rates:	As set forth in Addendum I hereto.
	 	 
	Maturity Date:	The Incremental Term Facility shall be subject to repayment according to the Scheduled Amortization (as hereinafter defined), with the final payment of all amounts outstanding, plus accrued interest, being due on March 20, 2024 (being the “Term Loan Maturity Date” under the Existing Credit Agreement).
	 	 
	Scheduled Amortization:	The Incremental Term Facility will be subject to quarterly amortization of principal, with 2.5% of the initial aggregate Incremental Term Facility to be payable in the first year following the Closing Date and 5.0% of the initial aggregate Incremental Term Facility to be payable in each year following the first anniversary the Closing Date (collectively, the “Scheduled Amortization”).
	 	 
	Increase in the 	 
	Senior Credit Facility:	As set forth in the Existing Credit Agreement. 
	 	 
	 	 
	Collateral:	The Collateral (as set forth in the Existing Credit Agreement and the Loan Documents) shall ratably secure the relevant party’s obligations in respect of the Senior Credit Facility, including the Incremental Term Facility, and any treasury management, interest protection or other hedging arrangements entered into by any Loan Party with a Lender (or an affiliate thereof).
	 	 
	Voluntary Prepayments 	 
	and Commitment 	 
	Reductions:	As set forth in the Existing Credit Agreement, provided, that prepayments of the Incremental Term Facility shall be pro rata with the Existing Term Facility. 
	 	 
	Mandatory Prepayments 	 
	and Commitment 	 
	Reductions:	The Incremental Term Facility shall share pro rata with the Existing Term Facility with respect to mandatory prepayments set forth in the Existing Credit Agreement.  

 

    	Confidential	2	 

     

    

 

	Conditions Precedent 	 
	to Closing:	The closing and funding of the Incremental Term Facility on the Closing Date shall be conditioned only upon the conditions set forth in paragraph D of the Commitment Letter to which this Summary of Principal Terms and Conditions is attached (the “Commitment Letter”) and those conditions set forth on Addendum II hereto.  
	 	 
	Representations 	 
	and Warranties:	As set forth in the Existing Credit Agreement.
	 	 
	Covenants:	As set forth in the Existing Credit Agreement.  
	 	 
	Events of Default:	As set forth in the Existing Credit Agreement. 
	 	 
	Participations and 	 
	Assignments:	As set forth in the Existing Credit Agreement.  
	 	 
	Waivers and 	 
	Amendments:	As set forth in the Existing Credit Agreement.  
	 	 
	Governing Law:	As set forth in the Existing Credit Agreement.

 

    	Confidential	3	 

     

    

 

ADDENDUM I

PRICING, FEES AND EXPENSES

 

	Interest Rates:	Interest rates per annum applicable to the Incremental Term Facility will be LIBOR plus the Applicable Margin (as hereinafter defined) or, at the option of the Borrower, the Base Rate plus the Applicable Margin.  “Applicable Margin” means with respect to the Incremental Term Facility, (a) until delivery to the Agent of the financial statements for the fiscal quarter ending September 30, 2020, 3.50% per annum, in the case of LIBOR loans, and 2.50% per annum, in the case of Base Rate loans, and (b) thereafter, a percentage per annum to be determined in accordance with the pricing grid set forth below, based on the Consolidated Total Leverage Ratio. 
	 	 
	 	The Borrower may select interest periods as set forth in the Existing Credit Agreement for LIBOR loans. Interest shall be payable and default rate interest shall be as set forth in the Existing Credit Agreement. 
	 	 
	Calculation of 	 
	Interest and Fees:	All calculations of interest and fees shall be as set forth in the Existing Credit Agreement. 
	 	 
	Cost and Yield 	 
	Protection:	As set forth in the Existing Credit Agreement. 
	 	 
	Expenses:	The Borrower will pay all reasonable costs and expenses associated with the preparation, due diligence, administration, syndication and closing of all loan documentation with respect to the Incremental Term Facility, including, without limitation, the legal fees of counsel to the Lead Arrangers, regardless of whether or not the Incremental Term Facility is closed, as and to the extent set forth in the Commitment Letter.  The Borrower will also pay the expenses of the Agent and each Incremental Lender in connection with the enforcement of any of the loan documentation with respect to the Incremental Term Facility as and to the extent set forth in the Existing Credit Agreement.
	 	 
	Pricing:	The Applicable Margin for loans under the Incremental Term Facility, for any fiscal quarter, shall be the applicable rate per annum set forth in the table below opposite the Consolidated Total Leverage Ratio determined as of the last day of the immediately preceding fiscal quarter.  

 

PRICING GRID

 

	Pricing Tier	Consolidated Total 

Leverage Ratio	Applicable Margin for 

LIBOR Loans	Applicable Margin 

for Base Rate Loans
	I	< 1.75:1.0	2.75%	1.75%
	II	> 1.75:1.0 but < 2.00:1.0	3.00%	2.00%
	III	> 2.00:1.0 but < 2.50:1.0	3.25%	2.25%
	IV	> 2.50:1.0 but < 3.00:1.0	3.50%	2.50%
	V	> 3.00:1.0	3.75%	2.75%

 

    	Confidential	I-1	 

     

    

 

ADDENDUM II

SUMMARY OF ADDITIONAL CONDITIONS

 

The initial borrowings
under the Incremental Term Facility shall be subject to the following conditions:

 

		1.	The Acquisition shall have been consummated, or substantially simultaneously with the initial borrowing
under the Incremental Term Facility, shall be consummated, in all material respects in accordance with the terms of the Acquisition
Agreement, without giving effect to any amendments, consents or waivers by you thereto that are materially adverse to the Incremental
Lenders or the Lead Arrangers, without the prior consent of the Lead Arrangers (such consent not to be unreasonably withheld, delayed
or conditioned) (it being understood that (a) any increase in the purchase price of, or consideration for, the Acquisition is not
materially adverse to the interests of the Incremental Lenders or the Lead Arrangers so long as such increase is not financed with
the proceeds of indebtedness of the Borrower and its subsidiaries other than the Existing Facilities and (b) any substantive amendment
to the definition of “Material Adverse Effect” (as defined in the Acquisition Agreement) is materially adverse to the
interests of the Incremental Lenders and the Lead Arrangers).

 

		2.	All of the representations and warranties contained in the Loan Documents shall be true and correct
in all material respects (or, in all respects, if already qualified by materiality).

 

		3.	No Default or Event of Default under the Existing Credit Agreement has occurred and is continuing
immediately prior to or after giving effect to the Incremental Term Facility.

 

		4.	Receipt by the Agent of a Pro Forma Compliance Certificate demonstrating that, after giving effect
to incurrence of the Incremental Term Facility and the consummation of the Acquisition on a pro forma basis (i) the Loan Parties
will be in compliance with the financial covenants set forth in Article 8 of the Existing Credit Agreement for the most recently
completed four fiscal quarter period and (ii) the Consolidated Total Leverage Ratio (calculated on a pro forma basis) as of the
end of the most recently completed four fiscal quarter period would not be greater than 3.00:1.00.

 

		5.	All existing indebtedness of the Target and its subsidiaries, other than indebtedness permitted
to remain outstanding pursuant to the Existing Credit Agreement as if the Target was a party thereto, shall have been repaid, or
substantially simultaneously with the initial borrowing under the Incremental Term Facility, shall be repaid and all liens related
to such indebtedness shall be terminated.

 

		6.	Since December 31, 2019, there shall not have occurred a “Material Adverse Effect”
(as defined in the Acquisition Agreement).

 

		7.	The Agent and the Lead Arrangers shall have received at least five (5) business days prior to the
Closing Date, and be satisfied with, all documentation and other information about the Borrower and the Guarantors as has been
reasonably requested in writing at least ten (10) business days prior to the Closing Date by the Agent or the Lead Arrangers that
they reasonably determine is required by regulatory authorities under applicable “know your customer” and anti-money
laundering rules and regulations, including without limitation the Patriot Act and the Beneficial Ownership Regulation) (including,
if the Borrower qualifies as a “legal entity customer” under the Beneficial Ownership Regulation, a certification regarding
beneficial ownership required by the Beneficial Ownership Regulation).

 

    	Confidential	II-1	 

     

    

 

		8.	The execution and delivery of (i) the definitive documentation for the Incremental Term Facility,
which shall, in each case, be consistent with the Commitment Letter and Term Sheet and (ii) customary legal opinions, customary
evidence of authorization and any third party consents, customary officer’s certificates, a customary borrowing notice, good
standing certificates (to the extent applicable) in the jurisdiction of organization of the Borrower and each Guarantor and a solvency
certificate of the Borrower’s chief financial officer or other officer with equivalent duties, which shall, in each case,
be consistent with those delivered in connection with the Existing Credit Agreement.

 

		9.	The Lead Arrangers shall have received (i) a pro forma consolidated balance sheet and related pro
forma consolidated statement of income, shareholders’ equity and cash flows of the Borrower as of April 30, 2020
and as of the last day of each month ended at least 45 days prior to the Closing Date, prepared after giving effect to the Transactions
as if the Transactions had occurred as of such date (in the case of such balance sheet) or at the beginning of such period (in
the case of such statement of income) and (ii) a pro forma organizational chart, including disclosures as to each entity that will
incur Indebtedness in connection with the Transactions.

 

		10.	The Lead Arrangers shall have received the audited balance sheet of the Target as of December 31,
2019 and the related audited statements of income, shareholders’ equity and cash flows for the year then ended, and the related
notes to the financial statements.

 

		11.	The Lead Arrangers shall have received evidence that the net cash proceeds of any equity contribution
in a direct or indirect parent of the Borrower (the proceeds of which are intended to be used to consummate the Acquisition) shall
have been contributed to the Borrower in amount sufficient to consummate the Acquisition.

 

		12.	The Lead Arrangers shall have received evidence that the Agent has consented to Deutsche Bank AG
New York Branch and Royal Bank as Additional Lenders.

 

		13.	The Closing Date shall not occur prior to June 30, 2020.

 

		14.	All fees required to be paid on the Closing Date pursuant to the Joint Fee Letter and reasonable
out-of-pocket expenses required to be paid on the Closing Date pursuant to the Commitment Letter, shall have been paid.

 

    	Confidential	II-2Exhibit 10.23

 

EXECUTION
VERSION

CONFIDENTIAL

  

Certain
information in this document identified by brackets has been omitted because it is both not material and would be competitively
harmful if publicly disclosed.

 

 

 

STOCK PURCHASE AGREEMENT

 

AND

 

AGREEMENT AND PLAN OF MERGER

 

BY AND AMONG

 

ADAPTHEALTH CORP.,

 

ADAPTHEALTH LLC,

 

ELEANOR MERGER SUB, LLC,

 

SOLARA HOLDINGS, LLC,

 

AND

 

LCP SOLARA BLOCKER SELLER, LLC, IN
ITS CAPACITY AS BLOCKER SELLER AND THE REPRESENTATIVE

 

May 25, 2020

 

 

     

     

    

 

TABLE OF CONTENTS

 	 	 	Page
	 	 	 
	Article I THE BLOCKER PURCHASE 	2
	 	 
	1.01	Sale of the Blocker Shares	2
	1.02	Consideration	2
	1.03	Closing	2
	 	 	 
	Article II THE MERGER 	2
	 	 
	2.01	Merger	2
	2.02	Effective Time; Closing	2
	2.03	Effect of the Merger	3
	2.04	Certificate of Formation	3
	2.05	Limited Liability Company Agreement	3
	2.06	Managers and Officers	3
	2.07	Conversion of Company Units	3
	2.08	Conversion of Merger Sub Units	4
	2.09	Unitholders Payments; Letters of Transmittal	4
	2.10	Required Withholding	5
	 	 	 
	Article III CLOSING, TRANSACTION CONSIDERATION ADJUSTMENT 	5
	 	 
	3.01	The Closing	5
	3.02	Closing Transactions	5
	3.03	Estimated Closing Cash Payment Adjustment	8
	3.04	Purpose of Closing Statement; Cooperation	10
	3.05	Acquisition Targets	11
	 	 	 
	Article IV
    REPRESENTATIONS AND WARRANTIES OF BUYER, PARENT AND MERGER SUB 	11
	 	 
	4.01	Status	11
	4.02	Power and Authority	11
	4.03	Enforceability	12
	4.04	No Violations; Consents and Approvals	12
	4.05	Brokers	12
	4.06	Financing	12
	4.07	Capitalization	13
	4.08	Investment Representation	15
	4.09	Solvency	15
	4.10	Litigation	15
	4.11	SEC Documents	15
	4.12	No Additional Representations or Warranties	16

    i

     

    

 

	Article V REPRESENTATIONS AND WARRANTIES OF BLOCKER SELLER 	16
	 	 
	5.01	Status	16
	5.02	Power and Authority	16
	5.03	Enforceability	16
	5.04	No Violations; Consents and Approvals	17
	5.05	Capitalization; Ownership	17
	5.06	Investments	17
	5.07	Tax Matters	17
	5.08	Holding Company	20
	5.09	Litigation	20
	5.10	Investment Representations	20
	5.11	No Additional Representations or Warranties	21
	 	 	 
	Article VI REPRESENTATIONS AND WARRANTIES OF THE COMPANY 	21
	 	 
	6.01	Status	21
	6.02	Power and Authority	21
	6.03	Enforceability	21
	6.04	Capitalization; Ownership	21
	6.05	Subsidiaries	22
	6.06	No Violation; Consents and Approvals	22
	6.07	Financial Statements; No Undisclosed Liabilities	22
	6.08	Absence of Certain Developments	24
	6.09	Litigation Recalls; Other Product Issues	25
	6.10	Environmental Matters	25
	6.11	Title to Properties	26
	6.12	Compliance with Laws	27
	6.13	Labor and Employment Matters	27
	6.14	Employee Benefit Plans	28
	6.15	Tax Matters	30
	6.16	Insurance	32
	6.17	Licenses and Permits	33
	6.18	Affiliated Transactions	33
	6.19	Material Contracts	33
	6.20	Intellectual Property	35
	6.21	Data Privacy and Security	35
	6.22	Key Customers and Suppliers	35
	6.23	No Brokers	36
	6.24	Condition and Sufficiency of Assets	36
	6.25	Health Care Compliance	36
	6.26	HIPAA	39
	6.27	No Additional Representations or Warranties	40

 

    ii

     

    

	 	 	 
	Article VII PRE-CLOSING COVENANTS 	40
	 	 
	7.01	Reasonable Best Efforts	40
	7.02	Regulatory Filings	40
	7.03	Conduct of the Business	41
	7.04	Access to Information; Contact with Business Relations	42
	7.05	Exclusivity	43
	7.06	Confidentiality Agreement	43
	7.07	Pre-Closing Reorganization	43
	7.08	Notice of Certain Events	43
	7.09	Financing	44
	7.10	Company 2019 Audited Financials	46
	 	 	 
	Article VIII POST-CLOSING COVENANTS 	46
	 	 
	8.01	Further Assurances	46
	8.02	Director and Officer Liability and Indemnification	46
	8.03	R&W Policy	47
	8.04	Access to Books and Records	47
	8.05	Transfer Taxes	48
	8.06	Employment and Benefit Arrangements	48
	8.07	Name Change	48
	8.08	Overpaid Founder Earnout Amount	48
	8.09	Restrictive Covenants.	49
	8.10	Share Consideration Restrictions	49
	8.11	NASDAQ Listing	50
	8.12	Parent Common Stock Legend Removal	50
	 	 	 
	Article IX TAX COVENANTS 	50
	 	 
	9.01	Tax Return Filing	50
	9.02	Pre-Closing Tax Matters	51
	9.03	Tax Proceedings	51
	9.04	Cooperation	52
	9.05	No Code Section 338 or Section 336 Election	52
	9.06	Tax Refunds	52
	9.07	Straddle Period	53
	9.08	Closing of Tax Period	53
	9.09	Allocation of the Closing Cash Payment	54
	9.10	Tax Treatment of Payments	54
	9.11	Intermediary Transaction Tax Shelter	54
	 	 	 
	Article X
CONDITIONS TO THE OBLIGATIONS OF BUYER, PARENT AND MERGER SUB	54
	 	 
	10.01	Accuracy of Representations and Warranties	54
	10.02	Compliance with Covenants	54
	10.03	No Adverse Proceeding	55
	10.04	No Material Adverse Effect	55
	10.05	Termination of HSR Waiting Period	55

 

    iii

     

    

	 	 	 
	Article XI CONDITIONS TO THE OBLIGATIONS OF THE COMPANY AND BLOCKER SELLER 	55
	 	 
	11.01	Accuracy of Representations and Warranties	55
	11.02	Compliance with Covenants	55
	11.03	No Adverse Proceeding	55
	11.04	Termination of HSR Waiting Period	55
	 	 	 
	Article XII DEFINITIONS 	55
	 	 
	12.01	Defined Terms	55
	12.02	Other Definitional Provisions	68
	 	 	 
	Article XIII TERMINATION 	69
	 	 
	13.01	Termination	69
	13.02	Termination Fee	70
	13.03	Effect of Termination	71
	 	 	 
	Article XIV SURVIVAL OF REPRESENTATIONS AND WARRANTIES; INDEMNITY 	71
	 	 
	14.01	Survival	71
	14.02	Indemnification	71
	14.03	Release of Indemnity Escrow Account	74
	14.04	Release of Specific Escrow Account	75
	14.05	Exclusive Remedy	75
	 	 	 
	Article XV GENERAL PROVISIONS 	75
	 	 
	15.01	Notices	75
	15.02	Entire Agreement	76
	15.03	Expenses	76
	15.04	Amendment; Waiver	77
	15.05	Binding Effect; Assignment	77
	15.06	Counterparts	77
	15.07	Interpretation; Schedules	77
	15.08	Governing Law; Interpretation	78
	15.09	Forum Selection; Consent to Jurisdiction; Waiver of Jury Trial	78
	15.10	Specific Performance	79
	15.11	Arm’s Length Negotiations; Drafting	79
	15.12	Time	79
	15.13	Made Available	79
	15.14	Confidentiality; Publicity	79
	15.15	Designation of the Representative	80
	15.16	Acknowledgements	81
	15.17	Company Representation	82
	15.18	Non-Recourse Parties	83
	15.19	Guaranty of Obligations of Buyer	83
	15.20	Prevailing Party	83
	15.21	Debt Financing Arrangements	84

    iv

     

    

 

EXHIBITS 

 

	Exhibit A	 	     Unitholder Consent
	Exhibit B	 	     Form of Certificate of Merger
	Exhibit C	 	     Form of Paying Agent Agreement
	Exhibit D	 	     Form of Letter of Transmittal
	Exhibit E	 	     Allocation Schedule
	Exhibit F	 	     Form of Escrow Agreement
	Exhibit G	 	     Working Capital
	Exhibit H	 	     Pre-Closing Reorganization
	Exhibit I	 	     Accounting Principles
	Exhibit J	 	     Investment Agreement
	Exhibit K	 	     Debt Commitment Letter
	Exhibit L	 	     Indemnity Matters
	Exhibit M	 	     Specific Matters

    v

     

    

 

STOCK PURCHASE AGREEMENT AND AGREEMENT
AND PLAN OF MERGER

 

This STOCK PURCHASE
AGREEMENT AND AGREEMENT AND PLAN OF MERGER (this “Agreement”) is entered into as of May 25, 2020,
by and among AdaptHealth LLC, a Delaware limited liability company (“Buyer”), AdaptHealth Corp, a Delaware corporation
(“Parent” and, together with Buyer, the “Buyer Parties”), Eleanor Merger Sub, LLC, a Delaware
limited liability company and wholly owned subsidiary of Buyer (“Merger Sub”), Solara Holdings, LLC, a Delaware
limited liability company (the “Company”), LCP Solara Blocker Seller, LLC, a Delaware limited liability company
(“Blocker Seller”), and Blocker Seller in its capacity as the Representative (as hereinafter defined).
Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in Section 12.01.
Buyer, Parent, Merger Sub, the Company, Blocker Seller and Representative are referred to herein collectively as the “Parties”
and individually as a “Party.”

 

RECITALS

 

WHEREAS, Blocker Seller
is the record and beneficial owner of 100% of the issued and outstanding shares of capital stock (the “Blocker Shares”) of
LCP Solara Blocker Corp., a Delaware corporation (“Blocker”);

 

WHEREAS, as of the
date hereof, Blocker is the record and beneficial owner of certain limited partnership interests (the “Blocker Splitter
Interests”) of LCP Solara Splitter, LP, a Delaware limited partnership (“Splitter”);

 

WHEREAS, after giving
effect to the Pre-Closing Reorganization and immediately prior to the Closing, Blocker will be the record and beneficial owner
of certain Class A Preferred Units and Class A Common Units of the Company (collectively, the “Blocker Company
Units”);

 

WHEREAS, Blocker Seller
desires to sell to Parent, and Parent desires to purchase from Blocker Seller, 100% of the Blocker Shares, on the terms and subject
to the conditions set forth in this Agreement (the “Blocker Purchase”);

 

WHEREAS, immediately
following the closing of the Blocker Purchase, Buyer, Merger Sub and the Company desire to merge Merger Sub with and into the Company,
with the Company surviving the merger and continuing as the surviving company (the “Merger”);

 

WHEREAS, the board
of directors (or the equivalent governing body) of each Buyer, Merger Sub and the Company have each unanimously approved the
Merger and deemed it advisable and in the best interests of their respective equityholders and have directed that this Agreement
be submitted to their respective equityholders for adoption;

 

WHEREAS, the sole and
managing member of Blocker Seller has approved this Agreement and the Transactions;

 

WHEREAS, the board
of directors of Parent has unanimously approved this Agreement and the Transactions;

 

WHEREAS, Buyer, acting
as the sole equityholder of Merger Sub, has approved the Merger, this Agreement and the Transactions; and

 

WHEREAS, the Unitholders
holding, in the aggregate, not less than the minimum number of votes required to approve the Merger in accordance with the Delaware
Limited Liability Company Act (the “DLLCA”) and the LLC Agreement have approved the Merger, this Agreement
and the Transactions pursuant to a written consent, a copy of which is attached hereto as Exhibit A (the “Unitholder
Consent”).

 

    

     

    

 

AGREEMENT

 

NOW, THEREFORE, in
consideration of the mutual representations, warranties, agreements and covenants herein contained, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

Article I

THE BLOCKER PURCHASE

 

1.01         Sale
of the Blocker Shares. Subject to and upon the terms and conditions of this Agreement, immediately prior to the Effective
Time, Blocker Seller shall sell to Parent, and Parent shall purchase from Blocker Seller, all right, title and interest in and
to the Blocker Shares, free and clear of all Liens, other than Liens relating to the transfer of securities arising under the
Securities Act.

 

1.02         Consideration.
In consideration for the Blocker Shares, Parent shall pay Blocker Seller (collectively, the “Blocker Purchase Price”):

 

(a)            an
aggregate amount of cash equal to the portion of the Estimated Closing Cash Payment as set forth on the Estimated Closing Statement
under the heading “Blocker Closing Payment” (the “Blocker Closing Payment”); plus

 

(b)            an
aggregate amount of cash equal to the applicable portion (as determined by the Representative based on the Distribution Principles) of
any Future Distribution Amount; plus

 

(c)            the
portion of the Share Consideration payable to the Blocker Seller as set forth on the Estimated Closing Statement, in restricted
book-entry form in the books and records maintained by the transfer agent for Parent Common Stock; provided, that Blocker
Seller may, in its sole discretion, direct that any Share Consideration that is payable to Blocker Seller hereunder instead be
delivered at the Closing to, and registered in the name of, LCP IV-A.

 

1.03         Closing.
The closing of the Blocker Purchase shall take place on the Closing Date immediately prior to the Effective Time (the “Blocker
Closing”).

 

Article II

THE MERGER

 

2.01         Merger.
Subject to and upon the terms and conditions of this Agreement and the DLLCA, at the Effective Time, Merger Sub shall be merged
with and into the Company, whereupon the separate existence of Merger Sub shall cease and the Company shall continue as the surviving
limited liability company. The Company, as the surviving limited liability company in the Merger, is hereinafter sometimes referred
to as the “Surviving Company.”

 

2.02         Effective
Time; Closing. At the Closing, the Company, Buyer, and Merger Sub shall cause a certificate of merger in the form of Exhibit B
attached hereto (the “Certificate of Merger”) to be executed, acknowledged and filed with the Secretary
of State of the State of Delaware, and shall make all other filings or recordings required by the DLLCA to complete the Merger.
The Merger shall become effective at such time as the Certificate of Merger is duly filed with the Secretary of State of the State
of Delaware or at such other time as Buyer and the Company shall agree and shall specify in the Certificate of Merger (the “Effective
Time”).

 

    2

     

    

 

2.03         Effect
of the Merger. At the Effective Time, the effect of the Merger shall be as provided in this Agreement and the applicable provisions
of DLLCA. Without limiting the generality of the foregoing, from and after the Effective Time, all of the assets, property, rights,
privileges, powers and franchises of the Company and Merger Sub shall vest in the Surviving Company, and all debts, liabilities
and duties of the Company and Merger Sub shall become the debts, liabilities and duties of the Surviving Company.

 

2.04        Certificate
of Formation. The certificate of formation of the Company in effect at the Effective Time shall be the certificate of formation
of the Surviving Company until amended in accordance with applicable Law.

 

2.05        Limited
Liability Company Agreement. The limited liability company agreement of Merger Sub in effect at the Effective Time shall be
the limited liability company agreement of the Surviving Company until amended in accordance with applicable Law; provided
that, such limited liability company agreement shall maintain the same economics and ownership of the Blocker Company Units
owned by Blocker as was maintained by the limited liability company agreement of the Company immediately before the Effective
Time.

 

2.06         Managers
and Officers. From and after the Effective Time, until successors are duly elected or appointed in accordance with applicable
Law, the managers and officers of Merger Sub at the Effective Time shall be the managers and officers, as applicable, of the Surviving
Company.

 

2.07         Conversion
of Company Units. On the terms and subject to the conditions of this Agreement, at the Effective Time, by virtue of the Merger
and without any action on the part of the Parties or any of the Unitholders, the following shall occur:

 

(a)            Preferred
Units. Each Preferred Unit issued and outstanding immediately prior to the Effective Time (other than any Preferred Units to
be cancelled pursuant to Section 2.07(e), if any, and Blocker Company Units) shall be cancelled and extinguished
and shall be converted into the right to receive an amount in cash, without interest, equal to a portion of the Estimated Closing
Cash Payment and Share Consideration, in each case, as set forth on the Estimated Closing Statement.

 

(b)           Vested
Common Units. Each Vested Common Unit outstanding immediately prior to the Effective Time (other than the Class Z Common
Units outstanding immediately prior to the Effective Time, Vested Common Units to be cancelled pursuant to Section 2.07(e),
if any, and Blocker Company Units) shall be cancelled and extinguished and shall be converted into the right to receive a
portion of the Share Consideration as set forth on the Estimated Closing Statement and an amount in cash, without interest, equal
to:

 

(i)            a
portion of the Estimated Closing Cash Payment as set forth on the Estimated Closing Statement, plus

 

(ii)            the
applicable portion (as determined by the Representative based on the Distribution Principles) of any Future Distribution Amount.

 

(c)           Class Z
Common Units. Each Class Z Common Unit outstanding immediately prior to the Effective Time (other than Class Z Common
Units to be cancelled pursuant to 2.07(e), if any) shall be cancelled and extinguished and shall be converted into
the right to receive a portion of the Share Consideration as set forth on the Estimated Closing Statement and an amount in cash,
without interest, equal to:

    3

     

    

 

(i)            a
portion of the Estimated Closing Cash Payment as set forth on the Estimated Closing Statement, plus

 

(ii)            the
applicable portion (as determined by the Representative based on the Distribution Principles) of any Future Distribution Amount.

 

(d)           Unvested
Common Units. Each Unvested Common Unit outstanding immediately prior to the Effective Time shall be cancelled and extinguished
and no cash or other consideration shall be paid with respect thereto.

 

(e)           Cancellation
of Treasury Units. Each Preferred Unit and Common Unit (including any Unvested Common Unit) held immediately prior to
the Effective Time by the Company in treasury, if any, or held by any of the Buyer Parties or any of their respective Subsidiaries
(excluding the Blocker Company Units) shall be cancelled and no cash or other consideration shall be paid with respect thereto.

 

(f)           Blocker
Company Units. The Blocker Company Units shall be converted into and exchanged for an equal number of validly issued Preferred
Units and Class A Common Units of the Surviving Company (which newly issued Preferred Units and Class A Common Units
of the Surviving Company shall reflect the same economics and ownership of the Blocker Company Units owned by Blocker immediately
before the Effective Time) and there shall be no payments made to Buyer or Blocker in respect of the Blocker Company Units
pursuant to this Section 2.07.

 

2.08         Conversion
of Merger Sub Units. The units or limited liability company interests of Merger Sub issued and outstanding immediately prior
to the Effective Time shall be converted into and exchanged for validly issued Class A Preferred Units, Class B Preferred
Units, Class A Common Units, Class B Common Units and Class Z Common Units of the Surviving Company with the same
economics as the Class A Preferred Units, Class B Preferred Units, Class A Common Units, Class B Common Units
and Class Z Common Units outstanding immediately prior to the Effective Time (other than the Blocker Company Units owned
by Blocker).

 

2.09         Unitholders
Payments; Letters of Transmittal.

 

(a)           Prior
to the Closing, Buyer and the Representative shall enter into a payments administration agreement, in substantially the form attached
hereto as Exhibit C, with Acquiom Financial LLC (the “Paying Agent” and such agreement, the “Paying
Agent Agreement”). The Paying Agent shall act as paying agent in effecting payments to Designated Unitholders and the
exchange of cash for Class A Preferred Units, Class B Preferred Units, Class A Common Units, Class B Common
Units and Class Z Common Units (other than the Blocker Company Units and any Class A Preferred Unit, Class B Preferred
Unit, Class A Common Unit, Class B Common Unit and Class Z Common Unit cancelled pursuant to Section 2.07(d) or
2.07(e)).

 

(b)           Within
fifteen Business Days following the date hereof, to the extent not delivered prior to the date hereof, the Company shall, or shall
instruct the Paying Agent to, deliver to each Designated Unitholder a letter of transmittal, substantially in the form of Exhibit D
attached hereto (the “Letter of Transmittal”).

    4

     

    

 

(c)           If
a Designated Unitholder delivers its duly completed and validly executed Letter of Transmittal to the Paying Agent on or prior
to the Closing Date, then at the Closing the Company shall instruct the Paying Agent to deliver to such Designated Unitholder the
portion of the Estimated Closing Cash Payment payable to such Designated Unitholder pursuant to Section 2.07. If a
Designated Unitholder delivers its duly completed and validly executed Letter of Transmittal to the Paying Agent after the Closing
Date, then promptly thereafter, the Company shall instruct the Paying Agent to deliver to such Designated Unitholder the portion
of the Estimated Closing Cash Payment payable to such Designated Unitholder pursuant to Section 2.07, and any Future
Distribution Amount that such Designated Unitholder is entitled to receive pursuant to Section 2.07 at that time. From
and after the Closing, each Preferred Unit, Class A Common Unit and Class B Common Unit (other than the Blocker Company
Units and any Preferred Unit, Class A Common Unit and Class B Common Unit cancelled pursuant to Section 2.07(d) or
2.07(e)) shall represent solely the right to receive the portion of the Transaction Consideration into which the Class A
Preferred Units, Class B Preferred Units, Class A Common Units, Class B Common Units and Class Z Common Units
shall have been converted pursuant to Section 2.07, without interest. None of the Surviving Company or any other Party
shall be liable to a Designated Unitholder for any cash or interest thereon delivered to a public official pursuant to any applicable
abandoned property, escheat or similar applicable Law.

 

2.10        Required
Withholding. Each of Buyer, the Escrow Agent, the Paying Agent, the Surviving Company (and any other Person that has any withholding
obligation with respect to any payment made pursuant to this Agreement or any other agreements referenced herein) shall be
entitled to deduct and withhold from any consideration payable or otherwise deliverable pursuant to this Agreement or any other
agreements referenced herein such amounts as may be required to be deducted or withheld therefrom under the Code, or under any
provision of state, local or non-U.S. Tax Law; provided that, except with respect to payments in the nature of compensation
to be made to employees or former employees of the Company and its Subsidiaries, if Buyer, the Escrow Agent, the Paying Agent
or the Surviving Company determines that an amount is required to be deducted and withheld, Buyer shall provide the payee, at
least three Business Days prior to the date the applicable payment is scheduled to be made, (a) with written notice of the
intent to deduct and withhold, which shall include a copy of the calculation of the amount to be deducted and withheld and any
provision of applicable U.S. federal, state, local or non-U.S. Law pursuant to which such deduction or withholding is required
and (b) a reasonable opportunity to provide forms or other evidence that would exempt such amounts from withholding (or reduce
such withholding). To the extent such amounts are so deducted or withheld and remitted to the proper Taxing Authority, the amount
of such consideration shall be treated for all purposes under this Agreement as having been paid to the Person to whom such consideration
would otherwise have been paid.

 

Article III

CLOSING, TRANSACTION CONSIDERATION ADJUSTMENT

 

3.01        The
Closing. The closing of the Transactions (the “Closing”) shall take place via the electronic exchange
and release of signature pages to this Agreement and the other Transaction Documents, (a) at 10:00 a.m. local time
on the second Business Day following satisfaction or waiver of all of the closing conditions set forth in Article X
and Article XI hereof (other than those conditions which by their nature are to be satisfied at the Closing, but subject
to the satisfaction or, if permissible, waiver of such conditions at the Closing), or (b) on such other date and at such
time as are mutually agreed in writing by Buyer and the Company. The date on which Closing actually occurs is referred to herein
as the “Closing Date.”

 

3.02        Closing
Transactions. At the Closing:

 

(a)            the
Company and Merger Sub shall cause the Certificate of Merger to be executed, acknowledged and filed with the Secretary of State
of the State of Delaware;

 

    5

     

    

(b)           Buyer
shall deliver or cause to be delivered:

 

(i)            to
Blocker Seller (or LPC IV-A as provided in Section 1.02(c)), the Blocker Closing Payment and the portion of the Share
Consideration as set forth in the Estimated Closing Statement, in restricted book-entry form in the books and records maintained
by the transfer agent for Parent Common Stock reflecting the ownership of such shares of Parent Common Stock, along with evidence
from the transfer agent of such ownership;

 

(ii)            to
the Paying Agent, the Estimated Closing Cash Payment, less the Blocker Closing Payment;

 

(iii)            to
each Designated Unitholder that has delivered a Letter of Transmittal to the Paying Agent prior to the Closing, the Share Consideration
as set forth in the Estimated Closing Statement, in restricted book-entry form in the books and records maintained by the transfer
agent for Parent Common Stock reflecting the ownership of such shares of Parent Common Stock by such Designated Unitholder, along
with evidence from the transfer agent of such ownership; provided, that any Designated Unitholder may, in its sole discretion,
direct that any Share Consideration that is payable to such Designated Unitholder hereunder instead be delivered to, and registered
in the name of, any person or entity that such Designated Unitholder would otherwise be permitted to transfer the Share Consideration
to pursuant to Section 8.10;

 

(iv)            to
the Escrow Agent, the Adjustment Escrow Amount, the Indemnity Escrow Amount and the Specific Escrow Amount; and

 

(v)            to
the Representative, the Representative Holdback;

 

(c)           Buyer
shall pay, on behalf of the Company and its Subsidiaries, all amounts necessary to fully discharge the then-outstanding balance
of any Funded Debt listed on Schedule 3.02(c), pursuant to customary payoff letters from the holders of all such Funded
Debt by wire transfer of immediately available funds to the account(s) designated by the holders of such Funded Debt (the
 “Payoff Letters”);

 

(d)           Buyer
shall pay, on behalf of the Company and its Subsidiaries, all Transaction Expenses that remain unpaid as of the Effective Time,
in the amounts and to the Persons identified by the Company prior to Closing;

 

(e)           Blocker
Seller shall deliver to Parent:

 

(i)            the
stock certificate(s) representing the Blocker Shares, together with duly executed stock powers;

 

(ii)            a
certificate, dated as of the Closing Date and signed by an officer of Blocker Seller, stating that the conditions specified in
Sections 10.01 and 10.02 with respect to Blocker and Blocker Seller have been satisfied;

 

(iii)            a
certificate of the Secretary (or equivalent officer) of Blocker certifying that attached thereto are true and complete copies of
(A) the articles of incorporation of Blocker, and all amendments thereto, as certified by the Delaware Secretary of State;
and (B) the bylaws of Blocker, and all amendments thereto;

 

(iv)            a
certificate of good standing dated not more than ten days prior to the Closing Date for Blocker from the Delaware Secretary of
State, attesting to the good standing in such jurisdiction;

    6

     

    

 

(v)            duly
executed written resignations or removals, effective as of the Closing, of each such officers and members of the board of directors
of Blocker designated by Parent in writing at least five Business Days prior to Closing; and

 

(vi)            an
executed IRS Form W-9; provided that in no event shall Blocker Seller’s failure to provide such executed IRS
Form W-9 be deemed to be a failure of any condition set forth in Section 10.02 to have been met and the sole remedy
of any such failure shall be to withhold Taxes from the consideration otherwise payable to Blocker Seller hereunder in accordance
with Section 2.10;

 

(f)           the
Company shall deliver to Buyer:

 

(i)            a
certificate, dated as of the Closing Date and signed by an officer of the Company, stating that the conditions specified in Sections 10.01
and 10.02 with respect to the Company have been satisfied;

 

(ii)            an
executed IRS Form W-9 from each Designated Unitholder; provided that in no event shall any Designated Unitholder’s
failure to provide such executed IRS Form W-9 be deemed to be a failure of any condition set forth in Section 10.02
to have been met and the sole remedy of any such failure shall be to withhold Taxes from the consideration otherwise payable to
such Designated Unitholder hereunder in accordance with Section 2.10;

 

(iii)            duly
executed written resignations or removals, effective as of the Closing, of each such officers and members of the board of managers
of the Company designated by Buyer in writing at least five Business Days prior to Closing;

 

(iv)            evidence
that the Management Services Agreement has been terminated effective as of no later than the Closing;

 

(v)            a
certificate of the Secretary (or equivalent officer) of the Company certifying that attached thereto are true and complete copies
of (A) the certificate of formation of the Company, and all amendments thereto, as certified by the Delaware Secretary of
State; and (B) the LLC Agreement, and all amendments thereto;

 

(vi)            a
certificate of the Secretary (or equivalent officer) or member of each Subsidiary certifying that attached thereto are true and
complete copies of (A) the certificate of formation of such Subsidiary, and all amendments thereto, as certified by the Secretary
of State of the jurisdiction of formation of each such Subsidiary; and (B) the operating agreement of such Subsidiary, and
all amendments thereto;

 

(vii)            certificates
of good standing dated not more than ten days prior to the Closing Date for the Company and each of its Subsidiaries from the Secretary
of State of the jurisdiction of formation of each such entity, attesting to the good standing in such jurisdiction of such entity;
and

 

(viii)            the
Payoff Letters;

 

(g)          the
Representative shall deliver to Buyer (i) the Escrow Agreement, duly executed by the Representative and the Escrow Agent and
(ii) the Paying Agent Agreement, duly executed by the Representative and the Paying Agent; and

    7

     

    

 

(h)          The
Buyer Parties shall deliver to the Representative:

  

(i)            a
certificate, dated as of the Closing Date and signed by an officer of Buyer, stating that the conditions specified in Sections 11.01
and 11.02 with respect to Buyer and Merger Sub have been satisfied;

 

(ii)            a
certificate, dated as of the Closing Date and signed by an officer of Parent, stating that the conditions specified in Sections 11.01
and 11.02 with respect to Parent have been satisfied; and

 

(iii)            the
Escrow Agreement, duly executed by Buyer and the Escrow Agent; and

 

(iv)            the
Paying Agent Agreement, duly executed by Buyer and the Paying Agent.

 

3.03        Estimated
Closing Cash Payment Adjustment.

 

(a)            Estimated
Closing Cash Payment. Not less than two Business Days prior to the Closing Date, the Company shall deliver to Buyer a statement
(the “Estimated Closing Statement”) that sets forth (i) the Company’s good faith estimate of
the Cash Amount, the outstanding amount of all Funded Debt as of immediately prior to the Closing, the Transaction Expenses Amount,
the Working Capital and the Working Capital Surplus or Working Capital Deficit, if any, implied thereby and the Closing Cash Payment
resulting therefrom (the “Estimated Closing Cash Payment”), (ii) the Representative’s determination,
based on the Distribution Principles, of the portion of the Estimated Closing Cash Payment and Share Consideration payable to Blocker
Seller, and (iii) the Representative’s determination, based on the Distribution Principles, of the portion of the Estimated
Closing Cash Payment and Share Consideration payable to each Designated Unitholder, together with reasonable supporting detail
of each of the foregoing items described in clauses (i) – (iii).

    8

     

    

 

(b)           Final
Calculations.

 

(i)            Within
sixty days after the Closing Date, Buyer shall prepare and deliver to the Representative a statement setting forth Buyer’s
good faith calculation of (A) Working Capital (and the Working Capital Surplus or Working Capital Deficit, if any, implied
thereby), (B) the Cash Amount, (C) the outstanding amount of all Funded Debt as of immediately prior to the Closing,
(D) the Transaction Expenses Amount, and (E) the Closing Cash Payment resulting therefrom (the “Closing Statement”).
If Buyer does not deliver the Closing Statement to the Representative within sixty days after the Closing Date, the Representative
(acting in its sole discretion) may elect by written notice to Buyer to deem the Estimated Closing Statement as the final
Closing Statement that is final, binding and non-appealable by the Parties. After delivery of the Closing Statement, the Representative
and its accountants and other representatives shall be permitted to make inquiries of, and request documents, information and supporting
details from, Buyer and the Company and their accountants and other representatives regarding the Closing Statement. If the Representative
has any objections to the Closing Statement, the Representative shall deliver to Buyer a statement (an “Objection Statement”) setting
forth its objections (the “Objection Disputes”) to the Closing Statement and specific rationale for each
objection along with a reconciliation to the Closing Statement. If an Objection Statement is not delivered to Buyer within sixty
days after receipt of the Closing Statement by the Representative, then the Closing Statement as originally received by the Representative
shall be the final Closing Statement that is final, binding and non-appealable by the Parties. If an item in the Closing Statement
is not specifically included in any Objection Statement timely delivered to Buyer by the Representative, then as to such item the
Closing Statement as originally received by the Representative shall be the final Closing Statement that is final, binding and
non-appealable by the Parties. If an Objection Statement is timely delivered, then Buyer and the Representative shall negotiate
in good faith to resolve any Objection Disputes, but if they do not reach a final resolution within thirty days after the delivery
of the Objection Statement, the Representative and Buyer shall submit each unresolved Objection Dispute to Duff & Phelps
(the “Firm”) to resolve such Objection Disputes and only such Objection Disputes. If Duff & Phelps
refuses or is otherwise unable to act as the Firm, then Buyer and the Representative shall cooperate in good faith to appoint a
nationally recognized independent accounting or valuation firm mutually agreeable to Buyer and the Representative, in which event
 “Firm” shall mean such firm. The Firm shall be requested to render a written determination of the unresolved
Objection Disputes (acting as an expert and not as an arbitrator) within forty-five days following its retention, which determination
must be in writing and must set forth, in reasonable detail, the basis therefor and must be based solely on (I) the definitions
and other applicable provisions of this Agreement, (II) a single written presentation (which presentations shall be limited
to the unresolved Objection Disputes) submitted by each of Buyer and the Representative to the Firm within fifteen days after
its retention (which the Firm shall forward to the other Party) and (III) one written response submitted to the Firm
within fifteen days after receipt of each presentation (which the Firm shall forward to the other Party) and not on independent
review. Buyer and the Representative will instruct the Firm not to assign a value to any item in dispute greater than the greatest
value for such item assigned by Buyer, on the one hand, or the Representative, on the other hand, or less than the smallest value
for such item assigned by Buyer, on the one hand, or the Representative, on the other hand. The Firm’s determination of such
Objection Disputes shall be final and binding upon the Parties and not subject to review by a court or other tribunal. The terms
of appointment and engagement of the Firm shall be as reasonably agreed upon between Buyer and the Representative, and any associated
engagement fees shall initially be allocated 50% to Buyer and 50% to the Representative; provided that such fees, costs
and expenses of the Firm will ultimately be allocated between Buyer, on the one hand, and Representative, on the other hand, in
the same proportion that the aggregate amount of the disputed items so submitted to the Firm that is unsuccessfully disputed by
such Party (as finally determined by the Firm) bears to the total amount of disputed items submitted. For example, if the
Representative submits an adjustment of $1,000 for a specific item in the Objection Statement, and if Buyer contests only $500
of the amount claimed by the Representative, and if the Firm ultimately resolves the dispute by awarding the Representative $300
of the $500 contested, then the fees, costs and expenses of the Firm will be allocated 60% (i.e., 300/500) to Buyer and 40%
(i.e., 200/500) to the Representative. Except as provided in this Section 3.03(b)(i), all other costs and expenses
incurred by the Parties in connection with resolving any dispute hereunder before the Firm shall be borne by the Party incurring
such costs and expense. The process set forth in this Section 3.03(b) shall be the exclusive remedy of the Parties
for any disputes related to items required to be reflected on the Closing Statement or included in the calculation of Working Capital,
the Cash Amount, the outstanding amount of all Funded Debt as of immediately prior to the Closing or the Transaction Expenses Amount.

    9

     

    

 

 

(ii)            If
the Closing Cash Payment based on the final Closing Statement as finally determined pursuant to Section 3.03(b)(i) is
greater than the Estimated Closing Cash Payment, (x) Buyer shall promptly (but in any event within five Business Days after
the final Closing Statement determined pursuant to Section 3.03(b)(i)) pay (A) to Blocker Seller, an amount
equal to the applicable portion (as determined by the Representative based on the Distribution Principles) of such difference
(collectively, the “Blocker Adjustment Payment”) and (B) to the Paying Agent, (I) the amount
of such difference, less (II) the Blocker Adjustment Payment (which amount the Company shall instruct the Paying Agent
to distribute to the Designated Unitholders based upon each such Designated Unitholder’s applicable portion thereof (as determined
by the Representative based on the Distribution Principles), except as otherwise determined by the Representative in accordance
with Section 15.15), in each case, by wire transfer of immediately available funds to the account designated by Blocker
Seller or the Paying Agent, as applicable, and (y) Buyer and the Representative shall promptly (but in any event within five
Business Days after the final Closing Statement is finally determined pursuant to Section 3.03(b)(i)) deliver
to the Escrow Agent a joint written instruction instructing the Escrow Agent to release the Adjustment Escrow Funds (A) to
Blocker Seller, in an amount equal to the applicable portion (as determined by the Representative based on the Distribution Principles) of
the Adjustment Escrow Funds and (B) to the Paying Agent, the remaining portion of the Adjustment Escrow Funds (which amount
the Company shall instruct the Paying Agent to distribute to the Designated Unitholders based upon each such Designated Unitholder’s
applicable portion (as determined by the Representative based on the Distribution Principles) thereof, except as otherwise
determined by the Representative in accordance with Section 15.15), in each case, by wire transfer of immediately available
funds to such the accounts designated by Blocker Seller, or the Representative, as applicable.

 

(iii)            If
the Closing Cash Payment based on the final Closing Statement determined pursuant to Section 3.03(b)(i) is less
than the Estimated Closing Cash Payment, Buyer and the Representative shall promptly (but in any event within five Business Days
after the final Closing Statement is finally determined pursuant to Section 3.03(b)(i)) deliver to the Escrow
Agent a joint written instruction instructing the Escrow Agent to release the Adjustment Escrow Fund (x) to Buyer, in an amount
equal to the lesser of (A) the amount by which the Estimated Closing Cash Payment is greater than the Closing Cash Payment
based on the final Closing Statement determined pursuant to Section 3.03(b)(i), and (B) the Adjustment Escrow
Funds, (y) to Blocker Seller, in an amount equal to the applicable portion (as determined by the Representative based on the
Distribution Principles) of the remaining Adjustment Escrow Funds (after payment pursuant to clause (x)), and (z) to
the Paying Agent, the remaining portion of the Adjustment Escrow Fund (after payment pursuant to clauses (x) and (y)) (which
amount the Company shall instruct the Paying Agent to distribute to the Designated Unitholders based upon each such Designated
Unitholder’s applicable portion (as determined by the Representative based on the Distribution Principles) thereof,
except as otherwise determined by the Representative in accordance with Section 15.15), in each case, by wire transfer
of immediately available funds to such the accounts designated by Buyer, Blocker Seller or the Representative, as applicable. If
the amount of by which the Estimated Closing Cash Payment is greater than the Closing Cash Payment based on the final Closing Statement
determined pursuant to Section 3.03(b)(i) is greater than the Adjustment Escrow Funds, Buyer will be entitled
only to the full amount of the Adjustment Escrow Funds, which will be the sole and exclusive remedy and source of recovery for
the Buyer Parties and their Affiliates with respect to any such shortfall and no Buyer Party or any Affiliate thereof will have
any claim for any additional amounts from any Person in connection therewith.

 

    10

     

    

 

Certain information
in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if
publicly disclosed.

 

3.04        Purpose
of Closing Statement; Cooperation.

 

(a)            Purpose
of Closing Statement. The Parties agree that the purpose of preparing the Closing Statement and calculating the Closing Cash
Payment and the components thereof is solely to assess the accuracy of the amounts set forth in the Estimated Closing Statement,
and such processes are not intended to permit the introduction of different judgments, accounting methods, policies, principles,
practices, procedures, reserves classifications or estimation methodologies for the purpose of calculating the Closing Cash Payment
than were used in the calculation of the Estimated Closing Cash Payment. The Closing Statement will be prepared in a manner consistent
with the definitions of the terms Cash Amount, Funded Debt, Working Capital, Transaction Expenses Amount and the Accounting Principles.
The Closing Statement will entirely disregard (i) any and all effects on the assets or liabilities of the Company, Blocker
and their Subsidiaries as a result of the Transactions or of any financing or refinancing arrangements entered into at any time
by any of the Buyer Parties or any other transaction entered into by the Buyer Parties in connection with the consummation of the
Transactions, and (ii) any of the plans, transactions, or changes which Buyer or Parent intends to initiate or make or cause
to be initiated or made after the Closing with respect to the Company, Blocker or their Subsidiaries or their business or assets,
or any facts or circumstances that are unique or particular to Buyer or Parent or any of their assets or liabilities. The Closing
Statement will be based solely on facts and circumstances as they exist as of the Closing and will exclude the effect of any fact,
event, change, circumstance, act, development or decision occurring after the Closing.

 

(b)            Cooperation.
Following the Closing, Buyer shall, and shall cause the Surviving Company, its Subsidiaries and their respective officers, employees,
consultants, accountants and agents to (i) reasonably cooperate with the Representative and its accountants and other representatives
in connection with their review of the Closing Statement (including by providing the Representative with reasonable access to the
employees of the Surviving Company and its Subsidiaries who are knowledgeable about the information contained in, and the preparation
of, the Closing Statement) and (ii) provide any books, records and other information reasonably requested by the Representative
and its accountants or other representatives in connection therewith.

 

(c)            Post-Closing
Share Consideration. Buyer shall deliver or cause to be delivered to each Designated Unitholder that did not receive its Share
Consideration at the Closing pursuant to Section 3.02(b)(iii) the Share Consideration as set forth in the Estimated
Closing Statement, in restricted book-entry form in the books and records maintained by the transfer agent for Parent Common Stock
reflecting the ownership of such shares of Parent Common Stock by such Designated Unitholder, along with evidence from the transfer
agent of such ownership, within three Business Days of receiving confirmation from the Paying Agent that it has received a Letter
of Transmittal from such Designated Unitholder; provided, that any Designated Unitholder may, in its sole discretion, direct that
any Share Consideration that is payable to such Designated Unitholder hereunder instead be delivered to, and registered in the
name of, any person or entity that such Designated Unitholder would otherwise be permitted to transfer the Share Consideration
to pursuant to Section 8.10.

 

3.05        Acquisition
Targets. [***]

 

Article IV

REPRESENTATIONS AND WARRANTIES OF BUYER, PARENT AND MERGER SUB

 

Buyer, Parent
and Merger Sub jointly and severally represent and warrant to the Company and Blocker Seller as follows, as of the date hereof
and as of the Closing:

 

4.01        Status.
Buyer is a limited liability company, duly organized, validly existing and in good standing under the Laws of the State of Delaware.
Merger Sub is a limited liability company duly organized, validly existing and in good standing under the Laws of the State of
Delaware. Parent is a corporation duly organized, validly existing and in good standing under the Laws of the State of Delaware.

 

4.02       Power
and Authority. Each of Buyer, Parent and Merger Sub has all requisite power and authority to execute and deliver this Agreement
and the other Transaction Documents to which it is a party, to perform its obligations hereunder and thereunder and to consummate
the Transactions. All acts or proceedings required to be taken by Buyer, Parent, or Merger Sub applicable to authorize the execution
and delivery of this Agreement and the other Transaction Documents to which it is a party and the performance of Buyer’s,
Parent’s, and Merger Sub’s obligations hereunder and thereunder have been properly taken. The issuance and delivery
by Buyer of the Share Consideration to Blocker Seller and the Unitholders does not require any vote or other approval or authorization
of any holder of any capital stock of Parent or any of its Subsidiaries.

 

    11

     

    

 

4.03        Enforceability.
This Agreement and the other Transaction Documents have been or will be duly authorized, executed and delivered by each of Buyer,
Parent and Merger Sub, as applicable, and assuming the due and valid authorization, execution and delivery of this Agreement and
the other Transaction Documents by the other parties hereto and thereto, this Agreement and the other Transaction Documents constitute
or will constitute the legal, valid and binding obligation of each of Buyer, Parent and Merger Sub, as applicable, enforceable
against each in accordance with its terms, except as the same may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium or similar Laws affecting or relating to creditors’ rights generally and general equitable principles (the “Bankruptcy
and Equity Exceptions”).

 

4.04        No
Violations; Consents and Approvals. The execution and delivery of this Agreement and the other Transaction Documents by Buyer,
Parent and Merger Sub, and the consummation of the Transactions will not (a) violate any provision of the organizational
documents of any of Buyer, Parent or Merger Sub, (b) violate any material Law applicable to, binding upon or enforceable
against any of Buyer, Parent or Merger Sub, (c) result in any material breach of, or constitute a material default (or an
event which would, with the passage of time or the giving of notice or both, constitute a material default) under, or give
rise to a right of payment under or the right to terminate any Contract to which any of Buyer, Parent or Merger Sub is a party
or bound, (d) result in the creation or imposition of any Lien upon any of the material property or material assets of any
of Buyer, Parent or Merger Sub, or (e) require the consent or approval of any Governmental Authority or any other Person,
other than (i) the filing of a certificate of merger with respect to the Merger with the Delaware Secretary of State and
appropriate documents with the relevant authorities of other states in which the Company is qualified to do business, and (ii) compliance
with any applicable requirements of the Hart-Scott-Rodino Act.

 

4.05        Brokers.
Except for fees payable to Deutsche Bank AG, none of Buyer, Parent nor Merger Sub has incurred any obligation for any finder’s
or broker’s or agent’s fees or commissions or similar compensation in connection with the Transactions for which Blocker
Seller or any Unitholder may be liable.

    12

     

    

 

4.06        Financing.
The Buyer Parties have delivered to the Company on the date hereof true, correct and complete copies of (i) an executed
investment agreement (the “Investment Agreement”), which is attached hereto as Exhibit J, pursuant
to which One Equity Partners VII, L.P. shall invest, subject to (and only to) the terms and conditions set forth therein, cash
in Parent in the aggregate amount set forth therein (being collectively referred to as the “Equity Financing”)
and (ii) an executed debt commitment letter from the lender(s) signatory thereto (collectively, including (x) any
replacement, amendment or modification thereof and (y) all exhibits, schedules and annexes (other than the Fee Letters, which
may be redacted as set forth below) to such letter, the “Debt Commitment Letter” and, together with the Investment
Agreement, the “Financing Letters”), which is attached hereto as Exhibit K, pursuant to which the
lenders party thereto have committed, subject to (and only to) the terms and conditions set forth therein, to provide debt financing
in the amounts set forth therein for, among other things, the purposes of financing the transactions contemplated by this Agreement
(being collectively referred to as the “Debt Financing”, and together with the Equity Financing, the “Financing”).
As of the date hereof, the Financing Letters have not been amended, modified or replaced, and none of the provisions thereof have
been waived, no such amendment, modification, replacement or waiver is pending or contemplated by the Buyer Parties or Merger
Sub, or their respective Subsidiaries, or, to any of the Buyer Parties’ or Merger Sub’s, or their respective Subsidiaries’,
knowledge, the other parties thereto, and the respective commitments contained in such letters have not been withdrawn, terminated
or rescinded in any respect. As of the date hereof, other than the Financing Letters, there are no other agreements, side letters
or other arrangements to which the Buyer Parties or Merger Sub, or their respective Subsidiaries, is a party relating to the Financing
or any of the Financing Letters. Buyer has delivered true, correct and complete copies to the Company of any fee letters in respect
of the Financing on the date hereof (which letters may be redacted in a customary manner so long as such redacted provisions do
not reduce the amount of the net cash proceeds of either the Equity Financing or the Debt Financing available to the Buyer Parties
on the Closing Date or relate to or affect the conditionality of the Financing) (such fee letters, the “Fee Letters”).
The Buyer Parties have fully paid or caused to be fully paid any and all commitment fees or other fees required to be paid as
of the date hereof by the Financing Letters (or otherwise in respect of the Financing). There are no conditions precedent (including
any subsequent approval process) to the obligations of the counterparties to the Financing Letters to fund the full amount of
the Financing, other than (i) in the case of the Investment Agreement, the conditions expressly set forth therein, and (ii) in
the case of the Debt Commitment Letter, the conditions expressly set forth therein. Assuming that the Financing is funded in accordance
with the Financing Letters, the aggregate proceeds contemplated by the Financing, together with Buyer’s cash on hand, will
be sufficient for the Buyer Parties on the Closing Date to (A) make the payments contemplated to be made or caused to be
made by the Buyer Parties pursuant to Section 1.02 and (B) pay any and all fees and expenses required to be paid
by the Buyer Parties in connection with the Closing and the Financing. As of the date hereof, no event has occurred which, with
or without notice, lapse of time or both, would constitute a default or material breach on the part of the any of the Buyer Parties
or Merger Sub, or their respective Subsidiaries, or, to the knowledge of the Buyer Parties or Merger Sub, or their respective
Subsidiaries, any other parties thereto, under the Financing Letters, and none of the Buyer Parties or Merger Sub, or their respective
Subsidiaries, has any reason to believe that any of the conditions to the Financing will fail to be satisfied on a timely basis
or that the full amount of the Financing will be unavailable on the Closing Date. The execution, delivery and performance of the
Financing Letters and the Fee Letters have been duly and validly authorized by all requisite action on the part of the Buyer Parties,
and no other proceedings on the part of any of the Buyer Parties or that of their respective members or equityholders are necessary
to authorize the execution, delivery or performance of the Financing Letters and the Fee Letters. As of the date hereof, the Financing
Letters and the Fee Letters have been duly executed and delivered by the Buyer Parties and, to the knowledge of the Buyer Parties
and Merger Sub and their respective Subsidiaries, each other party thereto and are valid and binding on the Buyer Parties and,
to the knowledge of the Buyer Parties, each other party thereto, and are in full force and effect as of the date hereof, and enforceable
in accordance with their terms, except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium
and other laws affecting creditors’ rights generally and except insofar as the availability of equitable remedies may be
limited by applicable law. Neither the execution and delivery of the Financing Letters and the Fee Letters by the Buyer Parties,
nor compliance by the Buyer Parties with any of the provisions of the Financing Letters and the Fee Letters (I) conflicts
with or results in a breach of any provisions of the organizational documents of Parent or Buyer, (II) results in any material
breach of or constitutes (with or without notice or lapse of time or both) a default or requires any consent, in each case, under
any material contract to which Parent or Buyer is a party or is subject or by which it or its assets are bound, or (III) violates
any governmental order, law or permit applicable to Parent or Buyer or any of their properties or assets. Each of the Buyer Parties
and Merger Sub hereby affirms and acknowledges that neither the obtaining of the Debt Financing or the Equity Financing, nor the
completion of any issuance of debt or securities contemplated by the Debt Financing or the Equity Financing, is a condition to
the Closing.

    13

     

    

 

4.07        Capitalization.

 

(a)            The
total number of shares of all classes of capital stock which Parent is authorized to issue is 250,000,000 shares, which consists
of (a) 245,000,000 shares of common stock, par value $0.0001 per share (“Common Stock”), which Common Stock
consists of (i) 210,000,000 shares of Class A Common Stock (“Class A Common Stock”) and (ii) 35,000,000
shares of Class B Common Stock (“Class B Common Stock”) and (b) 5,000,000 shares of preferred
stock, par value $0.0001 per share (“Preferred Stock”). As of the close of business on March 31, 2020 (the
 “Capitalization Date”), there were 43,354,251 shares of Class A Common Stock outstanding, 30,563,799 shares
of Class B Common Stock outstanding and no shares of Preferred Stock outstanding. As of the close of business on the Capitalization
Date, (i) 3,037,761 shares of Class A Common Stock remained available for issuance pursuant to the AdaptHealth Corp.
2019 Stock Incentive Plan (the “Stock Plan”), (ii) options to purchase 3,416,666 shares of Class A
Common Stock (“Parent Stock Options”) pursuant to the Stock Plan were outstanding, (iii) 1,486,956 unvested
shares of Class A Common Stock granted pursuant to the Stock Plan were outstanding (together with the Parent Stock Options,
the “Parent Stock Awards”), (iv) 1,000,000 shares of Class A Common Stock remained available for issuance
pursuant to the AdaptHealth 2019 Employee Stock Purchase Plan and (v) public and private warrants to acquire 8,728,036 shares
of Class A Common Stock were outstanding. All of the issued and outstanding shares of Common Stock have been duly authorized
and validly issued and are fully paid, nonassessable and free of preemptive or similar rights. From the Capitalization Date through
and as of the date of this Agreement, no other shares of Common Stock or Preferred Stock have been issued other than shares of
Common Stock issued in respect of the exercise of Parent Stock Options or grant or payment of Parent Stock Awards in the ordinary
course of business. Parent does not have outstanding stockholder purchase rights or “poison pill” or any similar arrangement
in effect. The issuance of the Share Consideration is not, and will not be, subject to any preemptive rights, anti-dilution rights,
rights of first refusal, rights of first offer, notice rights, approval/consent rights, voting rights, review rights or similar
rights of any third party.

 

(b)            As
of the date hereof, the issued and outstanding equity interests of Buyer consists of 73,932,507 units, of which 43,368,708 units
are held, beneficially and of record by Parent. Parent possesses all power and control over the governance, management and internal
affairs of Buyer.

 

(c)            Parent
owns, directly or indirectly, all of the issued and outstanding shares of capital stock or other equity ownership interests of
each of its subsidiaries that is a “Significant Subsidiary” (as such term is defined in Rule 1-02 of Regulation
S-X promulgated under the Exchange Act), free and clear of any Liens (other than Liens arising under such Person’s organizational
documents or Liens arising under any agreement governing indebtedness of Parent or any of its subsidiaries).

 

(d)            Except
for changes resulting from the exercise or settlement of instruments set forth in Section 4.07(a) in accordance
with their respective terms, there are no outstanding (i) equity securities of Parent, (ii) securities of Parent convertible
or exercisable into or exchangeable for, at any time, equity securities of Parent, (iii) options or other rights to acquire
from Parent, and no obligations of Parent to issue, any equity securities or securities convertible or exercisable into or exchangeable
for equity securities of Parent, (iv) securities of Parent reserved for issuance for any purpose, (v) statutory or contractual
rights of pre-emption or rights of first refusal with respect to, or obligation to repurchase, redeem or otherwise acquire, securities
of Parent, or (vi) outstanding contracts to make any distribution of any kind with respect to any securities of Parent or
any securities convertible, exercisable or exchangeable into any such security of Parent.

 

(e)            Parent
has sufficient authorized, unissued and unreserved shares of Parent Common Stock pursuant to its organizational documents to issue
the shares constituting the Share Consideration, and such shares have been duly authorized and, when issued and delivered in accordance
with the terms of this Agreement, will have been validly issued, fully paid and nonassessable and free of restrictions on transfer
(other than those expressly set forth in Section 8.10) and the issuance thereof will be free of any option, call, subscription,
preemptive or similar right or Liens except for those created by the Blocker Seller or the Unitholders or arising under applicable
securities Laws, and, assuming the accuracy of the representations of Blocker Seller in Article V and each Unitholder
in such Unitholder’s Letter of Transmittal, such shares will, when issued, have been issued in compliance with all applicable
federal and state securities Laws.

    14

     

    

 

4.08         Investment
Representation. The Buyer Parties are acquiring Blocker and the Company for their own
account with the present intention of holding the securities of Blocker and the Company for investment purposes and not with a
view to or for sale in connection with any public distribution of such securities in violation of any federal or state securities
Laws. Each of Parent, Buyer and Merger Sub is an “accredited investor” as defined in Regulation D promulgated by the
Securities and Exchange Commission under the Securities Act.

  

4.09         Solvency.
Immediately after giving effect to the Transactions and assuming the satisfaction of the conditions to Closing set forth in Article X,
each of Parent, Buyer and assuming the accuracy of the representations set forth in Articles V and VI, Blocker and
the Surviving Company and its Subsidiaries shall (a) be able to pay their respective debts as they become due; (b) own
property which has a fair saleable value greater than the amounts required to pay their respective debts as and when they become
due (including a reasonable estimate of the amount of all contingent liabilities); and (c) have adequate capital to carry
on their respective businesses. No transfer of property is being made and no obligation is being incurred in connection with the
Transactions with the intent to hinder, delay or defraud either present or future creditors of Parent, Buyer, Merger Sub, Blocker
or the Company or its Subsidiaries.

 

4.10         Litigation.
There are no Proceedings pending or, to Buyer’s knowledge, threatened in writing against Parent, Buyer, or Merger Sub, at
law or in equity, before or by any Governmental Authority which would reasonably be expected to affect the legality, validity
or enforceability of this Agreement or the consummation of the Transactions.

 

4.11        SEC
Documents.

 

(a)            Parent
has filed with or furnished to the U.S. Securities and Exchange Commission (the “SEC”), on a timely basis or
having received the appropriate extension of time within which to file, all reports, schedules, forms, statements, prospectuses,
registration statements and other documents required to be filed or furnished by Parent with or to the SEC, including all reports
that Parent was required to file pursuant to Section 13 of the U.S. Securities Exchange Act of 1934 (such Act, the “Exchange
Act”, and such documents, the “Parent SEC Documents”). As of their respective filing dates or, in
the case of a registration statement under the Securities Act, as of the date such registration statement was declared effective
by the SEC, or, if amended (or deemed amended), as of the date of the last amendment or deemed amendment, (i) the Parent SEC
Documents complied as to form in all material respects with then-applicable requirements of the Securities Act, the Exchange Act,
and the Sarbanes-Oxley Act of 2002, and (ii) none of the Parent SEC Documents contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in
light of the circumstances under which they were made, not misleading. No subsidiary of Parent is, or has been, required by applicable
regulations promulgated by the SEC to file or furnish under the Exchange Act, or otherwise submit to the SEC, any form, report,
registration statement or other document.

 

(b)            Each
of the consolidated financial statements of Parent (including, in each case, any related notes thereto where applicable) contained
in the Parent SEC Documents (i) was prepared in accordance with GAAP applied on a consistent basis throughout the periods
involved (except, in each case, as otherwise described therein or, in the case of unaudited statements, as permitted by Form 10-Q
of the SEC), (ii) complied as to form, as of their respective dates of filing with the SEC, in all material respects with
applicable accounting requirements and the published rules and regulations of the SEC with respect thereto and (iii) fairly
presents in all material respects, as applicable, the consolidated financial position of Parent and its subsidiaries as of the
respective dates thereof and the consolidated results of Parent’s and its subsidiaries’ operations and cash flows for
the periods indicated (subject, in the case of unaudited statements, to year-end audit adjustments and the absence of footnotes
and subject to restatements filed with the SEC prior to the date of this Agreement).

 

    15

     

    

(c)            Parent
has established and maintains disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under
the Exchange Act). Such disclosure controls and procedures are reasonably designed to ensure that material information relating
to Parent, including its consolidated Subsidiaries, required to be disclosed in Parent’s periodic and current reports under
the Exchange Act, is made known to Parent’s chief executive officer and its chief financial officer by others within those
entities to allow timely decisions regarding required disclosures as required under the Exchange Act.

 

(d)            Parent
and its subsidiaries have established and maintain a system of internal control over financial reporting (as defined in Rules 13a-15(f) and
15d-15(f) under the Exchange Act) designed to provide reasonable assurance regarding the reliability of Parent’s financial
reporting and the preparation of Parent’s financial statements for external purposes in accordance with GAAP. Parent, based
on its most recent evaluation of Parent’s internal control over financial reporting prior to the date hereof, has not identified
(i) any significant deficiencies and material weaknesses in the design or operation of Parent’s internal control over
financial reporting which are reasonably likely to adversely affect Parent’s ability to record, process, summarize and report
financial information and (ii) any fraud, whether or not material, that involves management or other employees who have a
significant role in Parent’s internal control over financial reporting.

 

(e)            Parent
is in compliance in all material respects with all current listing and corporate governance requirements of the NASDAQ Capital
Market applicable to Parent.

 

4.12        No
Additional Representations or Warranties. Except for the representations and warranties contained in this Article IV,
none of the Buyer Parties nor Merger Sub nor any other Person on behalf of the Buyer Parties or Merger Sub makes any other express
or implied representation or warranty with respect to the Buyer Parties or Merger Sub.

 

Article V

REPRESENTATIONS AND WARRANTIES OF BLOCKER SELLER

 

Blocker Seller hereby
represents and warrants to Buyer, Parent and Merger Sub as follows, as of the date hereof and as of the Closing:

 

5.01        Status.
Blocker is a corporation, duly organized, validly existing and in good standing under the Laws of the State of Delaware. Blocker
Seller is a limited liability company duly organized, validly existing and in good standing under the Laws of the State of Delaware.

 

5.02        Power
and Authority. Blocker Seller has all requisite power and authority to execute and deliver this Agreement and the other Transaction
Documents to which it is a party, to perform its obligations hereunder and thereunder and to consummate the Transactions. All
acts or proceedings required to be taken by Blocker Seller applicable to authorize the execution and delivery of this Agreement
and the other Transaction Documents to which it is a party and the performance of Blocker Seller’s obligations hereunder
and thereunder have been properly taken.

 

5.03        Enforceability.
This Agreement and the other Transaction Documents to which Blocker Seller is a party have been or will be duly authorized, executed
and delivered by Blocker Seller and, assuming the due and valid authorization, execution and delivery of this Agreement and the
other Transaction Documents by the other parties hereto and thereto, this Agreement and the other Transaction Documents to which
Blocker Seller is a party constitute or will constitute the legal, valid and binding obligation of Blocker Seller, enforceable
against Blocker Seller in accordance with its terms, except as the same may be limited by the Bankruptcy and Equity Exceptions.

 

    16

     

    

5.04        No
Violations; Consents and Approvals. The execution and delivery of this Agreement and the other Transaction Documents to which
Blocker Seller is a party by Blocker Seller, and the consummation of the Transactions will not (a) violate any provision
of the organizational documents of either Blocker Seller or Blocker, (b) violate any material Law applicable to, binding
upon or enforceable against either Blocker Seller or Blocker, (c) result in any material breach of, or constitute a material
default (or an event which would, with the passage of time or the giving of notice or both, constitute a material default) under,
or give rise to a right of payment under or the right to terminate any Contract to which either Blocker Seller or Blocker is a
party or bound, (d) result in the creation or imposition of any Lien upon the Blocker Shares or any of the material property
or material assets of Blocker, or (e) require the consent or approval of any Governmental Authority or any other Person,
other than compliance with any applicable requirements of the Hart-Scott-Rodino Act.

  

5.05       Capitalization;
Ownership. All of the issued and outstanding equity securities in the Blocker have been duly authorized and validly issued
and are fully paid, and were issued in compliance with all applicable state and federal securities Laws. All Blocker Shares are
held of record and beneficially by Blocker Seller and are free and clear of all Liens, other than Permitted Liens, and have not
been issued in violation of, and are not subject to, any preemptive or subscription rights. Blocker Seller has good and valid
title to the Blocker Shares. There are no outstanding rights, options, warrants, convertible securities, subscription rights,
conversion rights, exchange rights or other agreements that require Blocker to issue or sell any of its equity interests (or securities
convertible into or exchangeable for its equity interests).

 

5.06       Investments.
As of the date hereof, Blocker does not own any equity interests in any Person other than Splitter. Following the consummation
of the Pre-Closing Reorganization and immediately prior to the Closing, Blocker will own not own any equity interests in any Person
other the Blocker Company Units.

 

5.07       Tax
Matters.

 

(a)            Blocker
has timely filed all Tax Returns that are required to be filed by it (taking into account any extensions of time to file). All
Taxes shown as owing by Blocker on all such Tax Returns have been fully and timely paid or properly accrued, and all such Tax Returns
are true and correct in all respects and do not contain a disclosure statement under Section 6662 of the Code or any predecessor
provision or comparable provision of applicable Law.

 

(b)            All
Taxes that Blocker is obligated to withhold from amounts owing to any employee, creditor or third party have been fully paid (or
remitted, as applicable) or properly accrued.

 

(c)            No
claim has been made by any Taxing Authority in any jurisdiction where Blocker does not file Tax Returns that it is or may be subject
to Tax by that jurisdiction nor is there any factual basis for such a claim.

 

(d)            Blocker
has not filed, nor was it required to have filed, a disclosure schedule pursuant to Temp. Treas. Reg. § 1.6011-4T. Blocker
is and has been in compliance with all applicable material Laws pertaining to Taxes, including all applicable material Laws relating
to record retention.

 

(e)            Blocker
is not, and has not been, party to any Tax allocation, Tax sharing, Tax indemnity, Tax reimbursement agreement or arrangement (other
than (i) any customary agreements with customers, vendors, lenders, lessors or the like entered into in the ordinary course
of business, (ii) property Taxes payable with respect to any properties leased, and (iii) other agreements for which
Taxes are not the principal subject matter).

 

    17

     

    

(f)            Blocker
is not currently the subject of any audit or other examination of any Taxes by the Taxing Authorities with respect to any open
Tax years and, to Blocker Seller’s knowledge, no such audit or other examination is contemplated or pending. Blocker has
not waived any statute of limitations in respect of any Taxes payable by it, which waiver is currently in effect. Blocker has not
agreed to any extension of time with respect to a Tax assessment or deficiency, which period (after giving effect to such extension
or waiver) has not yet expired. Blocker is not a party to or bound by any closing agreement or offer in compromise with any Taxing
Authority.

  

(g)            There
are no Liens for Taxes (other than Permitted Liens) upon any of the assets of Blocker.

 

(h)            Blocker
does not have any liability for Taxes of any Person other than Blocker under Treasury Regulations Section 1.1502-6 or any
corresponding provision of state, local or foreign income Laws pertaining to Taxes, as transferee or successor, by contract or
otherwise (other than (i) any customary agreements with customer, vendors, lenders, lessors or the like entered into in the
ordinary course of business, (ii) property Taxes payable with respect to any properties leased and (iii) other agreements
for which Taxes are not the principal subject matter). Blocker has not made a consent dividend election under Section 565
of the Code. Blocker has not been a personal holding company under Section 542 of the Code.

 

(i)            Blocker
will not be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period
(or portion thereof) beginning after the Closing Date as a result of any (i) change in method of accounting for a taxable
period ending on or prior to the Closing Date, (ii) installment sale or open transaction disposition made on or prior to the
Blocker Closing, (iii) “closing agreement” as described in Section 7121 of the Code (or any corresponding
or similar provision of state, local or non-U.S. income Laws pertaining to Taxes) executed prior to the Blocker Closing, (iv) intercompany
transaction or excess loss account described in Treasury Regulations under Section 1502 of the Code (or any corresponding
or similar provision of state, local or foreign Laws pertaining to Taxes), (v) prepaid amount or advance payment received
outside of the ordinary course of business on or prior to the Blocker Closing, (vi) the application of Section 362(e) of
the Code (or any corresponding or similar provision of state, local, or foreign Laws pertaining to Taxes), or (vii) election
under Section 108(i) of the Code.

 

(j)            Blocker
is not a party to any joint venture, partnership, or other arrangement or Contract that could be treated as a partnership for federal
income Tax purposes other than with respect to the Company.

 

(k)            None
of the assets of Blocker is property that such Blocker is required to treat as being owned by any other Person pursuant to the
so-called “safe harbor lease” provisions of former Section 168(f)(8) of the Internal Revenue Code of 1954,
as amended. None of the assets of Blocker directly or indirectly secures any debt the interest on which is tax exempt under Section 103(a) of
the Code. None of the assets of Blocker is “tax-exempt use property” within the meaning of Section 168(h) of
the Code. None of the assets of Blocker is required to be or is being depreciated pursuant to the alternative depreciation system
under Section 168(g)(2) of the Code.

 

(l)            Blocker
has not has agreed to make, nor is it required to make, any adjustment under Sections 481(a) or 263A of the Code or any comparable
provision of state, local or foreign Laws pertaining to Taxes by reason of a change in accounting method or otherwise. Blocker
has at all times used the accrual method of accounting for income Tax purposes.

 

    18

     

    

(m)            Blocker
is not a party to any Contract or plan that (i) has resulted or would result, separately or in the aggregate, in connection
with this Agreement or any change of control of Blocker, in the payment of any “excess parachute payments” within the
meaning of Section 280G of the Code or (ii) could obligate it to make any payments that will not be fully deductible
under Section 162(m) of the Code.

 

(n)            Prior
to the Closing, there is no limitation on the utilization of net operating losses, capital losses, built-in losses, tax credits
or similar items of Blocker under-Sections 269, 382 383, 384 or 1502 of the Code and the Treasury Regulations thereunder.

 

(o)            Blocker
has never been a “distributing corporation” or a “controlled corporation” in connection with a distribution
described in Section 355 of the Code.

 

(p)            Blocker
has not a “permanent establishment” in any foreign country, as defined in any applicable Tax treaty or convention between
the United States of America and such foreign country, or has otherwise taken steps or conducted business operations that may reasonably
be expected to cause it to be subject to the income taxing jurisdiction of a foreign country by virtue of such steps or conduct.

 

(q)            Blocker
has not entered into a gain recognition agreement pursuant to Treas. Reg. § 1.367(a)-8. Blocker has not transferred an
intangible the transfer of which would be subject to the rules of Section 367(d) of the Code.

 

(r)            None
of the assets of Blocker are currently escheatable to any Governmental Authority under any applicable escheatment Laws. Blocker
has (i) filed or caused to be filed with the appropriate Governmental Authority all unclaimed property reports required to
be filed and has remitted to the appropriate Governmental Authority all unclaimed property required to be remitted, or (ii) delivered
or paid all unclaimed property to its original or proper recipient.

 

(s)            Blocker
Seller is not a “foreign person” as that term is used in Treas. Reg. § 1.1445-2. Blocker is not, nor has
ever been, a United States real property holding corporation, as defined in Section 897(c)(2) of the Code, during the
applicable period specified in Section 897(c)(1)(a) of the Code.

 

(t)            Blocker
has not executed or entered into any ruling or agreement with any Taxing Authority or agreed with a Taxing Authority to make any
adjustment to its income or deductions pursuant to a change in its method of accounting.

 

(u)            Blocker
has not participated in an international boycott within the meaning of Section 999 of the Code.

 

(v)            Blocker
has not been a party to any “reportable transaction,” as defined in Section 6707A(c)(1) of the Code or Treasury
Regulation Section 1.6011-4(b).

 

(w)            Blocker
has not been a party to any “listed transaction” as defined in Section 6707A(c)(2) of the Code or Treasury
Regulation Section 1.6011-4(b)(2).

 

(x)            Blocker
has not at any time held directly, indirectly, or constructively shares of any “passive foreign investment company”
as that term has been defined from time to time in Section 1296 or 1297 of the Code.

 

(y)            Blocker
is not a party to any Tax exemption, Tax holiday or other Tax reduction agreement or order

    19

     

    

 

(z)            No
power of attorney has been granted by or with respect to Blocker with respect to any matter relating to Taxes that has not been
cancelled prior to the Blocker Closing.

 

(aa)     Blocker
has properly collected and remitted sales and similar taxes with respect to sales.

 

(bb)     For
all sales that are exempt from sales and similar taxes and that were made without charging or remitting sales or similar taxes,
Blocker has received and retained any appropriate tax exemption certificates and other documentation qualifying such sale as exempt.

 

(cc)     Blocker
is, and has been since its formation, properly treated as an association taxable as a corporation for U.S. federal income Tax purposes.

 

(dd)     At
no point during 2019 did Blocker have any plan or intention of disposing of its interest in the Company, whether via a contribution
to another entity taxed as a partnership for federal income Tax purposes or otherwise.

 

5.08         Holding
Company. Blocker has no material operations and no material assets, and does not engage in, and has never engaged in, any
business activities, other than (a) its ownership of the Blocker Splitter Interests and, following the Pre-Closing Reorganization,
its Blocker Company Units, (b) activities in connection with this Agreement and the Transactions, including the Pre-Closing
Reorganization, and (c) engaging in transactions related to its capital stock (including the issuance of the Blocker Shares
to Blocker Seller), in each case, including any activities related or incidental thereto. Blocker (i) has no, and has never
had any, employees and (ii) does not own or lease, and has never owned or leased, any real property or personal property.

 

5.09        Litigation.
There are no Proceedings pending or, to Blocker Seller’s knowledge, threatened in writing against Blocker Seller or Blocker,
at law or in equity, before or by any Governmental Authority which would reasonably be expected to affect the legality, validity
or enforceability of this Agreement or the consummation of the Transactions.

 

5.10        Investment
Representations. Blocker Seller is acquiring the Share Consideration solely for its own account for investment purposes and
not with a view to, or for offer or sale in connection with, any distribution thereof within the meaning of the Securities Act.
Blocker Seller acknowledges that the Share Consideration is not registered under the Securities Act (or any state securities or
blue-sky Laws of any jurisdiction), and that the Share Consideration may not be transferred, pledged, sold or otherwise disposed
of except as contemplated by Section 8.10 or pursuant to the registration provisions of the Securities Act or pursuant
to an applicable exemption therefrom and subject to state securities Laws and regulations, as applicable. Blocker Seller has sufficient
knowledge and experience in financial and business matters so as to be capable of evaluating the merits and risk of its, his or
her investment and have sought such accounting, legal and tax advice as Blocker Seller has considered necessary to make an informed
investment decision. Blocker Seller is an “accredited investor” as defined in Rule 501(a) under the Securities
Act. Blocker Seller and its advisors, if any, have been furnished with all materials relating to the business, finances, and operations
of Parent and materials relating to the offer and sale of the Share Consideration which have been requested by Blocker Seller
or its advisors. Blocker Seller and its advisors, if any, have been afforded the opportunity to ask questions of Parent. Blocker
Seller acknowledges that the book-entry position created in respect of the Share Consideration will bear customary restrictive
legends to reflect that such shares (a) have not been registered under the Securities Act, and (b) are subject to further
contractual restrictions on transfer set forth in Section 8.10 hereof. Accordingly, Blocker Seller understands and
agrees that it will be required to bear, and are capable of bearing, the risk of an investment in the Share Consideration for
an indefinite period.

    20

     

    

 

5.11        No
Additional Representations or Warranties. Except for the representations and warranties contained in this Article V,
neither Blocker nor Blocker Seller nor any other Person on behalf of Blocker or Blocker Seller makes any other express or implied
representation or warranty with respect to Blocker or Blocker Seller or with respect to any other information provided to Parent,
Buyer or their Affiliates.

 

Article VI

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

The Company hereby
represents and warrants to Buyer, Parent and Merger Sub as follows, as of the date hereof and as of the Closing:

 

6.01        Status.
The Company is a limited liability company duly organized, validly existing and in good standing under the Laws of the State of
Delaware. The Company has all requisite limited liability company power and authority to own or lease its properties and assets
and to carry on its business as now being conducted. The Company is legally qualified to transact business as a foreign company
in all jurisdictions where the nature of its properties and the conduct of its business as now conducted require such qualification,
except where the failure to be so qualified would not have a Material Adverse Effect. The Company has made available to the Buyer
correct and complete copies of the LLC Agreement, the Company’s certificate of formation, the operating agreement of each
Subsidiary, and the certificate of formation for each Subsidiary as in effect on the date hereof.

 

6.02        Power
and Authority. The Company has all requisite power and authority to execute and deliver this Agreement and the other Transaction
Documents to which it is a party, to perform its obligations hereunder and thereunder and to consummate the Transactions. All
acts or proceedings required to be taken by the Company applicable to authorize the execution and delivery of this Agreement and
the other Transaction Documents to which it is a party and the performance of the Company’s obligations hereunder and thereunder
have been properly taken, and no other limited liability company proceedings on the part of the Company are necessary to authorize
this Agreement, the Transaction Documents or to consummate the Transactions.

 

6.03        Enforceability.
This Agreement and the other Transaction Documents to which it is a party have been or will be duly authorized, executed and delivered
by the Company and, assuming the due and valid authorization, execution and delivery of this Agreement and the other Transaction
Documents by the other parties hereto and thereto, this Agreement and the other Transaction Documents to which it is a party constitute
or will constitute the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with
its terms, except as the same may be limited by the Bankruptcy and Equity Exceptions.

 

6.04        Capitalization;
Ownership. Schedule 6.04 sets forth the number of issued and outstanding equity securities in the Company and
the holder of record of each such equity securities as of the date hereof. All of the issued and outstanding equity securities
in the Company have been duly authorized and validly issued and are fully paid, and were issued in compliance with all applicable
state and federal securities Laws are owned free and clear of all Liens, and have not been issued in violation of, and are not
subject to, any preemptive or subscription rights except as set forth in the LLC Agreement. There are no outstanding options,
warrants, convertible securities, subscription rights, conversion rights, exchange rights or other agreements that require the
Company to issue or sell any equity securities (or securities convertible into or exchangeable for equity securities). The Company
is not subject to any obligation (contingent or otherwise) to redeem, repurchase or otherwise acquire or retire any of its equity
securities that would survive the Closing.

 

    21

     

    

6.05       Subsidiaries.

 

(a)            Schedule 6.05(a) lists
(i) each Subsidiary of the Company, and (ii) the record and beneficial owner of all issued and outstanding equity securities
in such Subsidiary of the Company, all of which are owned by the Persons set forth on Schedule 6.05(a) free and
clear of all Liens (other than Permitted Liens). All outstanding equity securities of each Subsidiary have been duly authorized
and validly issued and are fully paid. No such equity securities have been issued in violation of preemptive or similar rights.
Except as set forth on Schedule 6.05(a), neither the Company nor its Subsidiaries owns, holds or has the right to acquire
any stock, partnership interest, joint venture interest or other equity ownership interest in any other Person. Except as set forth
in the organizational documents of the Company’s Subsidiaries, there are no outstanding options, warrants, convertible securities,
subscription rights, conversion rights, exchange rights or other agreements that require the Company’s Subsidiaries to issue
or sell any of its equity ownership interests (or securities convertible into or exchangeable for shares of its equity ownership
interests). None of the outstanding equity interests of any Subsidiary was issued in violation of any applicable Laws.

 

(b)            Each
Subsidiary of the Company is validly existing and in good standing under the Laws of its jurisdiction of formation. Each Subsidiary
of the Company has all requisite power and authority to own or lease its properties and assets and to carry on its business as
now being conducted. Each Subsidiary of the Company is legally qualified to transact business as a foreign company in all jurisdictions
where the nature of its properties and the conduct of its business as now conducted require such qualification, except where the
failure to be so qualified would not have a Material Adverse Effect.

 

6.06        No
Violation; Consents and Approvals. Except as set forth on Schedule 6.06, the execution and delivery of this Agreement
and the other Transaction Documents by the Company, and the consummation of the Transactions will not (a) violate any provision
of the organizational documents of the Company or any of its Subsidiaries, (b) violate any Law applicable to, binding upon
or enforceable against the Company or any of its Subsidiaries, (c) result in any material breach of, or constitute a material
default (or an event which would, with the passage of time or the giving of notice or both, constitute a material default) under,
or give rise to a right of payment under or the right to terminate any Material Contract, (d) result in the creation or imposition
of any Lien upon any of the material property or material assets of the Company or any of its Subsidiaries or (e) require
the consent or approval of any Governmental Authority or any other Person, other than compliance with any applicable requirements
of the Hart-Scott-Rodino Act.

 

6.07        Financial
Statements; No Undisclosed Liabilities.

 

(a)            Attached
to Schedule 6.07(a) are copies of (i) the audited consolidated balance sheet of Solara Medical Supplies,
LLC, a California limited liability company, as of December 31, 2018 and the related audited consolidated statements of income
and cash flows for the fiscal year ended December 31, 2018 (the “2018 Year-End Financial Statements”),
(ii) the unaudited consolidated balance sheet of Solara Medical Supplies, LLC, a California limited liability company, as
of December 31, 2019 and the related unaudited consolidated statements of income and cash flows for the fiscal year ended
December 31, 2019 (the “2019 Year-End Financial Statements” and, together with the 2018 Year-End Financial
Statements, the “Year-End Financial Statements”) and (iii) the unaudited consolidated balance sheet
of Solara Medical Supplies, LLC as of April 30, 2020 (the “Latest Balance Sheet”) and the related
unaudited consolidated statements of income and cash flows for the four-month period then ended (collectively, with the Latest
Balance Sheet, the “Interim Financial Statements” and collectively with the Year-End Financial Statements, the
 “Financial Statements”). Except as set forth on Schedule 6.07(a), the Financial Statements fairly
present, in all material respects the financial position and results of operations of the Company and its Subsidiaries, as of the
dates and for the periods referred to therein and have been prepared in accordance with GAAP applied on a consistent basis throughout
the period involved (subject, in the case of the Interim Financial Statements, to the historical past practices of the Company
and its Subsidiaries (including audit adjustments to non-cash items at year-end, which adjustments include goodwill and deferred
Taxes, and the lack of footnote disclosures and other presentation items)). The Financial Statements are based on the books and
records of the Company, and fairly present, in all material respects, the financial condition of the Company for the periods indicated.
The Financial Statements do not misstate, in any material respect, the financial position and results of operations and cash flow
of the Company and its Subsidiaries, as applicable, as of the date thereof, or for the period related thereto, as applicable.

 

    22

     

    

 

(b)            Except
as set forth on Schedule 6.07(b), the Company and its Subsidiaries do not have any liabilities or obligations, except
(i) liabilities accrued on or reserved against in the Latest Balance Sheet or disclosed in the notes to the other Financial
Statements, (ii) liabilities that have arisen since the date of the Latest Balance Sheet in the Ordinary Course of Business,
(iii) liabilities to be included in the computation of Funded Debt outstanding as of immediately prior to the Closing, the
Transaction Expenses Amount or Working Capital, (iv) liabilities disclosed on another section of the Schedules and (v) other
liabilities or obligations which would not result in a Material Adverse Effect.

 

(c)            Except
as set forth on Schedule 6.07(c), the Company and its Subsidiaries have established a system of internal controls over financial
reporting sufficient in all material respects to provide reasonable assurance (in light of the fact that the neither the Company
nor any of its Subsidiaries is subject to the requirements imposed upon a publicly-traded company) (i) regarding the reliability
of its financial reporting and the preparation of its annual financial statements in accordance with GAAP, (ii) that material
receipts and expenditures are being made and material assets are being accounted for only in accordance with the authorization
of its management and directors and GAAP, and (iii) regarding prevention or timely detection of the unauthorized acquisition,
use or disposition of assets. The Company, based on its most recent evaluation of the Company’s internal control over financial
reporting prior to the date hereof, has not identified (i) any significant deficiencies and material weaknesses in the design
or operation of the Company’s internal control over financial reporting which are reasonably likely to adversely affect the
Company’s ability to record, process, summarize and report financial information and (ii) any fraud, whether or not
material, that involves management or other employees who have a significant role in the Company’s internal control over
financial reporting.

 

(d)            All
inventory of the Company and its Subsidiaries is valued on the books and records of the Company in accordance with GAAP in all
material respects and at the lower of cost or net realizable value, based upon the first-in, first out method of accounting, and
consists of a quality and quantity useable and saleable in the ordinary course of business, except for obsolete, damaged, defective
or slow-moving items, all of which have been written off or written down to net realizable value or for which reserves have been
established in accordance with GAAP. All such inventory is owned by the Company or its Subsidiaries free and clear of all Liens
(other than Permitted Liens), and no such inventory is held on a consignment basis.

 

(e)            (i) All
of the accounts and notes receivable of the Company and its Subsidiaries have arisen from bona fide transactions in the ordinary
course of business consistent with past practice and are properly reflected on the Company’s and its Subsidiaries’
books and records and the Financial Statements in accordance with GAAP applied in a manner consistent with the Financial Statements,
(ii) all reserves and allowances have been made on the books of the Company and its Subsidiaries, as applicable, in accordance
with the GAAP applied in a manner consistent with the Financial Statements, (iii) the accounts receivable of the Company and
its Subsidiaries that are reflected on the Latest Balance Sheet represent, as of the date of the Latest Balance Sheet, receivables
arising in the Ordinary Course of Business with third parties from sales actually made or services actually performed, and (iv) no
Person has any lien on such receivables or any part thereof, and no agreement for deduction, free services or goods, discount or
other deferred price or quantity adjustment will have been made with respect to any such receivables as of the Closing.

    23

     

    

 

6.08        Absence
of Certain Developments. Since the date of the Latest Balance Sheet through the date hereof:

 

(a)           the
business of the Company and its Subsidiaries has been conducted in all material respects in the Ordinary Course of Business;

 

(b)           there
has not occurred a Material Adverse Effect; and

 

(c)           except
as set forth on Schedule 6.08, neither the Company nor any of its Subsidiaries has:

 

(i)             issued,
delivered, reissued or sold, disposed or pledged any of its equity securities;

 

(ii)            made
any declaration or payment of any distributions (other than tax distributions) on or in respect of any equity securities in the
Company or any redemption, purchase or acquisition of any of the Company’s outstanding equity securities;

 

(iii)           created,
incurred, assumed or guaranteed any Funded Debt, other than (x) in the Ordinary Course of Business pursuant to the Company’s
existing credit facilities, or (y) pursuant to arrangements solely among or between the Company and one or more of its Subsidiaries;

 

(iv)           sold,
transferred, leased, mortgaged, pledged or otherwise subjected to any Lien (other than Permitted Liens) any material portion
of their assets or property (tangible or intangible), taken as a whole;

 

(v)            entered
into any Contract to make an acquisition (whether by merger, acquisition of stock or assets, or otherwise) of any business
or line of business;

 

(vi)           entered
into any Contract that would constitute a Material Contract except in the Ordinary Course of Business;

 

(vii)          accelerated,
terminated, made any material modification to or cancellation of any Material Contract;

 

(viii)         transferred,
assigned, sold or made any other disposition of any of the properties or assets shown or reflected in the Latest Balance Sheet
or cancellation of any indebtedness owed by third parties except for transactions entered into in the Ordinary Course of Business;

 

(ix)            transferred,
assigned or made any grant of any license or sublicense of any material rights under or with respect to any Intellectual Property
except in the Ordinary Course of Business;

 

(x)            made
any loan to (or forgiveness of any loan to), or entry into any other transaction or Contract with, any of its members, managers,
officers or employees (including any of the Unitholders) or any of their respective Affiliates (other than salaries, wages or benefits
paid in the Ordinary Course of Business);

 

    24

     

    

(xi)            made
any change in the organizational documents of the Company or any of its Subsidiaries;

 

(xii)           made
an election to change the tax classification of the Company or any of its Subsidiaries (as a corporation, partnership or disregarded
entity) for federal, state or local Tax purposes;

 

(xiii)          suffered
any damage, destruction or loss, regardless of whether covered by insurance, with respect to the property and assets of the Company
or any of its Subsidiaries having a replacement cost of more than $150,000;

 

(xiv)         except
in the Ordinary Course of Business as required by applicable Law or pursuant to the Plans or Contracts set forth on Schedule
6.19(a), (A) increased the salary payable or to become payable by it to any of the Company’s or its Subsidiaries’
employees whose base salary is in excess of $100,000, or (B) increased the coverage or benefits available under any severance
pay, termination pay, deferred compensation, bonus or other incentive compensation plan or arrangement;

 

(xv)          adopted
a plan of liquidation, dissolution, merger, consolidation or other reorganization (other than this Agreement);

 

(xvi)         made
a change in its accounting or Tax reporting methods, principles or policies or in cash management policies, including its existing
credit, collection and payment policies, procedures and practices with respect to accounts receivable and accounts payable, including
acceleration of collections, failure to make or delay collections (whether or not past due), acceleration of payments or failure
to pay or delay in payments of payables; and

 

(xvii)        committed
to do any of the foregoing.

 

6.09        Litigation
Recalls; Other Product Issues. Except as set forth on Schedule 6.09, there are no, and for the six years prior
to the date hereof there have not been any, material Proceedings pending or, to the Company’s Knowledge, threatened against
the Company or any of its Subsidiaries, at law or in equity, before or by any Governmental Authority. Neither the Company nor
any of its Subsidiaries is, or during the six years prior to the date hereof has been, subject to any outstanding judgment, order
or decree of any Governmental Authority that relates specifically to the Company or any of its Subsidiaries. During the six years
prior to the date hereof, the Company has not received any written notice of any recall with respect to any product manufactured,
marketed or sold by the Company or its Subsidiaries nor have any such recalls, to the Company’s Knowledge, been threatened.
There are no Proceedings pending or, to the Company’s Knowledge, threatened against the Company or its Subsidiaries with
respect to any product liability with respect to any product manufactured, sold, leased or delivered by the Company.

 

6.10        Environmental
Matters. Except as set forth on Schedule 6.10,

 

(a)            The
Company and its Subsidiaries are in compliance in all material respects with all applicable Environmental Laws. During the six
years prior to the date hereof, neither the Company nor any of its Subsidiaries has been cited, fined or otherwise notified in
writing of any material failure to comply with any material Environmental Laws that has not been paid or cured.

 

    25

     

    

 

 

(b)           The
Company and its Subsidiaries have obtained all material Permits that are required under Environmental Laws for the operation of
their business as currently conducted, which Permits are in full force and effect, and the Company and its Subsidiaries are and
for the six years prior to the date hereof have been in compliance in all material respects with all such Permits.

 

(c)           Neither
the Company nor any of its Subsidiaries has, during the six years prior to the date hereof, received any written notice of any
material liability arising under Environmental Laws, relating to the Company, its Subsidiaries or their facilities, the subject
of which is unresolved.

 

(d)           There
is no Proceeding pending or, to the Company’s Knowledge, threatened against the Company or its Subsidiaries alleging or
asserting any material violation of or material liability pursuant to Environmental Laws.

 

(e)           To
the Company’s Knowledge, the Company and its Subsidiaries have not released any hazardous materials, substances or wastes
at any of the Leased Real Property that currently requires material remediation or other material corrective action by the Company
or its Subsidiaries under Environmental Laws.

 

6.11         Title
to Properties.

 

(a)           The
Company or one of its Subsidiaries has valid title to, or a valid leasehold interest in (or other right to use), all of the tangible
personal property shown to be owned by the Company or one of its Subsidiaries on the Latest Balance Sheet, free and clear of all
Liens (other than Permitted Liens), except for assets disposed of in the Ordinary Course of Business since the date of the Latest
Balance Sheet.

 

(b)           The
Leased Real Property by the Company and its Subsidiaries pursuant to the leases described on Schedule 6.11(b) constitutes
all of the real property leased by, and used by, the Company and its Subsidiaries. Except as set forth on Schedule 6.11(b),
(i) the Company and its Subsidiaries hold a good and valid leasehold interest in all of the Leased Real Property, free
of any Liens (other than Permitted Liens); (ii) the assignment of the Leased Real Property to Buyer pursuant to this Agreement
does not require the consent of any other party to such lease, will not result in a breach or default under such lease, or otherwise
cause such lease to cease to be legal, valid, binding and in full force and effect; and (iii) the Company or Subsidiaries
have not collaterally assigned or granted any other security interest in any Leased Real Property. Each of the leases described
on Schedule 6.11(b) is legal, valid, binding and in full force and effect, subject to proper authorization and
execution of such lease by the other party and the application of any Bankruptcy and Equity Exceptions. The Company has made available
to Buyer true and correct copies of each lease described on Schedule 6.11(b), including all amendments thereto. The
Company’s or Subsidiary’s possession and quiet enjoyment of the Leased Real Property has not been disturbed, and neither
the Company nor any of its Subsidiaries is in default under any lease described on Schedule 6.11(b), and no event
has occurred or circumstance exists which, with the delivery of notice, passage of time or both, would constitute such a breach
or default. The use and occupancy of the Leased Real Property by the Company and its Subsidiaries and the conduct of the business
thereat as presently conducted does not violate in any material respect any applicable Laws (including zoning). To the Company’s
Knowledge, all buildings, structures, facilities and improvements located on the Leased Real Property (i) comply in all material
respects with the certificates of occupancy or similar permits to the extent required by Laws for the use thereof; (ii) conform
in all material respects with all applicable Laws (including but not limited to building codes, setback requirements, zoning laws,
and land use law); and (iii) have received all approvals of governmental authorities (including licenses and permits) required
in connection with the ownership or operation thereof (as applicable) and have been operated and maintained in accordance with
applicable Laws. The buildings, structures, facilities and improvements located on the Leased Real Property are in all material
respects (i) in good operating condition and repair (ordinary wear and tear excepted) and (ii) suitable and adequate
for continued use in the manner in which they are presently being used. Except with respect to the sublease referenced in Schedule
6.11(b), there are no parties (other than the Company and its Subsidiaries) in possession of the Leased Real Property. All
facilities located on the Leased Real Property are supplied with utilities and other services necessary for the operation of such
facilities, including gas, electricity, water, sanitary sewer, and storm sewer, all of which services are adequate in all material
respects to operate such facilities.

 

    26

     

    

 

(c)            The
Company does not own any real property.

 

6.12         Compliance
with Laws. The Company and its Subsidiaries are in compliance in all material respects with all applicable Laws and Healthcare-Related
Laws. During the three years prior to the date hereof, neither the Company nor any of its Subsidiaries have been cited, fined
or otherwise notified of any failure to comply with any Laws or Healthcare-Related Laws that has not been paid or cured. To the
Company’s Knowledge, no investigation by any Governmental Authority with respect to the Company or any of its Subsidiaries
is pending or expressly threatened.

 

6.13         Labor
and Employment Matters. 

 

(a)           Except
as set forth on Schedule 6.13(a), the Company and its Subsidiaries, as applicable, are, and for the three years prior to
the date hereof have been, in compliance in all respects with all applicable Laws relating to employment and employment practices,
including all Laws relating to labor relations, equal employment opportunities, fair employment practices, discrimination, harassment,
retaliation, reasonable accommodation, disability rights or benefits, immigration, wages, hours, overtime compensation, child
labor, hiring, promotion, termination of employment, working conditions, meal and break periods, privacy, health and safety, workers’
compensation, leaves of absence, paid sick leave and unemployment insurance. Except as would not result in material liability,
(i) all individuals characterized by the Company and/or its Subsidiaries as independent contractors or consultants are properly
treated as independent contractors under applicable Laws and (ii) all employees of the Company and/or its Subsidiaries who
are classified as exempt under the Fair Labor Standards Act and state and local wage and hour laws are properly classified under
applicable Laws. The Company and its Subsidiaries are in compliance with and for the last three years have complied in all material
respects with all applicable immigration laws, including Form I-9 requirements and any applicable mandatory E-Verify obligations.

 

(b)           Except
as set forth on Schedule 6.13(b), there are no lawsuits, actions, charges, governmental audits, investigations, administrative
proceedings, or complaints concerning the Company’s or its Subsidiaries’ employment practices pending, or to the Company’s
Knowledge, threatened to be brought or filed against the Company, by or with any Governmental Authority or arbitrator in connection
with any current or former applicant, employee, consultant or individual independent contractor of any of the Company or its Subsidiaries.

 

(c)           Schedule
6.13(c) hereto contains a true and accurate list of the Company’s and its Subsidiaries’ employees as of the
date hereof, together with each such person’s name, date of hire, title or job position, exempt/non-exempt classification
or status as an independent contractor or consultant, current hourly wage or salary, and full-time or part-time status. The Company
and its Subsidiaries have paid or made provision for the payment of wages and any other forms of compensation for all employees,
independent contractors, and consultants required to be paid through the date hereof.

 

(d)          Except
as set forth on Schedule 6.13(d), to the Company’s Knowledge, no employee, independent contractor, or consultant
of the Company or its Subsidiaries is party to any non-compete, nondisclosure, confidentiality, employment, consulting, or similar
restrictive covenant with a third party in material conflict with the Company’s present business activities, and the Company
and its Subsidiaries have not received any written notice alleging that any violation of such restrictive covenants has occurred
in the last three years.

 

    27

     

    

 

(e)           The
Company and its Subsidiaries are not, and have never been, a party to, bound by, or negotiating any collective bargaining agreement
or other Contract with a union, works council or labor organization (collectively, “Union”), and to the Company’s
Knowledge, there is not, nor has there been in the last three years, any Union representing or purporting to represent any employee
of the Company or its Subsidiaries, and no Union or group of employees is seeking or in the last three years has sought to organize
employees for the purpose of collective bargaining. There is not, nor has there been in the last three years any threat of, any
strike, slowdown, work stoppage, lockout, concerted refusal to work overtime or other similar material labor disruption or material
dispute against the Company or its Subsidiaries or any of their employees. To the Company’s Knowledge, the Company and its
Subsidiaries have no duty to bargain with any Union.

 

(f)            Except
as indicated on Schedule 6.13(f), no current employee, to the Company’s Knowledge, has indicated to the Company or
its Subsidiaries that he or she intends to terminate his or her employment or seek a material change in his or her duties or status
in the six month period following the Closing. Except as provided in Schedule 6.13(f) and Schedule 6.14(a),
all employees of the Company and its Subsidiaries are terminable at will without any penalty or severance obligation on the part
of the Company.

 

6.14         Employee
Benefit Plans.

 

(a)           Schedule 6.14(a) sets
forth a list as of the date hereof of all material Plans. For the purposes of this Agreement, “Plans” means
any employee benefit plan as such term is defined in Section 3(3) of ERISA (whether or not subject to ERISA), and each
other bonus, pension, profit sharing, executive compensation, deferred compensation, incentive compensation, stock compensation,
stock purchase, stock option, stock appreciation, phantom stock option, employment agreement, pension, retirement, vacation, holiday,
paid time off, cafeteria, fringe benefit, health or other medical, dental, life, disability or other welfare benefit insurance
plan, program, agreement or arrangement, whether written or unwritten, sponsored, maintained or contributed to or required to
be contributed to by the Company and its Subsidiaries for the benefit of their employees or former employees and their dependents
or beneficiaries, or for which Blocker, the Company and its Subsidiaries has or may have any liability other than any plan, program,
policy, practice, contract, agreement or arrangement established pursuant to statute or sponsored or maintained by a Governmental
Authority.

 

(b)           Each
of the Plans that is intended to be qualified under Section 401(a) of the Code has either received a favorable determination
letter from the Internal Revenue Service or is a prototype plan that is subject to a favorable opinion letter from the Internal
Revenue Service and, to the Company’s Knowledge, nothing has occurred that would reasonably be expected to adversely affect
the qualification of such Plan. The Plans comply in form and in operation, and have been established, maintained, funded and administered
in all material respects, with the requirements of the Code, ERISA and all applicable Laws.

 

(c)           With
respect to the Plans, all required contributions have been timely made or properly accrued on the most recent consolidated balance
sheet filed or incorporated by reference in the Company’s or its Subsidiaries’ financial statements prior to the date
of this Agreement. With respect to each Plan, all tax, annual reporting and other governmental filings required by ERISA and the
Code have been timely filed with the appropriate Governmental Authority and all notices and disclosures have been timely provided
to participants.

 

    28

     

    

 

(d)           Except
as set forth on Schedule 6.14(d), the Company has made available to Buyer true and correct copies of (as applicable with
respect to the Plans set forth on Schedule 6.14(a)): (i) Plan documents (and if not written, a summary of its
material terms), including all amendments and related trust agreements, insurance contracts or other funding vehicles and all
amendments thereto, (ii) the three most recent annual Form 5500 report filed with the Department of Labor and all schedules
and attachments thereto, (iii) the latest financial statements for the Plans, (iv) the most recent summary plan description
(as well as any modifications or amendments thereto), (v) the most recent actuarial reports or other financial statement
relating to such Plan, (vi) the most recent determination or opinion letter, if any, issued by the Internal Revenue Service
and any pending request for such a letter, (vii) the most recent nondiscrimination tests performed under the Code, (viii) all
non-routine filings made with any Governmental Authority in the past six (6) years, including but not limited to any filings
under the Employee Plans Compliance Resolution System or the Department of Labor Delinquent Filer Program, and (ix) all Forms
1094-C and 1095-C for all calendar years beginning in 2018, or evidence that the full tax penalty liability for calendar years
2016 and 2017 has been assessed, paid and satisfied by the Company, as required under the Patient Protection and Affordable Care
Act of 2010 (“PPACA”).

 

(e)           No
Plan is and the Company and its Subsidiaries do not maintain or have maintained, and are not required to contribute to participate
in or have any liability or obligation (including on account of any ERISA Affiliate), whether actual or contingent, under or with
respect to: (i) any defined benefit pension plan or any plan, program or arrangement that is or was subject to Title IV or
Section 302 of ERISA, (ii) any Multiemployer Plan (as defined in Section 4001(a)(3) of ERISA), (iii) any
 “plan maintained by more than one employer” (within the meaning of Section 413(c) of the Code), or (iv) any
multiple employer welfare arrangement (within the meaning of Section 3(40) of ERISA).

 

(f)           No
Plan is a voluntary employees’ beneficiary association under Section 501(c)(9) of the Code. The Company, its Subsidiaries,
and each ERISA Affiliate are in compliance in all material respects with (i) the requirements of the applicable health care
continuation and notice provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, and the regulations (including
proposed regulations) thereunder, Section 4980B of the Code and any similar state Law (“COBRA”), (ii) the
applicable requirements of HIPAA and the regulations (including the proposed regulations) thereunder and (iii) the applicable
requirements of the PPACA. No Plan provides, and none of the Company, any of its Subsidiaries, or any ERISA Affiliate has any
liability to provide post-employment or post-service health, life or other welfare benefits for anyone other than as required
by COBRA or similar state law for which the covered individual pays the full cost of coverage.

 

(g)           No
Proceeding, including any audit or inquiry by the Internal Revenue Service, United States Department of Labor or any other Governmental
Authority, is pending with respect to any Plan or the administration or the investment of the assets of any such Plan (other than
routine undisputed claims for benefits), or, to Company’s Knowledge, threatened. Neither the Company nor any of its Subsidiaries
or any current or former employee, officer or director has engaged in, and, to the Knowledge of the Company, there has otherwise
been no, prohibited transaction (within the meaning of Section 406 of ERISA or Section 4975 of the Code and other than
a transaction that is exempt under a statutory or administrative exemption) or breach of fiduciary duty (as determined under ERISA)
with respect to any Plan that would result in liability to the Company or any of its Subsidiaries.

 

(h)           Each
Plan that constitutes a “nonqualified deferred compensation plan” (as defined under Section 409A(d)(1) of
the Code) subject to Section 409A of the Code has been operated and administered in all respects in compliance with Section 409A
of the Code. Neither the Company nor any of its Subsidiaries have any obligation to “gross-up” or otherwise indemnify
any individual for the imposition of the excise tax under Section 4999 of the Code or under Section 409A of the Code.

 

    29

     

    

 

(i)            No
payment or benefit which could be made with respect to any current or former employee, officer, stockholder, director or service
provider of the Company or its Subsidiaries who is a “disqualified individual” (as defined in Section 280G of
the Code and the regulations thereunder) could be characterized as a “parachute payment” within the meaning of Section 280G(b)(2) of
the Code.

 

(j)            Neither
the execution of this Agreement nor the consummation of the Transactions, will (i) result in any payment becoming due to
any current or former employee, director, or consultant of the Company or any of its Subsidiaries, (ii) increase any compensation
or benefits otherwise payable under any Plan, or (iii) accelerate the time of payment, funding, or vesting, or increase the
amount of benefits due to any current or former employee, director or consultant of the Company or any of its Subsidiaries under
any Plan.

 

6.15         Tax
Matters.

 

(a)           The
Company and its Subsidiaries have timely filed all Tax Returns that are required to be filed by them (taking into account any
extensions of time to file). All Taxes shown as owing by the Company and its Subsidiaries on all such Tax Returns have been fully
and timely paid or properly accrued, and all such Tax Returns are true and correct in all respects and do not contain a disclosure
statement under Section 6662 of the Code or any predecessor provision or comparable provision of applicable Law.

 

(b)           All
Taxes that the Company or any of its Subsidiaries is obligated to withhold from amounts owing to any employee, creditor or third
party have been fully paid (or remitted, as applicable) or properly accrued.

 

(c)           No
claim has been made in the six years prior to the date hereof by any Taxing Authority in any jurisdiction where either Company
or any of its Subsidiaries does not file Tax Returns that it is or may be subject to Tax by that jurisdiction nor is there any
factual basis for such a claim.

 

(d)           Neither
Company nor its Subsidiaries has filed, nor is Company or any of its Subsidiaries required to have filed, a disclosure schedule
pursuant to Temp. Treas. Reg. § 1.6011-4T. Blocker is and has been in compliance with all applicable material Laws pertaining
to Taxes, including all applicable material Laws relating to record retention.

 

(e)           Neither
the Company nor any of its Subsidiaries is currently or has been a party to any Tax allocation, Tax sharing, Tax indemnity, Tax
reimbursement agreement or arrangement (other than (i) any customary agreements with customers, vendors, lenders, lessors
or the like entered into in the Ordinary Course of Business, (ii) property Taxes payable with respect to any properties leased,
and (iii) other agreements for which Taxes are not the principal subject matter).

 

(f)           Neither
the Company nor its Subsidiaries is currently the subject of any audit or other examination of any Taxes by the Taxing Authorities
with respect to any open Tax years and, to the Company’s Knowledge, no such audit or other examination is contemplated or
pending. Neither the Company nor its Subsidiaries has waived any statute of limitations in respect of any Taxes payable by any
of them, which waiver is currently in effect. Neither the Company nor its Subsidiaries have agreed to any extension of time with
respect to a Tax assessment or deficiency, which period (after giving effect to such extension or waiver) has not yet expired.
Neither Company nor its Subsidiaries is a party to or bound by any closing agreement or offer in compromise with any Taxing Authority.

 

(g)           There
are no Liens for Taxes (other than Permitted Liens) upon any of the assets of the Company or any of its Subsidiaries.

 

    30

     

    

 

(h)            Neither
the Company nor its Subsidiaries has any liability for Taxes of any Person other than such Company and its Subsidiaries under
Treasury Regulations Section 1.1502-6 or any corresponding provision of state, local or foreign income Laws pertaining to
Taxes, as transferee or successor, by contract or otherwise (other than (i) any customary agreements with customers, vendors,
lenders, lessors or the like entered into in the Ordinary Course of Business, (ii) property Taxes payable with respect to
any properties leased, and (iii) other agreements for which Taxes are not the principal subject matter). Neither the Company
nor its Subsidiaries has made a consent dividend election under Section 565 of the Code. Neither the Company nor its Subsidiaries
has been a personal holding company under Section 542 of the Code.

 

(i)            Neither
the Company nor its Subsidiaries will be required to include any item of income in, or exclude any item of deduction from, taxable
income for any taxable period (or portion thereof) beginning after the Closing Date as a result of any (i) change in method
of accounting for a taxable period ending on or prior to the Closing Date, (ii) installment sale or open transaction disposition
made on or prior to the Closing, (iii) “closing agreement” as described in Section 7121 of the Code (or
any corresponding or similar provision of state, local or non-U.S. income Laws pertaining to Taxes) executed prior to the Closing,
(iv) intercompany transaction or excess loss account described in Treasury Regulations under Section 1502 of the Code
(or any corresponding or similar provision of state, local or foreign Laws pertaining to Taxes), (v) prepaid amount or advance
payment received outside of the Ordinary Course of Business on or prior to the Closing, or (vi) election under Section 108(i) of
the Code.

 

(j)            Neither
the Company nor its Subsidiaries is a party to any joint venture, partnership, or other arrangement or Contract that could be
treated as a partnership for federal income tax purposes.

 

(k)            None
of the assets of either the Company or any of its Subsidiaries is property that such Company or such Subsidiary is required to
treat as being owned by any other Person pursuant to the so-called “safe harbor lease” provisions of former Section 168(f)(8) of
the Internal Revenue Code of 1954, as amended. None of the assets of either Company or any of its Subsidiaries directly or indirectly
secures any debt the interest on which is tax exempt under Section 103(a) of the Code. None of the assets of either
Company or any of its Subsidiaries is “tax-exempt use property” within the meaning of Section 168(h) of
the Code. None of the assets of either Company or any of its Subsidiaries is required to be or is being depreciated pursuant to
the alternative depreciation system under Section 168(g)(2) of the Code.

 

(l)            Neither
the Company nor its Subsidiaries has agreed to make, nor is it required to make, any adjustment under Sections 481(a) or
263A of the Code or any comparable provision of state, local or foreign Laws pertaining to Taxes by reason of a change in accounting
method or otherwise. Each of the Company and its Subsidiaries has at all times used the accrual method of accounting for income
Tax purposes.

 

(m)           Neither
the Company nor its Subsidiaries is a party to any Contract or plan that has resulted or would result, separately or in the aggregate,
in connection with this Agreement or any change of control of such Company or its Subsidiaries, in the payment of any “excess
parachute payments” within the meaning of Section 280G of the Code.

 

(n)           Neither
the Company nor its Subsidiaries has a “permanent establishment” in any foreign country, as defined in any applicable
Tax treaty or convention between the United States of America and such foreign country, or has otherwise taken steps or conducted
business operations that may reasonably be expected to cause it to be subject to the income taxing jurisdiction of a foreign country
by virtue of such steps or conduct.

 

    31

     

    

 

(o)           Neither
the Company nor its Subsidiaries has entered into a gain recognition agreement pursuant to Treas. Reg. § 1.367(a)-8.
Neither the Company nor its Subsidiaries has transferred an intangible the transfer of which would be subject to the rules of
Section 367(d) of the Code.

 

(p)           None
of the assets of either the Company or any of its Subsidiaries are currently escheatable to any Governmental Authority under any
applicable escheatment Laws. Each of the Company and its Subsidiaries have (i) filed or caused to be filed with the appropriate
Governmental Authority all unclaimed property reports required to be filed and has remitted to the appropriate Governmental Authority
all unclaimed property required to be remitted, or (ii) delivered or paid all unclaimed property to its original or proper
recipient.

 

(q)           Neither
the Company nor its Subsidiaries have executed or entered into any ruling or agreement with any Taxing Authority, in each case,
that will have continuing effect after the Closing Date, or agreed with any Taxing Authority to make any adjustment to its income
or deductions pursuant to a change in its method of accounting.

 

(r)           Neither
the Company nor its Subsidiaries have participated in an international boycott within the meaning of Section 999 of the Code.

 

(s)           Neither
the Company nor its Subsidiaries has been a party to any “reportable transaction,” as defined in Section 6707A(c)(1) of
the Code or Treasury Regulation Section 1.6011-4(b).

 

(t)            Neither
the Company nor its Subsidiaries have been a party to any “listed transaction” as defined in Section 6707A(c)(2) of
the Code or Treasury Regulation Section 1.6011-4(b)(2).

 

(u)           Neither
the Company nor its Subsidiaries have at any time held directly, indirectly, or constructively shares of any “passive foreign
investment company” as that term has been defined from time to time in Section 1296 or 1297 of the Code.

 

(v)           Neither
the Company nor any of its Subsidiaries is a party to any Tax exemption, Tax holiday or other Tax reduction agreement.

 

(w)          No
power of attorney has been granted by or with respect to either the Company or its Subsidiaries with respect to any matter relating
to Taxes that has not been cancelled prior to the Closing.

 

(x)            Each
of the Company and its Subsidiaries have properly collected and remitted sales and similar taxes with respect to sales.

 

(y)           For
all sales that are exempt from sales and similar taxes and that were made without charging or remitting sales or similar taxes,
each Company and its Subsidiaries have received and retained any appropriate tax exemption certificates and other documentation
qualifying such sale as exempt.

 

(z)           Each
of the Company and its Subsidiaries is, and has been since its formation, properly treated as either a “partnership”
or “disregarded entity” for U.S. federal income Tax purposes and no election has been made pursuant to Treasury Regulation
Section 301.7701-3(c) to treat the Company or any of its Subsidiaries as an association taxable as a corporation for
U.S. federal income Tax purposes.

 

6.16         Insurance. Schedule 6.16 lists
each insurance policy in effect as of the date hereof that is maintained by the Company and its Subsidiaries, including the
name of the insurer and policy number (the “Insurance Policies”). The Insurance Policies are in full force
and effect, to the Company’s Knowledge no application therefor included a material misstatement or omission, all
premiums due thereon have been paid, and, to the Company’s Knowledge, neither the Company nor any of its Subsidiaries
is in breach or default thereunder. Except as set forth on Schedule 6.16, neither the Company nor its
Subsidiaries has any self-insurance or co-insurance programs. No written notice of cancellation, termination or reduction of
coverage has been received with respect to any such policy. No claim currently is pending under any such policy involving an
amount in excess of $100,000.00. The activities and operations of the Company and its Subsidiaries have been conducted in a
manner so as to conform in all material respects to all applicable provisions of such insurance policies. The consummation of
the Transactions will not cause a cancellation or reduction in the coverage of such policies.

 

    32

     

    

 

6.17         Licenses
and Permits. The Company and its Subsidiaries possess all licenses, permits, registrations and approvals issued by a Governmental
Authority, including health care permits required under any Healthcare-Related Law that are necessary to the operation of their
business as currently conducted (collectively, the “Permits”), and all such Permits are in full force and effect.
There are no other such Permits which are material to the Company, which the Company has not obtained or which in good industry
practice the Company should hold for the conduct of the business. Except as set forth on Schedule 6.17, each Permit is
valid and in full force and effect, and, during the three years prior to the date hereof, no provision, condition, or limitation
of any Permit has been breached or violated. There are no changes in the circumstances under which any Permit was obtained that
would result in its termination, suspension, modification or limitation. The Company is not in default, nor has it received any
written notice of, nor is there, to the Company’s Knowledge, any claim or threatened claim of default, with respect to any
such Permit. Neither the Company nor any of its Subsidiaries is in default or violation under any of the Permits. There are no
Proceedings pending or, to the Company’s Knowledge, expressly threatened in writing relating to the suspension, revocation
or material and adverse modification of any of the Permits. No loss or expiration of any Permit is pending or scheduled within
the next twelve months except with respect to Permits the Company intends to renew in the Ordinary Course of Business nor is any
loss or expiration of any Permit threatened or reasonably foreseeable. The Permits are in full force and the consummation of the
Transactions will not itself cause the termination of such Permits, except to the extent such Permits will be terminated and new
Permits of substantially the same type will be issued by the applicable Governmental Authorities.

 

6.18         Affiliated
Transactions. Except as set forth on Schedule 6.18, no Unitholder or Affiliate of a Unitholder, or any
officer, director or senior management-level employee of the Company or any of its Subsidiaries or, to the Company’s
Knowledge, any Affiliate or immediate family member of any such officer, director or senior management-level employee
(a) is a party to any agreement or transaction with the Company or its Subsidiaries, other than (i) loans and other
extensions of credit to officers, directors and employees of the Company and its Subsidiaries for travel, business or
relocation expenses or other employment-related purposes in the ordinary course, (ii) customary employment arrangements
in the Ordinary Course of Business and (iii) the Plans or (b) has any material interest or right in any material
asset, property or right, tangible or intangible, used by the Company or any of its Subsidiaries.

 

6.19         Material
Contracts.

 

(a)           Schedule 6.19(a) sets
forth a list of all Contracts in effect as of the date hereof to which the Company or any of its Subsidiaries is a party or by
which the Company or any of its Subsidiaries is bound, meeting any of the descriptions set forth below (collectively referred
to herein as the “Material Contracts”):

 

(i)            all
Contracts relating to any completed material business acquisition by the Company or any of its Subsidiaries;

 

    33

     

    

 

(ii)           all
collective bargaining agreements with any labor union;

 

(iii)            all
Contracts for the employment of any current officer, employee of the Company or any of its Subsidiaries person with annual base
salary in excess of $350,000;

 

(iv)          all
Contracts for Funded Debt and all guarantees of any obligation for Funded Debt;

 

(v)          all
Contracts under which the Company or any of its Subsidiaries is lessee of, or holds or operates, any personal property owned by
any other party, for which the annual rental exceeds $250,000 and that are not terminable by the Company or such Subsidiary upon
notice of sixty days or fewer;

 

(vi)         all
Contracts under which the Company or any of its Subsidiaries is lessor of, or permits any third party to hold or operate, any
personal property;

 

(vii)        contracts
regarding the licensing, ownership, development or use of any material Intellectual Property (except for “shrink-wrap”
or “click-through” license agreements pertaining to software that is available in consumer retail stores or otherwise
commercially available where the aggregate value of all licenses of the same or substantially identical software is less than
$250,000);

 

(viii)       all
Contracts that prohibit the Company or any of its Subsidiaries from freely engaging in business or competing with any Person anywhere
in the world (other than non-disclosure agreements and customer contracts entered into in the Ordinary Course of Business that
contain non-solicitation obligations);

 

(ix)          all
Contracts relating to joint ventures, partnerships, profit sharing or similar arrangements;

 

(x)           all
Contracts with Key Suppliers and Key Customers;

 

(xi)           any
Contract granting any Person a Lien on all or any material portion of the assets of the Company or its Subsidiaries other than
Permitted Liens;

 

(xii)         all
Contracts that provide for the indemnification by the Company of any Person or the assumption of any Tax, environmental or other
liabilities or obligations of any Person;

 

(xiii)        all
Contracts between or among the Company or a Subsidiary on the one hand and a Unitholder or any Affiliate of a Unitholder (other
than the Company) on the other hand (other than employment-related agreements entered into in the Ordinary Course of Business);

 

(xiv)       Contracts
with a Third Party Payor involving the payment of amounts in excess of $50,000 in any year; and

 

(xv)         all
agreements involving any resolution or settlement of any actual or threatened Proceeding and providing for payments by the Company
or its Subsidiaries after the date hereof in excess of $250,000 or any material ongoing requirements or restrictions on the Company
or its Subsidiaries.

 

    34

     

    

 

(b)          Except
as set forth on Schedule 6.19(b), the Company has made available to Buyer a true and correct copy of all written Material
Contracts, together with all amendments thereto. Neither the Company nor any of its Subsidiaries nor, to the Company’s Knowledge,
any other party to any Material Contract is in breach of, or in default under, any Material Contract. Each Material Contract is
a valid, binding and enforceable obligation of the Company and its Subsidiaries and, to the Company’s Knowledge, each of
the other parties thereto, except as enforceability may be limited by the Bankruptcy and Equity Exceptions, and is in full force
and effect. As of the date of this Agreement, no party to any Material Contract has given written notice to the Company or any
of its Subsidiaries of its intention to cancel or otherwise terminate any such agreement. No Material Contract requires the consent
of any party thereto in connection with the consummation of the Transactions. No event or circumstance has occurred that, with
notice or lapse of time or both, would constitute an event of default under any Material Contract or result in a termination thereof
or would cause or permit the acceleration or other changes of any right or obligation or the loss of any benefit thereunder.

 

6.20         Intellectual
Property. Schedule 6.20 sets forth a complete list of all registered Intellectual Property and applications therefor
owned by the Company and its Subsidiaries as of the date hereof. Except as set forth in Schedule 6.20, (a) the
Company or its Subsidiaries exclusively own all right, title, and interest in and to the Intellectual Property set forth on Schedule 6.20,
free and clear of all Liens other than Permitted Liens; (b) the Company and its Subsidiaries own, or possess the right to
use, all Intellectual Property used in the operation of the businesses of the Company and its Subsidiaries as currently conducted;
(c) to the Company’s Knowledge, the Company and its Subsidiaries (i) are not infringing, misappropriating, or
otherwise violating of the Intellectual Property of any third party, (ii) in the three years prior to the date hereof have
not infringed, misappropriated, or otherwise violated, the Intellectual Property of any third party, and (iii) have not,
in the three years prior to the date hereof received any written notices from any third party alleging material infringement or
misappropriation of such third party’s Intellectual Property by the Company or any of its Subsidiaries, and (d) to
the Company’s Knowledge, as of the date hereof, no third party is infringing or misappropriating any material Intellectual
Property owned by the Company or any of its Subsidiaries.

 

6.21        Data
Privacy and Security. The Company and its Subsidiaries are in compliance in all material respects with all applicable
data privacy and data security Laws. Except as set forth on Schedule 6.21, to the Company’s Knowledge, during
the three years prior to the date hereof neither the Company nor its Subsidiaries has been subject to any breach of security
whereby personally identifiable information in the possession of the Company or its Subsidiaries was disclosed or exfiltrated
in a manner that requires notice to affected individuals under applicable data privacy and data security Laws.

 

6.22         Key
Customers and Suppliers. 

 

(a)            Schedule 6.22(a) lists
the top fifteen customers by dollar amount of attributable revenue of the Company and its Subsidiaries (on a consolidated basis) for
the twelve-month period ended December 31, 2019 (each, a “Key Customer”). None of the Key Customers has
(i) terminated or given notice to the Company or its Subsidiaries evidencing its intention to terminate its relationship
with the Company or its Subsidiaries, or (ii) given notice to the Company or its Subsidiaries evidencing that it plans to
materially reduce the quantity of products or services that it purchases from the Company or its Subsidiaries.

 

(b)           Schedule 6.22(b) lists
the top fifteen suppliers by dollar sales volume of the Company and its Subsidiaries (on a consolidated basis) for the twelve-month
period ended December 31, 2019 (each, a “Key Supplier”). None of the Key Suppliers has (i) terminated
or given notice to the Company or its Subsidiaries evidencing its intention to terminate its relationship with the Company or
its Subsidiaries, or (ii) given notice to the Company or its Subsidiaries evidencing that it plans to materially reduce the
quantity of products or services that it provides to the Company or its Subsidiaries.

 

    35

     

    

 

6.23         No
Brokers. Except for the fees payable to Robert W. Baird & Co. Incorporated, neither the Company nor any of its Subsidiaries
has incurred any obligation for any finder’s or broker’s or agent’s fees or commissions or similar compensation
in connection with the Transactions.

 

6.24        Condition
and Sufficiency of Assets. The buildings, plants, structures, furniture, fixtures, machinery, equipment, vehicles and
other items of tangible personal property of the Company and its Subsidiaries are structurally sound, are in good operating
condition and repair (subject to ordinary course wear and tear), and are adequate for the uses to which they are being put,
and none of such buildings, plants, structures, furniture, fixtures, machinery, equipment, vehicles and other items of
tangible personal property is in need of maintenance or repairs except for ordinary, routine maintenance and repairs that are
not material in nature or cost. The buildings, plants, structures, furniture, fixtures, machinery, equipment, vehicles and
other items of tangible personal property currently owned or leased by the Company and its Subsidiaries, together with all
other properties and assets of the Company and its Subsidiaries, are sufficient for the continued conduct of the
Company’s business after the Closing in substantially the same manner as conducted prior to the Closing and constitute
all of the rights, property and assets necessary to conduct the business of the Company as currently conducted.

 

6.25         Health
Care Compliance.

 

(a)           Schedule
6.25(a) sets forth all of the Company’s and its Subsidiaries’ Federal Health Care Program and Third Party
Payor provider or supplier numbers, National Provider Identifier Numbers, Provider Transaction Access Numbers, and Federal Tax
Identification Numbers linked to such number(s ) (“Provider Identification Number(s)”), all of which are current
and valid and the Company or its Subsidiaries have not allowed, permitted, authorized or caused any other person or entity to
use any such Provider Identification Number. All such Provider Identification Numbers are in full force and effect and, to the
Company’s Knowledge, there is no basis for any breach thereof by the Company. The Company and its Subsidiaries are in compliance
with the Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies (“DMEPOS”) Supplier Standards
listed in 42 C.F.R. 424.57(c) and the DMEPOS Quality Standards established by CMS under the Medicare Modernization Act of
2003 and any conditions of credentialing, enrollment or participation requirements established by any Third Party Payor. The Company
and its Subsidiaries have received all approvals or qualifications necessary for reimbursement for services and products provided
by the Company and its Subsidiaries to Medicare and Medicaid or any other Federal Health Care Program beneficiaries. Except as
set forth on Schedule 6.25(a), the Company and its Subsidiaries have not been notified in writing by any Governmental Authority
or other Person during the immediately preceding twelve-month period that such license, Permit, certificate, authorization, accreditation,
approval or that penalties or other disciplinary action has been, is threatened to, or will be assessed or taken against the Company
or its Subsidiaries by any Governmental Authority. To the Company’s Knowledge, no basis exists for the denial of applications
for Medicare and Medicaid contracting or participation including any participation with any Medicare Advantage Plan (as defined
under 42 C.F.R § 422.2) or any Medicaid Managed Care Plan (as defined under 42 C.F.R § 438.2).

 

(b)           Except
as disclosed on Schedule 6.25(b), no audit or investigation whether conducted internally, by third parties or at the discretion
of any Governmental Authority or Third Party Payor, other than audits conducted in the ordinary course, has resulted in any determination
that the Company or any of its Subsidiaries was overpaid in any of the most recent three fiscal years in excess of $50,000 covered
by such audit or investigation. The Company and its Subsidiaries has no liability to any payor, including Medicare, Medicaid,
any Medicare Advantage Plan or any Medicare Managed Care Plan or Third Party Payor in excess of $50,000, and no deductions, disallowances,
recoupments, offsets, or repayment obligations directly or indirectly under or in connection with the Medicaid or Medicare programs
or any other Federal Health Care Programs or Third Party Payor, nor are there any facts which could cause any such deductions,
disallowances, recoupments, offsets, or repayment obligations to arise in the future with respect to operations prior to the Closing
Date.

 

    36

     

    

 

(c)           Schedule
6.25(c) sets forth all of the Company’s and its Subsidiaries’ Medicare DMEPOS supplier numbers and accreditations.
The Company is and has been continuously enrolled as a Medicare DMEPOS supplier at all times since the date of enrollment with
Medicare as a DMEPOS supplier. The Company is and has been accredited by the accrediting bodies identified in Schedule 6.25(c) at
all times since the date of accreditation.

 

(d)           Except
as disclosed in Schedule 6.25(d), the Company, its Subsidiaries, each Unitholder, and all Company and Subsidiary officers,
managers, directors and employees and other Persons who provide professional services to patients of the Company or the Subsidiaries,
has been and are in compliance with Medicare, Medicaid and any other Federal Health Care Program statutes, as amended, and the
regulations, guidance and conditions of participation promulgated thereunder or related state and local statutes, regulations
and rules of professional conduct. Except as disclosed in Schedule 6.25(d), the Company, its Subsidiaries, each Unitholder,
and all Company and Subsidiary officers, managers, directors and employees and other Persons who provide professional services
to patients of the Company or the Subsidiaries, have not at any time:

 

(i)            knowingly and willfully made or caused to be a false statement or representation of a material fact in any
application for any benefit or payment to any Federal Health Care Program or Third Party Payor;

 

(ii)           knowingly
and willfully made or caused to be a false statement or representation of a material fact for use in determining rights to any
benefit or payment from any Federal Health Care Program or Third Party Payor;

 

(iii)          directly
or indirectly presented or caused to be presented a claim for reimbursement for services under Medicare or Medicaid, or other
state or Federal Health Care Programs or any Third Party Payor that is for an item or service that is known or should be known
to be (A) not provided as claimed, or (B) false or fraudulent;

 

(iv)          failed
to disclose knowledge by a claimant of the occurrence of any event affecting the initial or continued right to any benefit or
payment on its own behalf or on behalf of another, with intent fraudulently to secure such benefit or payment from any Federal
Health Care Program or Third Party Payor;

 

(v)           knowingly
and willfully offered, paid, solicited or received any remuneration (including any kickback, bribe, or rebate), directly or indirectly,
overtly or covertly, in cash or in kind (A) in return for referring an individual to a Person for the furnishing or arranging
for the furnishing of any item or service for which payment may be made in whole or in part by Medicare or Medicaid, or other
state or Federal Health Care Programs, or (B) in return for purchasing, leasing, ordering or arranging for or recommending
purchasing, leasing or ordering any good, facility, service, or item for which payment may be made in whole or in part by Medicare,
Medicaid or other state or Federal Health Care Programs;

 

(vi)          offered
or transferred any remuneration to any individual eligible for benefits under Medicare, Medicaid or other state or Federal Health
Care Program that such person knew or should have known would be likely to influence such individual to order or receive any item
or service from the Company for which payment may be made, in whole or in part by Medicare, Medicaid or other state or Federal
Health Care Programs;

 

    37

     

    

 

(vii)         knowingly
made a payment, directly or indirectly, to a physician as an inducement to refer individuals who are under the direct or indirect
care of the physician and who are entitled to benefits under Medicare, Medicaid, Third Party Payors or other state or Federal
Health Care Programs;

 

(viii)        knowingly
and willfully (A) charged and been paid a rate in excess of the rates established by a Federal Health Care Program including
any rates established as part of the Medicare Competitive Bidding Program, as applicable, or (B) for services covered in
whole or in part by Medicare or Medicaid, charged, solicited, accepted or received, in addition to amounts paid by Medicare or
Medicaid, any gift, money, donation or other consideration as a precondition of treating the patient, or as a requirement for
the patient’s continued treatment;

 

(ix)           completed
Certificates of Medical Necessity or any physician written orders or prescriptions on behalf of physicians in violation of Medicare,
Medicaid and Third Party Payors’ directives;

 

(x)            violated
the FDA’s guidelines or OSHA regulations and 29 C.F.R. 1910, 1030 Occupational Exposure to Bloodborne Pathogens;

 

(xi)           had
or has any “financial relationship” with any “referring physician” or an immediate family member or such
physician, within the meaning of those terms under 42 U.S.C. § 1395nn, or any party in a position to refer or recommend
business or patients that may be reimbursed in whole or in part by Medicare, Medicaid or any other Federal Health Care Program
or Third Party Payor, that is prohibited by 42 U.S.C. § 1395nn (commonly referred to as the “Stark Law”)
or any similar state law;

 

(xii)          had
or has engaged in any activities with any Persons which are prohibited by the Federal Health Care Program anti-kickback law, 42
U.S.C. §§ 1320a-7b et seq. and the regulations promulgated thereunder (commonly referred to as the “Anti-Kickback
Law”) or any similar state law that prohibits the payment or receipt of remuneration in return for referring an individual
to the Company or the furnishing or arranging for the furnishing of any item or service for which payment is made in whole or
in part by a Third Party Payor, or in return for purchasing, leasing or ordering or arranging for or recommending purchasing,
leasing or ordering any goods, facility, service, or item for which payment may be made in whole or in part by a Third Party Payor.

 

(xiii)         (A) has
been or is a party to a corporate integrity agreement, a Certificate of Compliance Agreement with the Office of Inspector General
of the Department of Health and Human Services, or similar government-mandated compliance program, (B) has any continuing
material reporting obligations pursuant to a settlement agreement or other remedial measure entered into with any Governmental
Authority; or (C) has been served with or received any pending search warrants, subpoenas, or civil investigative demands
from any Governmental Authority related to its business operations;

 

(xiv)         contracted
with or employed any person or entity excluded from participation in the Medicare or Medicaid programs;

 

(xv)          violated
or entered into any arrangement that violated any state statute or regulation respecting health care fraud and abuse; or

 

(xvi)        engaged
in activities such that the actions or inactions in the foregoing clauses (i) through (xv), individually or in the aggregate,
that could materially and adversely affect Company or Buyer.

 

    38

     

    

 

(e)           None
of the Unitholders, or any of the Company’s or its Subsidiaries’ current or former agents, contractors or employees
(at the time of, in connection with, arising from, or otherwise related to such agents’ or contractors’ employment
or retention by, or representation of the Company or its Subsidiaries): (i) has been convicted of or charged with any violation
of any law related to Medicare, Medicaid or any other healthcare program; (ii) has been convicted of, or entered into any
settlement or reformation agreement with any Governmental Authority to avoid conviction of, any violation of any laws; (iii) is
excluded, suspended, or debarred from participation, or has received a written notice of their exclusion, suspension, or debarment
from participation, or is otherwise ineligible to participate, in Medicare, Medicaid or any other government healthcare program;
(iv) has been convicted of, or entered into any settlement or reformation agreement with any Governmental Authority to avoid
conviction of, any criminal offense relating to the delivery of any item or service under a Federal Health Care Program, as that
term is defined in Section 1128B(f) of the Social Security Act, 42 U.S.C. § 1320a-7b(f), or had a civil monetary
penalty assessed against them under Section 1128A of the Social Security Act or any regulations promulgated thereunder; or
(v) has been designated a Specially Designated National or Blocked Person by the Office of Foreign Asset Control of the U.S.
Department of Treasury.

 

(f)           The
Company and its Subsidiaries currently have no revalidations pending with the Centers for Medicare and Medicaid Services in the
U.S. Department of Health and Human Services (“CMS”) or any other Federal Health Care Program nor are there
any revalidations with CMS or any other Federal Health Care Program that are required to be made by Company or its Subsidiaries
within twelve months of the Closing Date. The most recent revalidation of each Company and Subsidiary location was completed on
the date set forth opposite such location on Schedule 6.25(f) to this Agreement, and true, correct and complete copies
of all Medicare Provider Enrollment, Chain, and Ownership System (PECOS) profiles pertaining to such Company and Subsidiary locations
has been made available to Buyer. For purposes of this provision, a revalidation shall include any information provided as part
of or in connection with a CMS-855S application submitted by the Company or any Persons acting on behalf of the Company.

 

(g)           Except
as set forth on Schedule 6.25(g), the Company and its Subsidiaries do not have any rate appeal pending before any Governmental
Authority of any administrator of any Third Party Payor that is one of the five largest Key Customers. Except as set forth on
Schedule 6.25(g), the Company has not been notified by any Third Party Payor that is one of the five largest Key Customers
or any government or governmental entity of any reduction in reimbursement rates. Except as set forth on Schedule 6.25(g),
there are no impending proposed reductions in reimbursement from any Third Party Payor that is one of the five largest Key Customers
or any government or governmental entity.

 

6.26         HIPAA.
The Company is a Covered Entity pursuant to HIPAA and complies with HIPAA’s accompanying transaction set, privacy, breach
notification, and security regulations. Company is in compliance with the standard transaction requirements established by HIPAA
and has developed and has implemented reasonable and appropriate policies and procedures and training programs to ensure compliance
with HIPAA’s privacy, breach notification, security and standard transactions regulations. Except as set forth on Schedule
6.26, the Company is not engaged in any internal or external investigations regarding its or any of its agents’, employees’
or contractors’ uses or disclosures of, or security practices regarding, individually identifiable health information in
violation of HIPAA or any other applicable law relating to the privacy, breach notification, security and transmission of health
information. Except as set forth on Schedule 6.26, there has been no breach (as defined at 45 C.F.R. § 164.402),
involving unsecured protected health information (as defined at 45 C.F.R. § 164.402) held by, the Company or any of
its agents. To the extent required under HIPAA, the Company is a party to compliant business associate agreements and trading
partner agreements with all appropriate parties in accordance with HIPAA.

 

    39

     

    

 

6.27         No
Additional Representations or Warranties.

 

Except for the representations
and warranties contained in this Article VI, neither the Company nor any other Person on behalf of the Company makes
any other express or implied representation or warranty with respect to the Company or any of its Subsidiaries or with respect
to any other information provided to Parent, Buyer or their Affiliates.

 

Article VII

PRE-CLOSING COVENANTS

 

7.01            Reasonable
Best Efforts. Subject to the terms of this Agreement (including the limitations set forth in Section 7.02 and
this Section 7.01), the Company will, and will cause its Subsidiaries to, use their reasonable best efforts to take,
or cause to be taken, all actions, and to do, or cause to be done, and to assist and cooperate with the other Parties in doing,
all things necessary, proper or advisable to consummate and make effective, as promptly as practicable, the Transaction, including
using reasonable best efforts to cause the conditions to Closing set forth in Article X to be satisfied.

 

7.02            Regulatory
Filings. 

 

(a)            General.
Subject to Section 7.02(b), each of the Parties shall, and Buyer shall cause its Affiliates to, use reasonable best
efforts to (i) as promptly as practicable, obtain from any Governmental Authority any consent, approval, authorization, declaration,
waiver, license, franchise, permit, certificate or order required to be obtained or made by Buyer, Merger Sub, the Company or
any of its Subsidiaries, and to avoid any action or Proceeding by any Governmental Authority, in each case in connection with
the authorization, execution and delivery of this Agreement and the consummation of the Transactions and (ii) as promptly
as practicable, and in any event within ten Business Days after the date hereof, make all necessary filings, and thereafter make
any other required submissions, with respect to this Agreement required under any applicable Law. The Parties shall, and Buyer
shall cause its Affiliates to, cooperate with each other in connection with obtaining all such consents, approvals, authorizations,
declarations, waivers, licenses, franchises, permits or orders and the making of all such filings, including, if requested, providing
copies of all such non-proprietary documents to the non-filing Party and its advisors prior to filing and, if requested, to accept
all reasonable additions, deletions or changes suggested by the non-filing Party and its advisors in connection therewith. Buyer,
Merger Sub and the Company shall, and Buyer shall cause its Affiliates to, promptly furnish to each other all information required
for any application or other filing to be made by any Party in connection with the Transactions. Buyer will not, and will not
permit its Affiliates to, consent or agree to any voluntary delay of the consummation of the Transactions without the prior written
consent of the Company.

 

(b)           Antitrust
Laws. The Parties agree to make, and to cause their Affiliates to make, any necessary filings under the Hart-Scott-Rodino
Act and any other applicable antitrust Laws as soon as practicable and no later than ten Business Days after the date hereof (provided
that the Parties will use their respective reasonable best efforts to make such filings no later than five Business Days after
the date hereof), which filings shall include a request for early termination of the applicable waiting period under the Hart-Scott-Rodino
Act and any other antitrust Laws. The Parties shall, and shall cause its Affiliates to, comply at the earliest practicable date
with any request under the Hart-Scott-Rodino Act or, if applicable, such other antitrust Laws to provide information, documents
or other materials requested by any Governmental Authority. The Parties shall, and shall cause its Affiliates to use their reasonable
best efforts to respond to any questions or any objections asserted by any Governmental Authority with respect to this Agreement
or the Transactions and to resolve as soon as practicable. The Parties shall, and shall cause its Affiliates to, coordinate and
cooperate with each other in connection with their efforts to respond to any questions or objections, including (A) cooperating
in all respects in connection with any investigation or other inquiry, (B) keeping each other promptly informed of any material
communication received by Buyer or any of its Affiliates from any Governmental Authority, including the Federal Trade Commission
or U.S. Department of Justice or similar foreign Governmental Authority, regarding any of the Transactions, (C) providing
each other and their advisors with a reasonable opportunity to (x) review and approve the content of any communication, presentations,
white papers or other written materials to be submitted to any Governmental Authority in advance of any such submission, (y) consult
with each other prior to any meeting or conference with any Governmental Authority, and (z) to the extent permitted by such
Governmental Authority, attend and participate in such meetings or conferences, and (D) providing such other information
and assistance as the Parties may reasonably request in connection with the foregoing. Buyer and Company shall be equally responsible
for the payment of all filing fees under the Hart-Scott-Rodino Act and any other antitrust Laws.

 

    40

     

    

 

7.03            Conduct
of the Business.

 

(a)           From
the date hereof until the Closing Date or the earlier valid termination of this Agreement, except (a) as set forth on Schedule 7.03,
(b) as otherwise contemplated or permitted by this Agreement (including the consummation of the Pre-Closing Reorganization),
(c) as required by Law, (d) as consented to in writing by Buyer (which consent shall not be unreasonably withheld, conditioned
or delayed), or (e) for the use of available cash to repay any Funded Debt and pay Transaction Expenses prior to the Closing,
the Company and Blocker Seller (i) shall use its reasonable best efforts to carry on the business of the Company, Blocker
and their respective Subsidiaries in the Ordinary Course of Business and (ii) shall not, and shall cause its Subsidiaries
not to:

 

(i)            issue,
deliver, reissue or sell, dispose or pledge any of its equity securities;

 

(ii)            make
any declaration or payment of any non-cash distributions on or in respect of any equity securities in the Company or Blocker or
any redemption, purchase or acquisition of any of the Company’s or Blocker’s outstanding equity securities;

 

(iii)          create,
incur, assume or guarantee any Funded Debt, other than (x) in the Ordinary Course of Business pursuant to the Company’s
existing credit facilities, or (y) pursuant to arrangements solely among or between the Company and one or more of its Subsidiaries;

 

(iv)          enter
into any Contract to make an acquisition (whether by merger, acquisition of stock or assets, or otherwise) of any business
or line of business;

 

(v)           transfer,
assign, sell or make any other disposition of any of the properties or assets shown or reflected in the Latest Balance Sheet or
cancel any indebtedness owed by third parties except for transactions entered into in the Ordinary Course of Business;

 

(vi)          transfer,
assign or make any grant of any license or sublicense of any material rights under or with respect to any Intellectual Property
except in the Ordinary Course of Business;

 

(vii)         make
any loan to (or forgive any loan to), or enter into any other transaction or Contract with, any of its members, managers, officers
or employees (including any of the Unitholders) or any of their respective Affiliates (other than salaries, wages or benefits
paid in the Ordinary Course of Business);

 

(viii)        make
any change in the organizational documents of the Blocker, Company or any of its Subsidiaries;

 

    41

     

    

 

(ix)           make
an election to change the tax classification of the Company or any of its Subsidiaries (as a corporation, partnership or disregarded
entity) for federal, state or local Tax purposes;

 

(x)            except
in the Ordinary Course of Business, as required by applicable Law or pursuant to the Plans or Contracts set forth on Schedule
6.19(a), (A) increase the salary payable or to become payable by it to any of the Company’s or its Subsidiaries’
employees whose base salary is in excess of $100,000, or (B) increase the coverage or benefits available under any severance
pay, termination pay, deferred compensation, bonus or other incentive compensation plan or arrangement;

 

(xi)           terminate
or make any material modification to or cancellation of any Material Contract with a Third Party Payor (excluding, for the avoidance
of doubt, the expiration of any Material Contract in accordance with its terms); or

 

(xii)          adopt
a plan of liquidation, dissolution, merger, consolidation or other reorganization (other than this Agreement).

 

(b)           Notwithstanding
anything to the contrary in this Agreement, nothing in this Agreement shall prevent the Company or any of its Subsidiaries from
taking or failing to take any COVID-19 Measures or any action that is taken in good faith in response to COVID-19 and no such
action (or failure to act) shall serve as a basis for Buyer or Parent to terminate this Agreement or that any of the conditions
to the Closing contained herein have not been satisfied.

 

7.04         Access
to Information; Contact with Business Relations.

 

(a)           From
the date hereof until the Closing Date or the earlier valid termination of this Agreement, the Company shall provide Parent, Buyer
and their authorized agents and representatives reasonable access, to the extent permissible under applicable law, at reasonable
times and upon reasonable advance notice, to the Company’s and Blocker’s senior executive employees and the books
and records of the Company, Blocker and their respective Subsidiaries to the extent relating to the transition of the Company’s
and Blocker’s business to Buyer and Parent; provided that (i) such access does not unreasonably interfere with
the operation of the Company’s, Blocker’s and their respective Subsidiaries’ business, (ii) in no event
shall Parent or Buyer be permitted to conduct or cause to be conducted any environmental investigation, testing, sampling or other
intrusive assessment of the current or former operations, facilities or real property of the Company, Blocker or any of their
respective Subsidiaries without the prior written consent of the Company or Blocker, as applicable, which consent may be withheld
by the Company or Blocker, as applicable, in its sole discretion, and (iii) the Company, Blocker and their respective Subsidiaries
shall not be required to furnish to Parent, Buyer or any of their respective authorized agents or representatives or provide Parent,
Buyer or any of their respective authorized agents or representatives with access to information if such access (x) would
cause competitive harm to the Company, Blocker or any of their respective Subsidiaries if the Transactions are not consummated,
(y) would result in the waiver or forfeiture of any attorney-client privilege, work product doctrine or similar privilege
or (z) would be in violation of applicable Laws or the provisions of any Contract to which the Company, Blocker or any of
their respective Subsidiaries is a party.

 

(b)           From
the date hereof until the Closing Date or the earlier valid termination of this Agreement, Parent, Buyer and Merger Sub shall
not, and shall cause their Affiliates not to, contact any channel partner, customer, supplier, distributor, lessee, lessor, equityholder,
lender, noteholder or other material business relation of the Company or its Subsidiaries with respect to the Company, its Subsidiaries,
their businesses or the Transactions, in each case, without receiving the prior written consent of the Company.

 

    42

     

    

 

7.05         Exclusivity.
From the date hereof until the Closing Date or the earlier valid termination of this Agreement, the Company, Blocker and
their respective Subsidiaries shall not, and shall direct their respective directors, managers, officers, employees,
investment bankers and other representatives not to, (a) solicit, initiate or encourage the initiation of any
Acquisition Proposal, (b) participate in any discussions or negotiations with any third party regarding, or furnish to
any third party any information in connection with, any Acquisition Proposal, or (c) agree to or approve any Acquisition
Proposal.

 

7.06         Confidentiality
Agreement. Each of the Buyer Parties, for themselves and on behalf of their respective Affiliates, employees and advisors,
hereby agrees to be bound by and to comply with the letter agreement, dated as of February 13, 2020, by and between Robert
W. Baird & Co. (as agent for the Company) and Buyer (the “Confidentiality Agreement”). Any information
provided to the Buyer Parties and their respective authorized agents and representatives pursuant to Section 7.04(a) shall
be governed by the Confidentiality Agreement. Notwithstanding the foregoing or anything in this Agreement to the contrary, nothing
herein shall prevent the Buyer Parties from making any public announcement (whether in a press release, periodic securities filing
or other external announcement) related to the Transaction that Buyer Parties reasonably believe to be required by applicable
Law or the requirements of any stock exchange or quotation system. Buyer Parties may make earnings announcements and participate
in investor conferences in the ordinary course of business in which this Agreement and the Transactions are discussed.

 

7.07         Pre-Closing
Reorganization. Blocker Seller shall, and shall cause Blocker and Splitter to, consummate the Pre-Closing Reorganization prior
to the Closing.

 

7.08         Notice
of Certain Events.

 

(a)           From
the date hereof until the Closing or the earlier valid termination of this Agreement, the Company will use its reasonable best
efforts to promptly notify Buyer in writing if the Company, Blocker or their respective Subsidiaries receive any of the following:

 

(i)            receipt
of a written termination notice of any agreement with any Third Party Payor constituting 5% or more of the Company’s revenues
in the immediately preceding twelve (12) months period prior to the execution date of this Agreement;

 

(ii)            receipt
of written notice of governmental investigation or audit by the Office of the Inspector General of the Department of Health and
Human Services, the U.S. Department of Justice, Medicaid or any other Federal Health Care Program, other than routine claims audits
which shall be defined, for purposes this Section 7.08, as any audit that is not based upon a statistical sample or
any request for data or information, including medical records, relating to fewer than 50 paid claims for any items or services
furnished to patients by the Company;

 

(iii)          receipt
of written termination notice or a written dispute notice received from any vendor that supplies CGM monitors;

 

(iv)          any
written demand or written claim from any Person in excess of $500,000;

 

    43

     

    

 

(v)           any
written demand or written claim from any Taxing Authority in excess of $150,000;

 

(vi)          any
Class Action lawsuit filed by any Persons against the Company, regardless of any specified amount;

 

(vii)         any
written termination or written revocation notice from any Federal Health Care Program;

 

(viii)        any
written investigation, written claim or written demand asserted by any state licensure authority;

 

(ix)           any
written correspondence, written filing or other written communication with any Governmental Authority relating to the Phishing
Incident, opposing counsel in the Espinoza Litigation, or opposing counsel in the Data Breach Litigation (in each case, as such
terms are defined in the Schedules); or

 

(x)            written
notice of any data breach (as defined under 42 C.F.R. § 164.402) involving unsecured protected health information (as
defined under 42 C.F.R. § 164.402) associated with fifty (50) patient medical records or any other data breach that
would be reportable to the Office of Civil Rights.

 

(b)           The
Buyer’s receipt of information pursuant to this Section 7.08 shall not operate as a waiver or otherwise affect
any representation, warranty or agreement given or made by Blocker Seller or the Company in this Agreement and shall not be deemed
to amend or supplement the Schedules.

 

(c)           Notwithstanding
anything to the contrary in this Agreement, the condition set forth in Section 10.02, as it applies to the Company’s
obligations under this Section 7.08, shall be deemed satisfied so long as the Company does not, with knowledge (actual
or constructive) or negligently, materially breach its obligations under this Section 7.08.

 

    44

     

    

 

7.09         Financing.
Each of the Buyer Parties and Merger Sub will use reasonable best efforts to take, or cause to be taken, all actions and to do,
or cause to be done, all things necessary or advisable to arrange, obtain and consummate the Financing no later than the date
the Closing is required to be effected in accordance with this Agreement, including using reasonable best efforts to (a) comply
in all material respects with their obligations under the Financing Letters, (b) maintain the Financing Letters in full force
and effect in accordance with its terms, (c) satisfy (or, if deemed advisable by Parent or Buyer, to obtain the waiver of)
on a timely basis all conditions applicable to Parent’s or Buyer’s obtaining the Financing, (d) negotiate and
enter into definitive agreements with respect thereto consistent with the terms and conditions described in the Financing Letters
(and any flex provisions in the Fee Letters) or on terms and conditions not less favorable to Parent or Buyer with respect to
conditionality than the terms and conditions contained in the Financing Letters so long as such terms shall not in any respect
expand on the conditions to funding of the Financing at or prior to the Closing or reduce (or could have the effect of reducing)
the aggregate amount of the Financing below the amount required (together with other financial resources of the Buyer Parties
and their Subsidiaries, including cash on hand of Parent or Buyer and its Subsidiaries) to pay the aggregate consideration and
other amounts payable by the Buyer Parties on the Closing Date, to refinance any indebtedness required to be refinanced in connection
with the Transactions and to pay all Transaction Expenses to be borne by the Buyer Parties in connection with this Agreement on
the Closing Date, (e) enforce their rights under the Financing Letters, and (f) in the event that all conditions to
the Financing have been satisfied or waived (and that the funding of such Financing is necessary to pay the aggregate consideration
payable by Parent and Buyer on the Closing Date, to refinance any indebtedness required to be refinanced in connection with the
Transactions and to pay all Transaction Expenses to be borne by Buyer in connection with this Agreement on the Closing Date),
cause the equity sources, lenders and other Persons providing Financing to fund on the Closing Date the Financing, if and to the
extent necessary for the foregoing purposes. Without limiting the generality of the foregoing, prior to the Closing, the Buyer
Parties shall give the Company reasonably prompt notice (i) of any material breach or default related to the Financing of
which any Buyer Party becomes aware, (ii) of the receipt or delivery of any written notice or other written communication,
in each case from any Person party to the Financing Letters (or any Affiliate of such Person) with respect to (1) any actual
or threatened breach, default, termination, or repudiation by any party to the Financing Letters with respect to the obligation
to fund the Financing, (2) any material dispute or disagreement between or among parties to any of the Financing Letters
with respect to the obligation to fund the Financing or the amount of the Financing to be funded at the Closing (but excluding,
for the avoidance of doubt, any ordinary course negotiations with respect to the terms of the Financing or the Financing Letters)
or (3) the assertion of any “material adverse effect” with respect to the Company or the Buyer Parties or Merger
Sub (or their respective Subsidiaries), or any term of similar meaning, (iii) of the expiration or termination for any reason
of the Financing Letters or any definitive documentation with respect to the Financing entered into in connection therewith (or
if any Person party thereto attempts or purports in writing to terminate the Financing Letters or any definitive agreements entered
into in connection therewith, whether or not such attempted or purported termination is valid), and (iv) if at any time for
any reason any of the Buyer Parties or Merger Sub believes in good faith that all or any portion of the Financing is unavailable
on the terms and conditions contemplated by the Financing Letters. In connection with any notice thereof, the Buyer Parties shall
promptly provide information reasonably requested by the Company relating to any circumstance referred to in clause (i), (ii),
(iii), or (iv) of the immediately preceding sentence (other than information to the extent that the provision thereof would
violate or waive any attorney-client or other privilege, constitute attorney work product or violate or contravene any law, rule or
regulation, or any obligation of confidentiality). If any portion of the Financing for any reason becomes unavailable on the terms
and conditions contained in the Financing Letters, the Buyer Parties shall (A) notify the Company of such unavailability
and (B) use reasonable best efforts to obtain, as promptly as practicable following the occurrence of such event, alternative
financing, including from alternative sources, with conditions not less favorable in any material respect to the Buyer Parties
than the conditions contained in the Financing Letters (the “Alternative Financing”). Prior to the Closing,
without the prior written consent of the Company, the Buyer Parties shall not agree to, or permit, any amendment, modification,
supplement, termination, replacement or waiver under, the Financing Letters, Fee Letter or definitive documentation relating to
the Financing; provided that the Buyer Parties shall have the right from time to time to amend, supplement, modify, terminate,
waive, replace or extend the Financing Letters, Fee Letter or definitive documentation with respect to the Financing so long as
such amendment, modification, supplement, termination, waiver, extension or replacement would not reasonably be expected to (A) reduce
(or could have the effect of reducing) the amounts available to be funded under the Financing on the Closing Date below the amount
required (together with other financial resources of the Buyer Parties, Merger Sub and their respective Subsidiaries, including
cash on hand of the Buyer Parties, Merger Sub and their respective Subsidiaries) to pay the aggregate consideration and other
amounts payable by the Buyer Parties on the Closing Date, to refinance any indebtedness required to be refinanced in connection
with the Transactions and to pay all Transaction Expenses to be borne by the Buyer Parties in connection with this Agreement on
the Closing Date, or (B) expand on, or impose new or additional conditions precedent or terms, or amend or modify any conditions
precedent or terms in each case which would reasonably be expected to (i) prevent, delay, or impair the availability of the
Financing when required to be funded or the satisfaction of the conditions to obtaining the Financing, in each case on the Closing
Date, or (ii) adversely affect the ability of the Buyer Parties to enforce its rights against the other parties to the Financing
Letters. After any amendment, supplement, modification, replacement or waiver of the Financing Letters or the definitive documentation
(prior to the Closing) with respect to the Financing in accordance with this Section 7.09, the Buyer Parties shall
promptly deliver to the Company true and complete copy thereof (and in the case of the Fee Letters, redacted in a manner consistent
with Section 4.06). For purposes of this Agreement, the terms “Financing Letters” and “Fee Letters”
shall include and mean such documents as amended, supplemented, modified, waived, replaced or extended in compliance with this
Section 7.09 (including any Alternative Financing) and references to “Financing” shall include and mean
the financing contemplated by the Financing Letters or Fee Letters, as applicable, as so amended, supplemented, modified, waived,
replaced or extended, as applicable, or any Alternative Financing, if applicable. Notwithstanding anything in this Agreement to
the contrary, none of the Company, the Blocker, the Blocker Seller or any of their respective Subsidiaries or Affiliates shall
have any agreement, covenant or obligation to assist any of the Buyer Parties or any other Person with respect to the Financing.
Notwithstanding anything herein to the contrary, in no event shall “reasonable best efforts” of Buyer Parties or Merger
Sub under this Section 7.09 be deemed or construed to require any Buyer Party or Merger Sub to instigate or pursue
litigation against any of the Debt Financing Sources.

 

    45

     

    

 

7.10         Company
2019 Audited Financials. On or before June 30, 2020, the Company shall deliver to Parent copies of the audited consolidated
balance sheet of Solara Medical Supplies, LLC, a California limited liability company, as December 31, 2019 and the related
audited consolidated statements of income and cash flows for the fiscal year ended December 31, 2019 (collectively, the “2019
Audited Financials”). The 2019 Audited Financials shall fairly present in all material respects the financial position
and results of operations of Solara Medical Supplies, LLC and its subsidiaries as of the date and for the period referred to therein
and shall be prepared in accordance with GAAP applied on a consistent basis throughout the period involved. From and after the
date on which the 2019 Audited Financials are delivered to Parent pursuant to this Section 7.10 until the Closing
or the earlier valid termination of this Agreement, the Company will in good faith assist Parent with its efforts to obtain any
consents or approvals required from the auditor of the 2019 Audited Financials so that Parent may include the 2019 Audited Financials
in any periodic securities filing or other external announcement of Parent to the extent required by applicable Law or the requirements
of any stock exchange or quotation system. Notwithstanding anything to the contrary in this Agreement, the condition set forth
in Section 10.02, as it applies to the Company’s obligation to in good faith assist Parent with its efforts
to obtain any consents or approvals required from the auditor of the 2019 Audited Financials shall be deemed satisfied so long
as the Company does not knowingly and willfully materially breach its obligations under this Section 7.10.

 

Article VIII

POST-CLOSING COVENANTS

 

8.01         Further
Assurances. From and after the Closing, upon the reasonable request of any Party and at such Party’s expense, any other
Party shall execute, acknowledge and deliver, or cause to be executed, acknowledged and delivered, all such further documents
and instruments and shall take, or cause to be taken, all such further actions as the requesting Party may reasonably deem necessary
or desirable to evidence and effectuate the Transactions.

 

8.02         Director
and Officer Liability and Indemnification. 

 

(a)           For
a period of six years after the Closing Date, Buyer shall not, and shall not permit Blocker, the Company or any of its Subsidiaries
to amend, repeal or modify any provision in Blocker’s, the Company’s or any of its Subsidiaries articles of incorporation
or bylaws (or equivalent organizational documents) relating to the exculpation or indemnification of any current or former officer
or director or person exercising similar authority (the “D&O Indemnified Persons”) (unless required by
Law), it being the intent of the parties that the D&O Indemnified Persons shall continue to be entitled to such exculpation
and indemnification to the fullest extent of the law.

 

(b)           During
the period from the Closing until the six-year anniversary thereof, Buyer shall, and shall cause Blocker, the Company and each
of its Subsidiaries to (i) indemnify, defend and hold harmless each D&O Indemnified Person against all claims, liabilities,
losses, damages, judgments, fines, penalties, costs (including amounts paid in settlement or compromise) and expenses (including
fees and expenses of legal counsel) in connection with any actual or threatened claim, suit, action, proceeding or investigation
(whether civil, criminal, administrative or investigative) (each, a “D&O Claim”), whenever asserted, arising
out of, relating to or in connection with any action or omission relating to their position with Blocker, the Company or its Subsidiaries,
as applicable, occurring or alleged to have occurred before or at the Closing (including any D&O Claim relating in whole or
in part to this Agreement or the Transactions), to the fullest extent permitted under applicable Law and (ii) assume all
obligations of Blocker, the Company and its Subsidiaries, as applicable, to the D&O Indemnified Persons in respect of limitation
of liability, exculpation, indemnification and advancement of expenses as provided in (A) the respective organizational documents
of each of Blocker, the Company and its Subsidiaries as in effect on the date hereof and (B) any indemnification agreements
with a D&O Indemnified Person, which shall in each case survive the Closing and continue in full force and effect to the extent
permitted by applicable Law. Without limiting the foregoing, from and after the Closing, Buyer shall ensure that each of Blocker,
the Company and its Subsidiaries fulfills its obligations to the applicable D&O Indemnified Person pursuant to the terms of
the respective organizational documents of each of Blocker, the Company and its Subsidiaries as in effect on the date hereof;
provided, however, notwithstanding anything to the contrary, the sole recourse of any D&O Indemnified Person shall be the
proceeds of the Tail Policy and as provided in this Section 8.02.

 

    46

     

    

 

(c)           At
the Closing, Buyer will, or will cause the Company to, obtain and maintain irrevocable “tail” insurance policies (the
 “Tail Policy”) naming the D&O Indemnified Persons as direct beneficiaries with a claims period of six years
from the Closing Date from an insurance carrier with the same or better credit rating as the Company’s current insurance
carrier with respect to directors’ liability insurance in an amount and scope at least as favorable as the Company’s
existing policies with respect to matters existing or occurring at or prior to the Closing Date. Buyer will not, and will cause
the Company to not, cancel or change such insurance policies in any respect. All fees and expenses incurred in connection with
obtaining the Tail Policy shall be borne by the Unitholders (as a Transaction Expense).

 

(d)           If
Buyer, Blocker, the Company or any of its Subsidiaries or any of their respective successors or assigns (i) shall consolidate
with or merge into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or
merger or (ii) shall transfer all or substantially all of its properties and assets to any Person, then, and in each such
case, proper provisions shall be made so that the successors and assigns of Buyer, Blocker, the Company and its Subsidiaries shall
assume all of the obligations set forth in this Section 8.02. The provisions of this Section 8.02 are
intended for the benefit of, and will be enforceable by, each D&O Indemnified Person and his or her heirs and representatives,
and are in addition to, and not in substitution for, any other rights to indemnification or contribution that any such Person
may have had by contract or otherwise.

 

8.03         R&W
Policy. The R&W Policy shall provide that, except in the event of Fraud, the insurer or the insurers issuing such policy
shall have no right, and shall waive any right, of subrogation, contribution or otherwise against Blocker Seller and the Unitholders
or any of their representatives based upon, arising out of, or in any way connected to this Agreement, the transactions contemplated
hereby or the R&W Policy. Blocker Seller and the Unitholders shall be express third party beneficiaries under the R&W
Policy of the immediately preceding subrogation provision. The Buyer Parties and their Affiliates shall not agree to amend, waive,
modify or otherwise revise the foregoing subrogation provision without the prior written consent of the Representative.

 

8.04         Access
to Books and Records. From and after the Closing until the seventh anniversary of the Closing Date, Buyer shall, and shall
cause the Surviving Company and its Subsidiaries, (a) not to destroy, alter or otherwise dispose of any books and records
of the Surviving Company and its Subsidiaries, or any portions thereof, relating to periods prior to the Closing Date without
first giving reasonable prior written notice to the Representative and offering to surrender to the Representative (on behalf
of the Unitholders and Blocker Seller) such books and records or such portions thereof and (b) to provide the Representative
and its authorized representatives with reasonable access (for the purpose of examining and copying), during normal business hours,
to the books and records of the Surviving Company and its Subsidiaries with respect to periods prior to the Closing Date.

 

    47

     

    

 

8.05            Transfer
Taxes. Buyer shall pay, or cause to be paid, when due all stamp, stock transfer, documentary, filing, value-added, transfer
(including real property transfer or gains) tax, recording charge or other similar Tax, charge, or fee imposed on Blocker,
the Company and its Subsidiaries, Blocker Seller or one or more of the Unitholders as a result of the Transactions (collectively,
 “Transfer Taxes”) and shall file (at its own expense), or cause to be filed, all Tax Returns with respect
to such Transfer Taxes. The Representative shall use its reasonable best efforts to cooperate with Buyer in the filing of any
Tax Returns with respect to the Transfer Taxes.

 

8.06            Employment
and Benefit Arrangements. Except as required under applicable Law or as may be set forth in any employment agreement, nothing
herein shall obligate Buyer to cause the Company or its Subsidiaries to continue to employ any employee for any specific time
period, and, except as may be set forth in any employment agreement or required under applicable Law, employees shall be treated
as employees at will, subject to the employment policies implemented or continued by Buyer. During the twelve-month period following
the Closing, Buyer shall provide each employee of the Company and its Subsidiaries, who are employed by the Company and its Subsidiaries
as of the Closing Date (the “Continuing Employees”) with (a) base salary or wage rate and other compensation
and bonus opportunities (to the extent pursuant to a written bonus plan) no less favorable to that provided immediately prior
to the Closing Date, and (b) employee benefits that are substantially comparable, in the aggregate, to those employee benefits
and Plans provided to such employees immediately prior to the Closing Date. Nothing herein shall be construed to grant any employee,
independent contractor, or other Person, not party to this agreement, any rights or benefits, including as a third party beneficiary.
The Company or its Subsidiaries will provide all required notices and shall comply with all legal requirements regarding the termination
of any employees on and following the Closing including, but not limited to, the Worker Adjustment and Retraining Notification
Act and all similar Laws. Buyer shall use commercially reasonably efforts provide all Continuing Employees full service credit
for periods of employment with the Company and its Subsidiaries for all purposes under any employee benefit plans and arrangements
in which they participate following the Closing Date to the same extent such service is recognized by the Company and its Subsidiaries
immediately prior to Closing; provided, however, that Buyer shall not be required to recognize such service (i) for
purposes of benefit accrual under defined benefit pension plans, (ii) for purposes of plans that are frozen to new participants,
or (iii) to the extent that such credit would result in a duplication of benefits. To the extent that Buyer modifies any
coverage or benefit plans under which the Continuing Employees participate, Buyer shall use commercially reasonable efforts to
waive all applicable waiting periods, pre-existing conditions or actively-at-work requirements and shall give all such Continuing
Employees full credit under the new coverages or benefit plans for deductibles, co-insurance and out-of-pocket payments that have
been paid during the plan year in which such coverage or plan modification occurs. This Section 8.06 shall survive
the Closing, and shall be binding on all successors and assigns of Buyer, the Company and its Subsidiaries.

 

8.07            Name
Change. Within seven days after the Closing, Buyer shall cause Blocker to amend its organizational documents and file such
documents with the Delaware Secretary of State as are necessary to eliminate any reference to “Linden Capital Partners,”
 “Linden”, “LCP” or any derivation thereof.

 

8.08            Overpaid
Founder Earnout Amount. In the event that the Founder Earnout Amount included in the Estimated Closing Statement is greater
than the amount actually paid by the Company and its Subsidiaries pursuant to Section 2.6(b)(iv) of the 2018 Purchase
Agreement as finally determined in accordance with the 2018 Purchase Agreement (excluding any amounts that may become due and
payable under Section 2.6(k) of the 2018 Purchase Agreement) (the amount of such difference, the “Overpaid
Founder Earnout Amount”), then within two Business Days of such payment pursuant to Section 2.6(b)(iv) of
the 2018 Purchase Agreement, Buyer shall pay, or cause to be paid, to the Representative (for further distribution to Blocker
Seller and the Unitholders, as applicable) the Overpaid Founder Earnout Amount by wire transfer of immediately available funds.

 

    48

     

    

 

8.09            Restrictive
Covenants.

 

(a)           During
the period beginning on the Closing Date and ending on the second anniversary thereof, Blocker Seller will and will cause the
directors, managers, officers and employees of any investment fund that is an Affiliate thereof or a portfolio company that is
controlled by such investment fund (each a “Restricted Party”) not to solicit for hire or engagement or hire
or engage any person set forth on Schedule 8.09(a); provided, that the foregoing shall not prohibit (i) soliciting
or hiring any such person who responds to a general, non-targeted media advertising, (ii) soliciting or hiring any such person
whose employment with the Company or any of its Subsidiaries was terminated or otherwise ceases prior to the date of such initial
solicitation or hiring or (iii) the chief executive officer of the Company as of the date of this Agreement from serving
on any board of directors, board of managers or similar governing body of any portfolio company (as such term is commonly understood
among private equity professionals) of any investment fund that is an Affiliate of Blocker Seller.

 

(b)           Buyer,
on the one hand, and each Restricted Party on the other hand, agree that the duration and geographic scope of the restrictions
set forth in this Section 8.09 as applicable to such Restricted Party are fair, reasonable and necessary to protect
the legitimate business interests of Buyer and the goodwill of the Company. In the event that any court determines that the duration
or geographic scope, or both, are unreasonable and that such provision is to that extent unenforceable, each Restricted Party
agrees that the provision applicable to such Restricted Party shall remain in full force and effect for the greatest time period
and in the greatest area that would not render it unenforceable.

 

(c)           If
a court of competent jurisdiction should declare the covenants contained in this Section 8.09 unenforceable because
of any unreasonable restriction of activities, duration, and/or geographical area, then the parties hereby acknowledge and agree
that such court shall have the express authority to reform the covenants to provide for reasonable restrictions and/or grant the
Surviving Company and Buyer such other relief at law or in equity reasonably necessary to protect the interests of the Surviving
Company.

 

(d)           The
Restricted Parties acknowledge that a breach of any provision of this Section 8.09 by any such party would cause the
Surviving Company and Buyer to suffer immediate and irreparable harm, for which no adequate remedy at law exists. In the event
of a breach or threatened breach by any of the Restricted Parties of the provisions of the covenants contained in this Section 8.09,
the Surviving Company and Buyer shall be entitled to injunctive or mandatory relief to prevent or end such breach to enforce the
covenant. Nothing herein shall be construed as prohibiting the Surviving Company or Buyer from pursuing any other remedies available
to it at law or in equity for such breach or such threatened breach, including the recovery of damages.

 

    49

     

    

 

8.10         Share
Consideration Restrictions. Until the date which is one year following the Closing Date, Blocker Seller and the Unitholders
shall not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any Parent Common Stock constituting
Share Consideration, enter into any transaction which would have the same effect, or enter into any swap, hedge or other arrangement
that transfers, in whole or in part, any of the economic consequences of ownership of such Parent Common Stock, whether any such
aforementioned transaction is to be settled by delivery or such securities or such other securities, in case or otherwise; provided,
that, the restrictions set forth in this Section 8.10 shall not prohibit (a) any Unitholder who is a natural
person from transferring any Parent Common Stock either during his or her lifetime, or on death by will or intestacy, to (i) any
of his or her Family Members, (ii) a trust, the beneficiaries of which are exclusively such Unitholder or a Family Member
thereof or (iii) a family partnership, the partners of which consist exclusively of such Unitholder or a Family Member thereof
or (b) any Unitholder who is not a natural person from transferring any Parent Common Stock to any of its Affiliates, stockholders,
equityholders, general partners, limited partners, limited liability company members, or any investment fund managed by such person
or any of its Affiliates; provided, that each such transfer is made in compliance with applicable U.S. state and federal securities
Laws, the transferee agrees to be bound in writing by the terms of this Section 8.10 prior to such transfer and such
transfer shall not constitute a disposition for monetary value.

 

8.11         NASDAQ
Listing. Promptly following the issuance of the Share Consideration, Parent shall use reasonable best efforts to cause the
Share Consideration to be listed on the NASDAQ Capital Market.

 

8.12            Parent
Common Stock Legend Removal.

 

(a)           On
the date that is one year following the Closing Date, Parent shall remove, or cause its registrar and transfer agent to remove,
the restrictive legends referred to in Section 5.10 from the certificates evidencing the Share Consideration provided
that the holder of such Parent Common Stock is not, and has not been for three months preceding such date, an “affiliate”
of Parent as such term is defined in Section 501 of the Securities Act.

 

(b)           If
any restrictive legends referred to in Section 5.10 remain on the certificates evidencing the Share Consideration
following the one year anniversary of the Closing Date because the holders of such Parent Common Stock were an “affiliate”
of Parent, then upon request of a holder of Parent Common Stock and Parent’s receipt of an opinion of counsel for such requesting
holder that the removal of the restrictive legends referred to in Section 8.10 is in compliance with applicable Law,
Parent shall remove, or cause its registrar and transfer agent to remove, the restrictive legends referred to in Section 5.10
from the certificates evidencing the Share Consideration.

 

Article IX

TAX COVENANTS

 

9.01         Tax
Return Filing.

  

(a)            After
the Closing, Representative shall prepare or cause to be prepared all Income Tax Returns with respect to Pass-Through Income Tax
Matters of the Company and its Subsidiaries and of Blocker for periods ending on or before the Closing Date, in each case, the
due date of which (taking into account extensions of time to file) is after the Closing Date, but only to the extent not
filed prior to the Closing Date (the “Representative Returns”). Representative shall submit each such Representative
Return to Buyer at least thirty days prior to the due date (taking into account any extensions) for Buyer’s review,
comment and approval, which approval shall not be unreasonably withheld, conditioned or delayed.

 

(b)           Excluding
any Representative Returns, Buyer shall prepare or cause to be prepared all Tax Returns of the Company and its Subsidiaries and
for Blocker for periods ending on or before the Closing Date and for any Straddle Period, in each case, the due date of which
(taking into account extensions of time to file) is after the Closing Date (the “Buyer Returns”). Buyer
shall submit (i) each such Buyer Return related to the Company and its Subsidiaries to the Representative at least thirty
days prior to the due date (taking into account any extensions) for the Representative’s review, comment, and approval,
which approval shall not be unreasonably withheld, conditioned or delayed and (ii) each such Buyer Return related to Blocker
to Blocker Seller at least thirty days prior to the due date (taking into account any extensions) for Blocker Seller’s
review, comment, and approval, which approval shall not be unreasonably withheld, conditioned or delayed.

 

    50

     

    

 

(c)           All
Tax Returns prepared under Sections 9.01(a) or (b) shall be prepared and filed in a manner consistent
with the past procedures and practices and accounting methods of the Company and its Subsidiaries or Blocker, as applicable, and
this Article IX; provided that, with respect to the preparation and filing of the Tax Returns under this Section 9.01
with respect to Income Taxes, such Tax Returns shall reflect all applicable Transaction Tax Deductions in the Pre-Closing
Tax Period so long as such Transaction Tax Deductions are “more likely than not” deductible (or deductible at a higher
confidence level) in the Pre-Closing Tax Period (and, for that purpose, the safe-harbor election of Internal Revenue Service
Revenue Procedure 2011-29 (or corresponding state or local election) shall be made on the applicable Tax Return for any success-based
fees), and if any such Tax Return shows a net operating loss, the Company or its Subsidiaries shall carryback such net operating
loss to previous Pre-Closing Tax Periods to the maximum extent permitted by applicable Law. Buyer shall cause the Company and
its Subsidiaries and Blocker to timely file all Tax Returns prepared pursuant to this Section 9.01.

 

9.02          Pre-Closing
Tax Matters. After the Closing, Buyer shall not, and Buyer shall cause its Affiliates (including Blocker and the Company
and its Subsidiaries) not to, (a) other than Tax Returns that are filed pursuant to Section 9.01, file
or amend or otherwise modify any Tax Return relating to a Pre-Closing Tax Period, (b) after the date any Tax Return
filed pursuant to Section 9.01 is filed, amend or otherwise modify any such Tax Return, (c) extend or waive,
or cause to be extended or waived, any statute of limitations or other period for the assessment of any Tax or deficiency
related to a Pre-Closing Tax Period, (d) make or change any Tax election or accounting method or practice with respect
to, or that has retroactive effect to, any Pre-Closing Tax Period, (e) make or initiate any voluntary contact with a
Taxing Authority (including any voluntary disclosure agreement or similar process) regarding any Pre-Closing Tax Period,
or (f) take any other action with respect to a Pre-Closing Tax Period that could cause the Unitholders and/or Blocker
Seller to have additional Tax liability for any such Pre-Closing Tax Period.

 

9.03         Tax
Proceedings . Notwithstanding any other provision of this Agreement, after the Closing, the Company and its Subsidiaries
and Buyer (and any of their respective Affiliates) shall promptly notify the Representative in writing upon receiving notice
from any Taxing Authority of the commencement of any claim, audit, examination, or administrative or court proceeding relating
to any audits or assessments or other disputes regarding any Taxes or any Tax Return filed by the Company or its Subsidiaries
with respect to Pre-Closing Tax Periods for any Pass-Through Income Tax Matter (a “PT-Tax Proceeding”). Notwithstanding
any other provision of this Agreement, the Representative shall have the sole right in its discretion to elect to represent the
interests of the Company and its Subsidiaries and its direct and indirect owners in any PT-Tax Proceeding (including any settlement
or disposition thereof) that is not conducted pursuant to the Partnership Audit Tax Rules. Buyer shall take all action reasonably
necessary (including providing a power of attorney) to enable the Representative to exercise its control rights as set forth
in this Section 9.03; provided that Buyer shall have the right to participate in the defense thereof and to
employ counsel, at its own expense, separate from the counsel employed by the Representative. Notwithstanding the above, Representative
shall not consent to the entry of any judgment, or settle, compromise or discharge any PT-Tax Proceeding without the prior written
consent of Buyer (which shall not be unreasonably withheld, conditioned or delayed) if such action would have the effect
of increasing the Tax liability of the Company and its Subsidiaries or Blocker in a Post-Closing Tax Period. With respect to any
PT-Tax Proceedings that is not conducted pursuant to the Partnership Tax Audit Rules that the Representative does not elect
to control pursuant to this Section 9.03, Buyer shall have the sole responsibility for, and shall control, such PT-Tax
Proceeding, including the settlement and disposition thereof; provided, however, that (i) the Representative
shall have the right to participate in such PT-Tax Proceeding, including to review in advance and reasonably comment upon submissions
made in the course of such PT-Tax Proceeding and to attend any in-person or telephonic meetings, (ii) Buyer shall diligently
pursue such PT-Tax Proceeding in good faith as if it were the sole party in interest and (iii) the Representative’s
consent (not to be unreasonably withheld, conditioned or delayed) shall be required for any settlement that could affect
the Tax liability of the Unitholders or Blocker Seller. Buyer shall represent the interest of the Company and its Subsidiaries
and its direct and indirect owners in any PT-Tax Proceeding that is conducted pursuant to the Partnership Tax Audit Rules and
shall not make, nor shall Buyer allow any person serving as the “partnership representative” (as defined in Section 6223
of the Code) or “designated individual” of the Company to make, any election pursuant to Section 6226 of the
Code or any similar state or local law with respect to any such PT-Tax Proceeding.

 

    51

     

    

 

9.04            Cooperation.
Buyer, the Company and its Subsidiaries and Blocker and the Representative shall cooperate fully, as and to the extent reasonably
requested by any other Party, in connection with the preparation and filing of Tax Returns pursuant to Section 9.01
and any audit, litigation or other proceeding with respect to Taxes and the computation and verification of any amounts paid or
payable under this Article IX (including any supporting work papers, schedules and documents). Such cooperation shall
include the retention and (upon the other Party’s request) the provision of records and information which are reasonably
relevant to any such audit, litigation or other proceeding and making employees available on a mutually convenient basis to provide
additional information and explanation of any material provided hereunder. The Company shall, and shall cause its Subsidiaries
to, retain all books and records with respect to Tax matters pertinent to the Company or its Subsidiaries relating to any Tax
periods and shall abide by all record retention agreements entered into with any Taxing Authority, and shall give the Representative
reasonable written notice prior to transferring, destroying or discarding any such books and records prior to the expiration of
the applicable statute of limitations for that tax period, and if the Representative so requests, the Company shall, and shall
cause its Subsidiaries to, allow the Representative to take possession of such books and records rather than destroying or discarding
such books and records.

 

9.05            No
Code Section 338 or Section 336 Election. Buyer shall not, and shall cause its Affiliates (including Blocker
and the Company (and the Surviving Company) and its Subsidiaries) not to, make any election under Section 338 or 336
of the Code (or any similar provision under state, local or non-U.S. Law) with respect to the acquisition of Blocker pursuant
to this Agreement; provided that (a) Buyer or its Affiliates may, in their sole discretion, make an election under
Section 338(g) of the Code and (b) if an election under Section 338(g) of the Code is so made, Buyer
and its Affiliates shall pay all Taxes arising from or associated with such election under Section 338(g) of the Code
and shall indemnify and otherwise promptly reimburse Blocker Seller, the Unitholders, the Representative and any Affiliate or
direct or indirect owner, partner, shareholder or member of each of the foregoing with respect to any Taxes or other costs and
expenses arising from or attributable to such election under Section 338(g) of the Code.

 

9.06            Tax
Refunds. After the Closing Date, except to the extent (a) included as an asset in Working Capital as finally determined
hereunder or (b) attributable to the carryback of any loss from a Post-Closing Tax Period to a Pre-Closing Tax Period, Blocker
Seller and the Unitholders shall be entitled to all Tax refunds (including any Tax refunds resulting from the carryback of net
operating losses, capital loss or other tax attribute from one Pre-Closing Tax Period to another Pre-Closing Tax Period, to the
maximum extent permitted by applicable Law, including the CARES Act) (and Overpayment Credits) received by Buyer or any of
its Affiliates, the Company (including, for the avoidance of doubt, the Surviving Company) or any of its Subsidiaries or
Blocker for any Pre-Closing Tax Period; provided that, any such amounts with respect to the Blocker shall be for the sole
benefit of Blocker Seller. Buyer (or any of its Affiliates, including Blocker or the Surviving Company) will pay over to
the Representative (for further distribution to Blocker Seller and the Unitholders, as applicable) any such Tax refund promptly
(but in all cases within five Business Days) after actual receipt of such Tax refund (or, in the case of any Overpayment
Credits, promptly (but in all cases within five Business Days) upon filing the applicable Tax Return where such Overpayment
Credit is used to reduce Taxes otherwise payable). Buyer shall, and shall cause the Surviving Company, to elect to carry back
any item of loss, deduction, or credit from any Transaction Tax Deductions and any pre-closing losses generally to prior taxable
years to the fullest extent permitted by Law (using any available short-form or accelerated procedures) and, for the avoidance
of doubt, neither Parent nor Buyer shall, and each of them shall not allow the Surviving Company, its Subsidiaries, or the Blocker,
to make any election to waive the carryback of any net operating loss under Section 172(b)(3) of the Code (or any similar
state, local, or non-U.S. Law) or other Tax attribute or Tax credit incurred or realized in a Pre-Closing Tax Period by the Company
(including pursuant to Section 2303 of the CARES Act). To the extent permitted by applicable Law, Buyer (or any of its Affiliates,
including Blocker or the Surviving Company) shall request a refund (rather than a credit in lieu of a refund) with respect
to all Pre-Closing Tax Periods. If requested by the Representative, Buyer shall cause the Surviving Company, any Subsidiaries
thereof, or Blocker to amend any Tax Returns for any Pre-Closing Tax Period to conform to the provisions of the CARES Act that
apply to years ending on or prior to January 1, 2020, to the extent such amendment is reasonably expected to result in a
refund that is for the benefit of Blocker Seller or the Unitholders under Section 9.06.

 

    52

     

    

 

9.07            Straddle
Period. To the extent it is necessary for purposes of this Agreement to determine the allocation of Taxes among a Straddle
Period, Taxes of the Company and its Subsidiaries and Blocker, as applicable, based on or measured by income, gross or net sales,
or payments or receipts shall be allocated between the Pre-Closing Tax Period and the Post-Closing Tax Period based on an interim
closing of the books as of the close of business on the Closing Date and any other Taxes shall be allocated between the Pre-Closing
Tax Period and the Post-Closing Tax Period on a per diem basis.

 

9.08            Closing
of Tax Period.

 

(a)           The
Parties shall, to the extent permitted or required under applicable Law, treat the Closing Date as the last day of the taxable
period of the Company and its Subsidiaries for all Tax purposes; provided that the Parties agree that the Transactions
result in a continuation of the Company and applicable Subsidiaries and not a termination within the meaning of Section 708(b) of
the Code and no Party shall take a position inconsistent therewith for any Tax purpose. Notwithstanding anything in this
Section 9.08 to the contrary, following the Closing, Buyer may cause a termination within the meaning of Section 708(b) of
the Code.

 

(b)           With
respect to the preparation of any Income Tax Return for any Straddle Period, the Parties agree (a) the Company and its Subsidiaries
shall use the “interim closing method” (and the “calendar day convention”) pursuant to Section 706
of the Code (and any similar provision of state, local or non-U.S. law) to account for any varying interests in the Company
such that any income, gain, loss and deduction (and any other items) for the portion of such Straddle Period ending on and
including the Closing Date shall be allocated solely to the members of the Company with respect to the Pre-Closing Tax Period,
(b) all deductions of the Company and its Subsidiaries attributable to the Transactions (including any deductions attributable
to the Transaction Tax Deductions) shall be taken into account in the Pre-Closing Tax Period (and allocated solely to the
members of the Company with respect to the Pre-Closing Tax Period) to the extent “more likely than not” deductible
(or deductible at a higher level of confidence) in the Pre-Closing Tax Period, determined as if the Tax year ended on and
included the Closing Date, and applying the seventy percent safe-harbor election under Internal Revenue Service Revenue Procedure
2011-29 to any “success-based fees,” (c) any financing or refinancing arrangements entered into at any time by
or at the direction of the Buyer or its Affiliates or any other transactions entered into by or at the direction of the Buyer
or its Affiliates in connection with the Transactions shall not be taken into account in the Pre-Closing Tax Period, and (d) any
items of income, gain, loss and deduction attributable to transactions outside the ordinary course of business on the Closing
Date after the time of the Closing shall not be taken into account in the Pre-Closing Tax Period.

 

    53

     

    

 

(c)           Buyer
shall cause Blocker to join Buyer’s “consolidated group” (as defined in Treasury Regulation Section 1.1502-76(h)) effective
on the day after the Closing Date. The Parties agree that Buyer and its Affiliates and the Company and its Subsidiaries (i) shall
not make an election under Treasury Regulation Section 1.1502-76(b)(2)(ii)(D) to ratably allocate items (or any make
any similar election or ratably allocate items under any corresponding provision of state, local or non-U.S. Law) and (ii) shall
not apply the “next day” rule of Treasury Regulation Section 1.1502-76(b)(1)(ii)(B) with respect to
any of the Transaction Tax Deductions.

 

9.09         Allocation
of the Closing Cash Payment. For U.S. federal and applicable state income Tax purposes, the Representative shall allocate
the Transaction Consideration (other than the Blocker Purchase Price) plus a ratable share of the applicable liabilities
of the Company and its Subsidiaries and any other relevant items required to be taken into account for income Tax purposes in
accordance with the allocation principles set forth on the Allocation Schedule attached hereto as Exhibit E for
purposes of determining the portion of the gain or loss recognized upon the sale of the Preferred Units and the Common Units pursuant
to the Merger that is attributable to the Company’s “unrealized receivables” and “inventory items”
(as such terms are defined in Section 751 of the Code). The Parties shall not, and Buyer shall cause its Affiliates not to,
take any position in any audits, Tax Returns or otherwise which is inconsistent with such allocation unless required to do so
by a final “determination” pursuant to Section 1313(a) of the Code.

 

9.10          Tax
Treatment of Payments. Any adjustment payments pursuant to Section 3.03 and any payments of Tax refunds pursuant
to Section 9.06 will be deemed adjustments to the Closing Cash Payment, unless otherwise required by Law.

 

9.11         Intermediary
Transaction Tax Shelter. Buyer shall not take any action with respect to Blocker, the Company or any of its Subsidiaries
that would cause the Transactions to constitute part of a transaction that is the same as, or substantially similar to, the “Intermediary
Transaction Tax Shelter” described in Internal Revenue Service Notices 2001-16 and 2008-111.

 

Article X

CONDITIONS TO THE OBLIGATIONS OF BUYER, PARENT AND MERGER SUB

 

The obligations of
Buyer, Parent and Merger Sub to consummate the Transactions are subject to the satisfaction of the following conditions as of
the Closing Date, any or all of which may be waived in writing in whole or in part by Buyer:

 

10.01       Accuracy
of Representations and Warranties. The representations and warranties set forth in Article V and Article VI
shall be true and correct as of the Closing Date (disregarding all qualifications or limitations as to “materiality,”
 “in all material respects” or “Material Adverse Effect” set forth therein) as though such representations
and warranties had been made on and as of the Closing Date (except that any such representations and warranties that are made
as of a specified date shall be true and correct only as of such date), except where the failure of such representations and warranties
to be true and correct would not have a Material Adverse Effect.

 

10.02            Compliance
with Covenants. The Company and Blocker Seller shall have performed in all material respects all of the covenants and agreements
required to be performed by them under this Agreement at or prior to the Closing.

 

    54

     

    

 

 

10.03       No
Adverse Proceeding. No Proceeding by or before any Governmental Authority shall be pending against the Company or Blocker
Seller wherein an unfavorable judgment, decree or order would prevent the performance of this Agreement or the consummation of
any of the Transactions, declare unlawful the Transactions or cause such Transactions to be rescinded.

 

10.04       No
Material Adverse Effect. Since the date hereof, there has not been any Material Adverse Effect.

 

10.05       Termination
of HSR Waiting Period

 

. The waiting period
under the Hart-Scott-Rodino Act shall have expired or been terminated.

 

Article XI

CONDITIONS TO THE OBLIGATIONS OF THE COMPANY AND BLOCKER SELLER

 

The obligation of
the Company and Blocker Seller to consummate the Transactions is subject to the satisfaction of the following conditions as of
the Closing Date, any or all of which may be waived in writing in whole or in part by the Company and the Representative:

 

11.01       Accuracy
of Representations and Warranties. The representations and warranties set forth in Article IV shall be true and
correct as of the Closing Date (disregarding all qualifications or limitations as to “materiality,” “in all
material respects” or “Buyer Material Adverse Effect”), as though such representations and warranties had been
made on and as of the Closing Date (except that any such representations and warranties that are made as of a specified date shall
be true and correct only as of such date), except where the failure of such representations and warranties to be true and correct,
individually or in the aggregate has not, or would not, individually or in the aggregate, reasonably be expected to have a Buyer
Material Adverse Effect.

 

11.02       Compliance
with Covenants. Each of Buyer, Parent and Merger Sub shall have performed in all material respects all of the covenants and
agreements required to be performed by them under this Agreement at or prior to the Closing.

 

11.03       No
Adverse Proceeding. No Proceeding by or before any Governmental Authority shall be pending wherein an unfavorable judgment,
decree or order would prevent the performance of this Agreement or the consummation of any of the Transactions, declare unlawful
the Transactions or cause such transactions to be rescinded.

 

11.04       Termination
of HSR Waiting Period. The waiting period under the Hart-Scott-Rodino Act shall have expired or been terminated.

 

Article XII

DEFINITIONS

 

12.01       Defined
Terms. As used herein, the following terms shall have the following meanings:

 

“2018 Purchase
Agreement” means that certain Purchase Agreement, dated as of May 8, 2018, by and among Solara Intermediate, LLC,
a Delaware limited liability company, Tod Robinson, Solara Medical Holding Corporation, a California corporation, and Solara Medical
Supplies, a California corporation.

 

“2018 Year-End
Financial Statements” has the meaning set forth in Section 6.07(a).

 

“2019 Year-End
Financial Statements” has the meaning set forth in Section 6.07(a).

 

    55

     

    

 

Certain information in this document identified by brackets
has been omitted because it is both not material and would be competitively harmful if publicly disclosed.

 

“2019 Audited
Financials” has the meaning set forth in Section 7.10.

 

“Accounting
Principles” means (i) the accounting principles, policies, procedures and categorizations set out in Exhibit I
and (ii) to the extent not addressed in the preceding clause, GAAP.

 

[***]

 

“Acquisition
Proposal” means any proposal or offer from any Person (other than the Buyer Parties, Merger Sub and their respective
accountants, attorneys, consultants, advisors, investment bankers, or other representatives) relating to any merger, consolidation,
or recapitalization involving the Company or its Subsidiaries, sale of a majority of the equity securities, directly or indirectly,
in the Company, Blocker or any of their respective Subsidiaries, any sale, lease, or other disposition, directly or indirectly,
of all or substantially all of the assets of the Company, Blocker or any of their respective Subsidiaries or other similar transaction
involving the Company, Blocker or their respective Subsidiaries (excluding, for the avoidance of doubt, sales of inventory in
the ordinary course of business).

 

[***]

 

[***]

 

“Action”
means any claim, action, cause of action, demand, lawsuit, arbitration, inquiry, audit, notice of violation, proceeding, litigation,
citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether
at law or in equity.

 

“Adjustment
Escrow Amount” means $4,000,000.00.

 

“Adjustment
Escrow Funds” means, as of any date, the amount of funds then held by the Escrow Agent pursuant to the Escrow Agreement
in the account into which the Adjustment Escrow Amount was deposited at Closing.

 

“Adjustment
Time” means 12:01 a.m. prevailing Eastern Time on the Closing Date.

 

“Affiliate”
of any particular Person means any other Person controlling, controlled by or under common control with such particular Person,
where “control” means the possession, directly or indirectly, of the power to direct the management and policies
of a Person whether through the ownership of voting securities, contract or otherwise.

 

“Agreement”
has the meaning set forth in the Preamble.

 

“Alternative
Financing” has the meaning set forth in Section 7.09.

 

“Authorized
Action” has the meaning set forth in Section 15.15(d).

 

“Bankruptcy
and Equity Exceptions” has the meaning set forth in Section 4.03.

 

“Base Amount”
means $362,500,000.00.

 

“Blocker”
has the meaning set forth in the Recitals.

 

“Blocker
Adjustment Payment” has the meaning set forth in Section 3.03(b)(i).

 

“Blocker
Closing” has the meaning set forth in Section 1.03.

 

    56

     

    

 

“Blocker
Closing Payment” has the meaning set forth in Section 1.02(a).

 

“Blocker
Company Units” has the meaning set forth in the Recitals.

 

“Blocker
Purchase” has the meaning set forth in the Recitals.

 

“Blocker
Purchase Price” has the meaning set forth in Section 1.02.

 

“Blocker
Seller” has the meaning set forth in the Preamble.

 

“Blocker
Shares” has the meaning set forth in the Recitals.

 

“Business
Day” means any day, excluding Saturday, Sunday and any other day on which commercial banks in Chicago, Illinois
are authorized or required by law to close.

 

“Buyer”
has the meaning set forth in the Preamble.

 

“Buyer Material
Adverse Effect” means a material adverse effect on the ability of Buyer, Parent or Merger Sub to consummate the Transactions
and perform all of their respective obligations hereunder and under the other Transaction Documents to which they are party in
a timely manner.

 

“Buyer Returns”
has the meaning set forth in Section 9.01(b).

 

“CARES Act”
means the Coronavirus Aid, Relief, and Economic Security Act.

 

“Capitalization
Date” has the meaning set forth in the Section 4.07(a).

 

“Cash Amount”
means (a) the fair market value (expressed in United States dollars) of all cash and cash equivalents (including marketable
securities, checks, bank deposits, outstanding drafts, wire payments and short term investments) of the Company and its Subsidiaries,
less (b) issued but uncleared checks and bank overdrafts, plus (c) checks, other wire transfers, cash-in-transit
and drafts which have been received by the Company and its Subsidiaries but not yet cleared, in each case, as of as of the Adjustment
Time. For the avoidance of doubt, “Cash Amount” shall (i) not include restricted cash or security deposits, (ii) 
be reduced for any accrued and unpaid tax distribution owed by the Company to the Unitholders unless the obligation to provide
such tax distribution shall be terminated on or prior to the Closing and (iii) be determined on a consolidated basis.

 

“Certificate
of Merger” has the meaning set forth in Section 2.02.

 

“Class A
Common Units” has the meaning set forth in the LLC Agreement.

 

“Class A
Common Stock” has the meaning set forth in the Section 4.07(a).

 

“Class A
Preferred Units” has the meaning set forth in the LLC Agreement.

 

“Class B
Common Units” has the meaning set forth in the LLC Agreement.

 

“Class A
Common Stock” has the meaning set forth in the Section 4.07(a).

 

“Class B
Preferred Units” has the meaning set forth in the LLC Agreement.

 

“Class Z
Common Units” has the meaning set forth in the LLC Agreement.

 

    57

     

    

 

“Closing”
has the meaning set forth in Section 3.01.

 

“Closing
Cash Payment” means the amount equal to (a) the Base Amount, plus (b) the Cash Amount, minus
(c) the outstanding amount of all Funded Debt as of immediately prior to the Closing, minus (d) the Transaction
Expenses Amount, minus (e) the Adjustment Escrow Amount, minus (f) the Indemnity Escrow Amount, minus
(g) the Specific Escrow Amount, minus (h) the Representative Holdback, minus (i) the Working Capital
Deficit, if any, plus (j) the Working Capital Surplus, if any.

 

“Closing
Date” has the meaning set forth in Section 3.01.

 

“Closing
Failure Notice” has the meaning set forth in Section 13.01(c)(ii).

 

“Closing
Statement” has the meaning set forth in Section 3.03(b)(i).

 

“Code”
means the Internal Revenue Code of 1986, as amended.

 

“Common Units”
has the meaning set forth in the LLC Agreement.

 

“Common Stock”
has the meaning set forth in the Section 4.07(a).

 

“Company”
has the meaning set forth in the Preamble.

 

“Company’s
Knowledge” means the actual knowledge of Stephen Foreman, Aaron Heisler, Keith Crawford, and Marty Hoffman, after due
inquiry.

 

“Confidentiality
Agreement” has the meaning set forth in Section 7.06.

 

“Continuing
Employee” has the meaning set forth in Section 8.06.

 

“Contract”
means any contract or other legally binding agreement (whether written or oral).

 

“COVID-19”
means SARS-CoV-2 or COVID-19 and any related epidemics, pandemics or disease outbreaks.

 

“COVID-19
Measures” means any quarantine, “shelter in place”, “stay at home”, workforce reduction, social
distancing, closure sequester or other Law issued by any Governmental Authority in response to COVID-19.

 

“D&O
Claim” has the meaning set forth in Section 8.02(b).

 

“D&O
Indemnified Persons” has the meaning set forth in Section 8.02(a).

 

“Debt Commitment
Letter” has the meaning set forth in Section 4.06.

 

“Debt Financing”
has the meaning set forth in Section 4.06.

 

“Debt Financing
Source” has the meaning set forth in Section 15.21.

 

“Designated
Courts” has the meaning set forth in Section 15.09(a).

 

“Designated
Unitholder” means each Unitholder other than Blocker.

 

    58

     

    

 

“Distribution
Principles” means the principles of distribution set forth in Section 4.1 of the LLC Agreement (i.e., the
principles of distribution if all of the assets and properties of the Company and its Subsidiaries were sold and the resulting
proceeds were distributed among the members of the Company pursuant to Section 4.1 of the LLC Agreement) after giving effect
to any Participation Threshold (as defined in the LLC Agreement) applicable to any Common Unit; provided that (i) any
amounts that would otherwise be distributed to Blocker pursuant to the principles of distributions set forth in Section 4.1
of the LLC Agreement shall be distributed to Blocker Seller; and (ii) the portion of the Estimated Closing Cash Payment and/or
any Future Distribution Amount allocated to Blocker Seller will be increased by the Cash Amount held by Blocker (i.e.,
so that Blocker Seller receives 100% of the increase in the purchase price as a result of such Cash Amount) and will be decreased
by the total outstanding amount of Funded Debt of Blocker as of immediately prior to the Closing (i.e., so that Blocker
Seller bears 100% of the decrease in the purchase price as a result of such Funded Debt).

 

“DLLCA”
has the meaning set forth in the Recitals.

 

“Effective
Time” has the meaning set forth in Section 2.02.

 

“End Date”
means the date that is 120 days after the date hereof.

 

“Environmental
Laws” means all applicable Laws enacted and in effect on the Closing Date concerning pollution or protection of the
environment.

 

“Equity Financing”
has the meaning set forth in Section 4.06.

 

“ERISA”
means the Employee Retirement Income Security Act of 1974.

 

“ERISA Affiliate”
means any entity (whether or not incorporated) other than the Company that, together with the Company or any Subsidiary, is or
at any relevant time was required to be treated as a single employer under Section 414(b), (c), (m) or (o) of the
Code.

 

“Escrow Agent”
means Acquiom Financial LLC.

 

“Escrow Agreement”
means an Escrow Agreement substantially in the form of Exhibit F attached hereto, to be dated as of the Closing Date,
by and among the Escrow Agent, the Representative and Buyer.

 

“Estimated
Closing Cash Payment” has the meaning set forth in Section 3.03(a).

 

“Estimated
Closing Statement” has the meaning set forth in Section 3.03(a).

 

“Family Member”
of any natural person means such person’s spouse, parents, step-parents, step-children, mother-in-law, father-in-law, son-in-law,
daughter-in-law, domestic partners, grandparents and descendants, including adoptive relationships, together with any spouse of
any of the foregoing individuals.

 

“Federal
Health Care Program” has the meaning given it in 42 U.S.C. § 1320a-7b(f).

 

“Fee Letters”
has the meaning set forth in Section 4.06.

 

“Financial
Statements” has the meaning set forth in Section 6.07(a).

 

“Financing”
has the meaning set forth in Section 4.06.

 

“Financing
Letters” has the meaning set forth in Section 4.06.

 

    59

     

    

 

“Firm”
has the meaning set forth in Section 3.03(b)(i).

 

“Founder
Earnout Amount” means the amount of the Performance Payment (as that term is defined in the 2018 Purchase Agreement)
required to be paid pursuant to Section 2.6(b)(iv) of the 2018 Purchase Agreement as finally determined in accordance
with the 2018 Purchase Agreement. If the Founder Earnout Amount has not been finally determined prior to the Closing, then the
Founder Earnout Amount will be the maximum amount that could become payable by the Company and its Subsidiaries pursuant to Section 2.6(b)(iv) of
the 2018 Purchase Agreement (which amount shall be determined by the Representative in good faith). For the avoidance of doubt,
if the Performance Payment has been finally determined and paid by the Company or its Subsidiaries prior to the Closing, then
the Founder Earnout Amount shall be $0. In no event will the Founder Earnout Amount include any amounts that may become due and
payable under Section 2.6(k) of the 2018 Purchase Agreement.

 

“Fraud”
means intentional and knowing common law fraud under Delaware law in the representations and warranties set forth in this Agreement.
A claim for Fraud may only be made against the Party committing such Fraud. “Fraud” does not include equitable
fraud, constructive fraud, promissory fraud, unfair dealings fraud, unjust enrichment, or any torts (including fraud) or other
claim based on negligence or recklessness (including based on constructive knowledge or negligent misrepresentation) or any other
equitable claim.

 

“Funded Debt”
means, as of the time of determination, without duplication, (a) the amount of all indebtedness for borrowed money under
any credit facilities (including any unpaid principal, premium, accrued and unpaid interest, related expenses, prepayment penalties,
commitment and other fees, reimbursements and all other amounts payable in connection therewith) of the Company or any of
its Subsidiaries, (b) liabilities of the Company or any of its Subsidiaries evidenced by bonds, debentures, notes or other
similar instruments or debt securities, (c) any obligation of the Company or any of its Subsidiaries evidenced by any letters
of credit or bankers’ acceptances, in each case, solely to the extent drawn upon, (d) the Founder Earnout Amount, (e) any
liability or obligation of the Company or any of its Subsidiaries with respect to deferred and unpaid purchase price obligations
for equity, property or other assets (including all seller notes, “earn-out” payments or similar payments, whether
contingent or otherwise), solely to the extent not included in Working Capital, (f) any capitalized or lease obligation,
as determined under GAAP, (g) any obligation due and owing under any interest rate swap, forward contract or other hedging
arrangement, (h) an amount equal to $3,699,178.00 and any additional amounts received by the Company or any of its Subsidiaries
prior to the Closing Date pursuant to Section 3719 of the CARES Act; provided, however, that if, prior to the
final determination of the Closing Cash Payment pursuant to Section 3.03, it is determined by the Representative in
good faith and based upon available guidance issued by the applicable Governmental Authority that the Company’s obligation
to repay all or any portion of such amount will be forgiven by the U.S. Department of Health and Human Services without cash payment
therefor or otherwise as an offset or recoupment to any ongoing Medicare payments then such portion shall not constitute Funded
Debt, (i) any employee bonuses for employees of the Company or any of its Subsidiaries triggered by the Closing or as a result
of the consummation of the Transactions, (j) the Pre-Closing Tax Liability Amount, solely to the extent not reflected on
the Latest Balance Sheet, and (k) guarantees by the Company or any of its Subsidiaries of the foregoing (but only to the
extent called upon or drawn); provided that Funded Debt shall not include (i) any amounts included in the Transaction
Expenses Amount or Working Capital, (ii) any undrawn letters of credit or bankers acceptances or similar facilities, (iii) any
liabilities or obligations related to inter-company debt between or among the Company and its Subsidiaries or (iv) any fees
and expenses to the extent incurred by or at the direction of Buyer or any other liabilities or obligations incurred or arranged
by or on behalf of Buyer or any of its Affiliates in connection with the Transactions. For the avoidance of doubt, (w) the
term “Funded Debt” shall not include any known or identified overpayment paid to the Company or any of its Subsidiaries
from any Third Party Payor, Medicare, Medicaid or any other Federal Health Care Program, (x) the term “Funded Debt”
shall include any unpaid principal, accrued and unpaid interest, prepayment penalties, breakage costs, premiums and other expenses
incurred in connection with the repayment of any of the foregoing, (y) any amount of “Funded Debt” that is reduced
as a result of any payment of the Cash Amount at any time after the Adjustment Time and prior to the Closing shall be deemed to
still be outstanding as of immediately prior to the Closing for purposes of calculating the Closing Cash Payment under this Agreement,
and (z) if any liabilities meet the definition of both Funded Debt and Working Capital such liability shall be included in
Funded Debt for purposes of determining the Closing Cash Payment.

 

    60

     

    

 

“Future Distribution
Amount” means any amounts to be distributed to the Unitholders or Blocker Seller pursuant to the Escrow Agreement, Section 3.03(b),
Section 8.08, Section 9.06 or Section 15.15.

 

“GAAP”
means United States generally accepted accounting principles, consistently applied.

 

“Governmental
Authority” means any United States or non-United States, federal, state, provincial or local governmental or regulatory
commission, board, bureau, agency, court or regulatory or administrative body.

 

“Hart-Scott-Rodino
Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

 

“Healthcare-Related
Law” means (i) the Federal Healthcare Program Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)), (ii) the
federal Medicare statute, federal and state Medicaid statutes, Sections 1128, 1128A, 1128B, 1128C and 1877 of the Social Security
Act (42 U.S.C. §§ 1320a-7, 1320a-7a, 1320a-7b, 1320a-7c, 1395(y)(e) and 1395nn), (iii) statutes governing
TRICARE (10 U.S.C. § 1071 et seq.), (iv) the civil False Claims Act of 1863 (31 U.S.C. § 3729 et seq.),
(v) criminal false claims and false statements statutes (e.g., 18 U.S.C. §§ 287 and 1001), (vi) the Program
Fraud Civil Remedies Act of 1986 (31 U.S.C. § 3801 et seq.), (vii) the Health Insurance Portability and Accountability
Act of 1996 (e.g., 18 U.S.C. §§ 1035 and 1347), as amended by the Health Information Technology for Economic and
Clinical Health Act, and the regulations promulgated thereunder, including as regarding the transaction and code set standards,
and the privacy, breach, and security standards set forth at 45 C.F.R. Parts 160 and 164, (viii) all applicable federal and
state statutes and regulations applicable to the sale, storage, shipping, distribution or dispensing of durable medical equipment;
and (ix) all other applicable quality, safety certification and accreditation standards and requirements applicable to the
sale of durable medical equipment.

 

“Income Tax
Return” means all Tax Returns filed or required to be filed with any Taxing Authority with respect to Income Taxes,
including with respect to any Pass-Through Income Tax Matter.

 

“Income Taxes”
means Taxes imposed on, measured by, or determined by reference to (in whole or in part), net income.

 

“Indemnity
Escrow Account” means the account established by the Escrow Agent pursuant to the terms of the Escrow Agreement to hold
the Indemnity Escrow Funds.

 

“Indemnity
Escrow Amount” means $5,000,000.00.

 

“Indemnity
Escrow Funds” means, as of any date, the amount of funds then held by the Escrow Agent pursuant to the Escrow Agreement
in the Indemnity Escrow Account.

 

“Indemnity
Matters” has the meaning set forth in Section 14.02(b)(i).

 

“Insurance
Policies” has the meaning set forth in Section 6.16.

 

    61

     

    

 

“Intellectual
Property” means all (i) all copyrightable works, all copyrights, and all applications, registrations and renewals
thereof, (ii) trade names, fictional business names, trade dress rights, registered and unregistered trademarks, service
marks and logos and other proprietary indicia of goods and services, whether registered or unregistered, and including all registrations
and applications therefor, including intent-to-use applications, all issuances, extensions and renewals of such registrations
and applications and the goodwill connected with the use of and symbolized by any of the foregoing, together with all translations,
adaptations, derivations and combinations and like intellectual property rights, (iii) all inventions (whether patentable
or unpatentable and whether or not reduced to practice), all improvements thereto, and all patents, patent applications, and patent
disclosures, together with all reissuances, divisions, continuations, continuations-in-part, substitutes, extensions, and re-examinations
thereof, (iv) all proprietary formulations, know-how, show-how, confidential business information, trade secrets, research
and development results, compositions, techniques, processes, technical data, designs, drawings, diagrams, specifications, catalogs,
customer and supplier lists and contact information, pricing and cost information, business and marketing plans and proposals,
and manufacturing, engineering, quality control, testing, operations, logistical, maintenance and other technical information
and technology, (v) all mask works and all applications, registrations and renewals in connection therewith, (vi) all
computer software (including data and related documentation), whether purchased, licensed or internally developed; and (vii) all
copies and tangible embodiments of the above in whatever form or medium.

 

“Interim
Financial Statements” has the meaning set forth in Section 6.07(a).

 

“Investment
Agreement” has the meaning set forth in Section 4.06.

 

“Key Customer”
has the meaning set forth in Section 6.22(a).

 

“Key Supplier”
has the meaning set forth in Section 6.22(b).

 

“Latest Balance
Sheet” has the meaning set forth in Section 6.07(a).

 

“Law”
means any foreign, federal, state, local, municipal, or foreign order, constitution, law, ordinance, rule, regulation, statute
or treaty, but specifically excluding any Healthcare-Related Law.

 

“LCP IV-A”
means Linden Capital Partners IV-A LP, a Delaware limited partnership.

 

“Leased Real
Property” means all leasehold or subleasehold estates and other rights to use or occupy any land, buildings, structures,
improvements, fixtures or other interest in real property which is used or intended to be used in the business.

 

“Letter of
Transmittal” has the meaning set forth in Section 2.09(b).

 

“Lien”
means any lien, mortgage, deed of trust, pledge, security interest, easement or other material encumbrance, but excluding restrictions
on transfer generally arising under federal and state securities Laws.

 

“LLC Agreement”
means that Second Amended and Restated Limited Liability Company Agreement of the Company, dated February 4, 2015.

 

“Losses”
has the meaning set forth in Section 14.02(b).

 

“Management
Services Agreement” means that Management Services Agreement, dated as of May 31, 2018, by and between Solara Medical
Supplies, LLC and Linden Manager IV LP.

 

    62

     

    

 

“Material
Adverse Effect” means any state of facts, event, effect or development that, individually or in the aggregate, has had
or would reasonably be expected to have a material adverse effect upon the financial condition, business or operating results
of the Company and its Subsidiaries taken as a whole; provided that none of the following (or the results thereof), either
alone or taken together with other facts, events, effects or developments, will constitute, or be taken into account in determining
whether there has been or will be, a Material Adverse Effect: (i) any change or condition that is generally applicable to
the industries or markets in which the Company and its Subsidiaries operate, (ii) any national or international political,
regulatory or social conditions, including any acts of terrorism, sabotage, cyber-attack, military action, declaration of a national
emergency or war (regardless of whether declared), or any escalation or worsening thereof, (iii) conditions generally affecting
the United States or worldwide economy or credit, currency, oil, financial, banking, securities or capital markets (including
any increased cost, or decreased availability, of capital or pricing or terms related to any financing for the Transactions or
any disruption thereof and any decline in the price of any security, commodity or market index), (iv) any earthquake, hurricane,
tsunami, tornado, flood, mudslide or other natural disaster, weather condition, explosion or fire or other force majeure event
or act of God, whether or not caused by any Person, or any national or international calamity or crisis, (v) pandemic, epidemic
or disease outbreak (including COVID-19), (vi) changes in GAAP, (vii) changes or prospective changes in Laws or the
enforcement or interpretation thereof or any action required to be taken under any Law by which the Company or its Subsidiaries
(or any of their respective assets or properties) is bound, (viii) (a) the taking of any action permitted or required
by this Agreement or taken at the written request of Buyer or its Affiliates, (b) the failure to take any action if such
action is prohibited by this Agreement, (c) Buyer’s failure to consent to any of the actions restricted in Section 7.03
or (d) the negotiation or execution of this Agreement or any other Transaction Document or announcement, pendency or
consummation of this Agreement or the Transactions or the identity, nature or ownership of Buyer, including the impact thereof
on the relationships, contractual or otherwise, of the Company or any of its Subsidiaries with any of its or their business relations
or employees, (ix) failure, in and of itself, to meet any budgets, projections, forecasts, estimates, plans, predictions,
guidance, milestones, revenue, earnings or performance metrics or operating statistics or the inputs into such items (but, for
the avoidance of doubt, not the underlying causes of any such failure to the extent such underlying cause is not otherwise excluded
from the definition of Material Adverse Effect) or (x) any action taken by Buyer or its Affiliates with respect to the Transactions,
except, in the case of clauses (i) through (iv), to the extent such fact, event, effect or development has a disproportionate
impact on the Company and its Subsidiaries, taken as a whole, as compared to other participants engaged in the industries and
geographies in which the Company and its Subsidiaries operate.

 

“Material
Contracts” has the meaning set forth in Section 6.19(a).

 

“Merger”
has the meaning set forth in the Recitals.

 

“Merger Sub”
has the meaning set forth in the Preamble.

 

“Non-Party
Affiliates” has the meaning set forth in Section 15.18.

 

“Objection
Disputes” has the meaning set forth in Section 3.03(b)(i).

 

“Objection
Statement” has the meaning set forth in Section 3.03(b)(i).

 

“Ordinary
Course of Business” means an action taken, or omitted to be taken, by any Person in the ordinary course of such Person’s
business consistent with past practice (including, for the avoidance of doubt, any actions taken, or omitted to be taken, in good
faith in light of COVID-19 and actions to respond to COVID-19 Measures).

 

    63

     

    

 

“Overpayment
Credits” means any overpayment of Taxes from a Pre-Closing Tax Period or any prepayment of Taxes in a Pre-Closing Tax
Period applied to reduce Taxes in a tax period beginning after the Closing Date.

 

“Parent Common
Stock” means the Class A Common Stock, par value $0.0001 per share, of Parent.

 

“Parent Stock
Awards” has the meaning set forth in the Section 4.07(a).

 

“Parent Stock
Options” has the meaning set forth in the Section 4.07(a).

 

“Partnership
Tax Audit Rules” means Code Section 6221 through 6241, together with any guidance issued thereunder or successor
provisions and any similar provision of state or local Tax laws with respect to audits or assessments pursuant to which any resulting
Taxes are assessed at the partnership-level absent a contrary election.

 

“Party”
or “Parties” has the meaning set forth in the Preamble.

 

“Pass-Through
Income Tax Matter” means any matter relating to the determination of Income Taxes with respect to the operations of
the business of the Company and its Subsidiaries if any of Unitholders (or their direct and indirect owners) would be liable
as a matter of Law for such Income Taxes (e.g., the income tax liability for items of income, gain, loss, deduction and
credit passed-through to owners with respect to a partnership for U.S. federal or applicable state and local income Tax purposes).

 

“Paying Agent”
has the meaning set forth in Section 2.09(a).

 

“Paying Agent
Agreement” has the meaning set forth in Section 2.09(a).

 

“Payoff Letters”
has the meaning set forth in Section 3.02(b)(i).

 

“Permits”
has the meaning set forth in Section 6.17.

 

“Permitted
Liens” means (i) any restriction on transfer arising under applicable securities Laws, (ii) Liens for Taxes
not yet delinquent or for Taxes being contested in good faith through appropriate proceedings, (iii) customary Liens of lessors,
lessees, sublessors, sublessees, licensors or licensees arising under lease arrangements or license arrangements (provided appropriate
reserves required pursuant to GAAP have been made in respect thereof), (iv) Liens relating to Funded Debt included in the
calculation of the Closing Cash Payment pursuant to this Agreement, (v) Liens arising in the ordinary course of business
and not incurred in connection with the borrowing of money, none of which materially impacts the current use of the affected property,
(vi) mechanics Liens and similar Liens for labor, materials, or supplies arising in the ordinary course of business for amounts
not yet overdue, (vii) zoning, building codes, and other land use Laws regulating the use or occupancy of real property or
the activities conducted thereon that are imposed by any Governmental Authority having jurisdiction over such real property and
which are not violated in any material respect by the current use and operation of such real property by the Company and its Subsidiaries,
(viii) easements, servitudes, covenants, conditions, restrictions, and other similar non-monetary matters affecting title
to any assets of the Company or any of its Subsidiaries and other title defects that do not materially impair the use or occupancy
of such assets in the operation of the business of the Company and its Subsidiaries, taken as a whole, (ix) with respect
to the Leased Real Property, all Liens which are suffered or incurred by the fee owner, any superior lessor, sublessors or licensor,
or any inferior lessee, sublessee or licensee, (x) licenses to Intellectual Property granted in the ordinary course of business,
and (xi) Liens set forth on Schedule 12.01(i).

 

    64

     

    

 

“Person”
means an individual, partnership, corporation, limited liability company, business trust, joint stock corporation, estate, trust,
unincorporated association, joint venture, Governmental Authority or other entity, of whatever nature.

 

“Plan”
has the meaning set forth in Section 6.14(a).

 

“PPACA”
has the meaning set forth in Section 6.14(f).

 

“Pre-Closing
Reorganization” means the transactions set forth on Exhibit H.

 

“Pre-Closing
Tax Liability Amount” means an amount equal to the Tax Liability Amount of the Company and its Subsidiaries separately
calculated for (a) each jurisdiction in which the Company and its Subsidiaries are currently filing Tax Returns with respect
to Taxes and (b) each jurisdiction in which the Company and its Subsidiaries commenced activities and became subject to Tax
on or after January 1, 2020, and prior to the Closing Date.

 

“Preferred
Stock” has the meaning set forth in the Section 4.07(a).

 

“Post-Closing
Tax Period” means any taxable period beginning after the Closing Date and, for any Straddle Period, the portion beginning
after the Closing Date.

 

“Pre-Closing
Tax Period” means any taxable periods ending on or before the Closing Date and, for any Straddle Period, the portion
through the end of the Closing Date.

 

“Preferred
Units” means the Class A Preferred Units and the Class B Preferred Units.

 

“Proceeding”
means any litigation, suits, arbitration or similar proceeding.

 

“PT-Tax Proceeding”
has the meaning set forth in Section 9.03.

 

“R&W
Policy” means the buyer-side representations and warranties insurance policy purchased by, and issued to, Buyer by Liberty
Surplus Insurance Corporation.

 

“Representative”
has the meaning set forth in Section 15.15(a).

 

“Representative
Holdback” means $750,000.00.

 

“Representative
Returns” has the meaning set forth in Section 9.01(a).

 

“Restricted
Party” has the meaning set forth in Section 8.09(a).

 

“Schedules”
means the disclosure schedules to this Agreement.

 

“Securities
Act” means the Securities and Exchange Act of 1933.

 

“Share Consideration”
means 3,906,250 shares of Parent Common Stock.

 

“Specific
Matters” has the meaning set forth in Section 14.02(b)(ii).

 

“Specific
Escrow Account” means the account established by the Escrow Agent pursuant to the terms of the Escrow Agreement to hold
the Specific Escrow Funds.

 

    65

     

    

 

“Specific
Escrow Amount” means $5,100,000.00.

 

“Specific
Escrow Funds” means, as of any date, the amount of funds then held by the Escrow Agent pursuant to the Escrow Agreement
in the Specific Escrow Account.

 

“Splitter”
has the meaning set forth in the Recitals.

 

“Stock Plan”
has the meaning set forth in the Section 4.07(a).

 

“Straddle
Period” means any taxable period that includes, but does not end on, the Closing Date.

 

“Subsidiary”
or “Subsidiaries” of any Person means any corporation, partnership, limited liability company or other legal
entity in which such Person (either alone or through or together with any other Subsidiary), owns, directly or indirectly, fifty
percent or more of the stock or other equity or ownership interests, the holder of which is generally entitled to elect a majority
of the board of directors or other governing body of such legal entity.

 

“Surviving
Company” has the meaning set forth in Section 2.01.

 

“Surviving
Matters” has the meaning set forth in Section 14.02(b)(ii).

 

“Target Working
Capital” means $15,314,217.00.

 

“Tax Liability
Amount” means, with respect to any jurisdiction, an amount equal to the liability for Taxes unpaid as of the Closing
Date; provided that, for purposes of calculating any such liability for Taxes: (i) such liability for Taxes shall be calculated
in accordance with the past practice (including reporting positions, elections, accounting and valuations methods, and accounting
methods) of the Company and its Subsidiaries in preparing Tax Returns for Taxes; (ii) all Transaction Tax Deductions shall
be taken into account to the extent “more likely than not” deductible (or at a higher level of confidence) in the
Pre-Closing Tax Period and applying the seventy percent safe-harbor election under Revenue Procedure 2011-29 to any “success-based
fees”; (iii) any financing or refinancing arrangements entered into at any time by or at the direction of Parent, Buyer
or any of their respective Affiliates or any other transactions entered into by or at the direction of Parent, Buyer or any of
their respective Affiliates in connection with the transactions contemplated hereby shall not be taken into account; (iv) any
Taxes attributable to transactions outside the ordinary course of business on the Closing Date after the time the Closing shall
be excluded; (v) any liabilities for accruals or reserves established or required to be established under GAAP methodologies
with respect to contingent Taxes or with respect to uncertain Tax positions shall be excluded; (vi) any election made after
the Closing Date that increases the amount of income realized in (or Tax payable for) a Pre-Closing Tax Period (other than any
election actually made on any such Tax Return that is recurring in nature and was consistently made by the Company on Tax Returns
filed prior to the Closing Date) shall be excluded; (vii) all deferred Tax liabilities established or required to be established
for GAAP purposes shall be excluded; (viii) the amount of accruals for Taxes for the portion of any Straddle Period that
is a Pre-Closing Tax Period shall be consistent with Section 9.07; and (ix) any Taxes arising from or attributable
to any election made by Buyer or any of its Affiliates under Section 338(g) of the Code shall be excluded.

 

“Tax Return”
means any return, claim for refund, election, report, statement or information return relating to Taxes, including any schedule
or attachment thereto, and including any amendments thereof.

 

    66

     

    

 

Certain information
in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if
publicly disclosed.

 

“Taxes”
means all federal, provincial, territorial, state, municipal, local, U.S., non-U.S. or other taxes, imposts, and assessments including
ad valorem, capital, capital stock, customs and import duties, disability, documentary stamp, employment, excise, franchise, gains,
goods and services, gross income, gross receipts, income, intangible, inventory, license, mortgage recording, net income, occupation,
payroll, personal property, production, profits, property, real property, recording, rent, sales, social security, stamp, transfer,
transfer gains, unemployment, use, value added, windfall profits, and withholding, together with any interest, additions, fines
or penalties with respect thereto and any interest in respect of such additions, fines or penalties.

 

“Taxing Authority”
means the Internal Revenue Service and any other Governmental Authority that has the right to impose Taxes on the Company or any
of its Subsidiaries.

 

“Termination
Fee” has the meaning set forth in Section 13.02(a).

 

“Transaction
Consideration” means the sum of the Estimated Closing Cash Payment, plus the Share Consideration, plus the aggregate
of all Future Distribution Amounts.

 

“Third Party
Payor” means a private reimbursement program including any private commercial insurance carrier, plan or similar company
or organization that provides health insurance coverage, managed care or preferred provider organization or network, self-funded
health insurance plan as established under ERISA, or private or workers’ compensation insurance program under which the
Company has received payment other than the Plans.

 

“Transaction
Documents” has the meaning set forth in Section 15.02.

 

“Transaction
Expenses” means, to the extent not paid by the Company or its Subsidiaries as of the Adjustment Time, the amount of
(i) all fees, costs and expenses (including legal, accounting, investment banking, broker’s, finder’s and other
professional or advisory fees and expenses) of the Company and its Subsidiaries incurred by or on behalf of, or to be paid
by, the Company or any Subsidiary in connection with the negotiation and execution of this Agreement and the other Transaction
Documents and the consummation of the Transactions (but excluding any such fees costs and expenses incurred by the Company or
its Subsidiaries at the direction or request of Buyer or any of its Affiliates), (ii) 100% of all costs and expenses of the
Tail Policy, (iii) all bonus, incentive and similar change in control or retention payments payable to employees, officers
or directors of the Company and its Subsidiaries that, in each case, become payable solely as a result of the consummation of
the Transactions, together with the employer’s share of any payroll Taxes thereof and (iv) 50% of all costs and expenses
of the Paying Agent and the Escrow Agent.

 

“Transaction
Expenses Amount” means the aggregate amount of all Transaction Expenses that have not been paid prior to the Closing
Date.

 

[***]

 

“Transaction
Tax Deductions” means any deductions that would result from or be attributable to the Transactions (including the write-off
of deferred financing fees, costs and expenses, the payment of any transaction-related fees, costs or expenses and/or bonuses
(or similar amounts), and the payment of Funded Debt that is outstanding as of immediately prior to the Closing or the Transaction
Expenses) and, for such purpose, the Parties agree to apply the seventy percent safe-harbor election set forth in Internal
Revenue Service Revenue Procedure 2011-29 to determine the amount of deductions attributable to the payment of any success based
fees within the scope of such Revenue Procedure.

 

“Transactions”
means the transactions contemplated by this Agreement and the other Transaction Documents, including the Blocker Purchase and
the Merger.

 

    67

     

    

 

“Transfer
Taxes” has the meaning set forth in Section 8.05.

 

“Union”
has the meaning set forth in Section 6.13(e).

 

“Unitholder”
means each holder of record of Class A Preferred Units, Class B Preferred Units, Class A Common Units, Class B
Common Units or Class Z Common Units.

 

“Unitholder
Consent” has the meaning set forth in the Recitals.

 

“Unitholder
Percentage” means, with respect to each Unitholder or Blocker Seller, a percentage equal to the aggregate dollar amount
of Transaction Consideration actually received by such Unitholder or Blocker Seller, divided by the aggregate amount of Transaction
Consideration.

 

“Unvested
Common Unit” means a Common Unit that is not a Vested Common Units.

 

“Vested Common
Unit” means a Common Unit that, as of the Effective Time, is not subject to vesting or has vested in accordance with
the terms of the agreement pursuant to which such Common Unit was granted to the holder thereof.

 

“Working
Capital” means, as of the Adjustment Time, (a) the current assets of the Company and its Subsidiaries set forth
on Exhibit G attached hereto, minus (b) the current liabilities of the Company and its Subsidiaries set forth
on Exhibit G attached hereto, in each case, calculated on a consolidated basis, after eliminating any intercompany
amounts; provided that (i) Working Capital shall exclude the Cash Amount, any Funded Debt, any Transaction Expenses,
any current or deferred Tax assets or current or deferred Tax liabilities and shall include the adjustments under the heading
 “Net Working Capital Adjustments” on Exhibit G, (ii) Working Capital shall be calculated in accordance
with the Accounting Principles, and (iii) Working Capital shall (x) not include any purchase accounting or other adjustment
arising out of the consummation of the Transactions; and (y) be based on facts and circumstances as they exist prior to the
Closing and shall exclude the effect of any act, decision or event occurring on or after the Closing.

 

“Working
Capital Deficit” means the amount (if any) by which Working Capital is less than Target Working Capital.

 

“Working
Capital Surplus” means the amount (if any) by which Working Capital is greater than Target Working Capital.

 

“Year-End
Financial Statements” has the meaning set forth in Section 6.07(a).

 

12.02       Other
Definitional Provisions.

 

(a)           All
terms defined in this Agreement shall have such defined meanings when used in any certificates, reports or other documents made
or delivered pursuant hereto or thereto, unless the context otherwise requires or as otherwise indicated therein.

 

(b)           Terms
defined in the singular shall have a comparable meaning when used in the plural, and vice versa.

 

(c)           All
references to “$” in this Agreement shall be deemed references to United States dollars.

 

    68

     

    

 

(d)           Accounting
terms which are not otherwise defined in this Agreement have the meanings given to them under GAAP. To the extent that the definition
of an accounting term defined in this Agreement is inconsistent with the meaning of such term under GAAP, the definition set forth
in this Agreement will control.

 

Article XIII

TERMINATION

 

13.01       Termination

 

. This Agreement may
be terminated at any time prior to the Closing:

 

(a)           by
mutual written consent of Buyer, Parent and the Company;

 

(b)           by
Buyer or Parent, if:

 

(i)            there
has been a material breach by the Company or Blocker Seller of any covenant, representation or warranty contained in this Agreement
that has prevented or would prevent the satisfaction of any condition set forth in Article X and (A) Buyer has
provided written notice to the Company and the Representative of such material breach and its intent to terminate this Agreement
pursuant to this Section 13.01(b)(i); and (B) the Company or Blocker Seller, as applicable, has not cured such
material breach within twenty Business Days (or by the End Date, if sooner) after receiving written notice thereof from Buyer;
provided, however, that Buyer and Parent shall not be entitled to terminate this Agreement pursuant to this Section 13.01(b)(i) if
there has been a material breach by Buyer, Parent or Merger Sub of any covenant, representation or warranty contained in this
Agreement that has prevented or would prevent satisfaction of any condition set forth in Article XI; or

 

(ii)            the
Transactions have not been consummated by the End Date; provided, however, that Buyer and Parent shall not be entitled
to terminate this Agreement pursuant to this Section 13.01(b)(ii) if Buyer’s, Parent’s or Merger
Sub’s breach of this Agreement has substantially contributed to the failure of the Transactions to occur by the End Date,
or has prevented the consummation of Transactions; provided, further, that the Company may extend the End Date up
to an additional 30 days to the extent necessary to satisfy the condition set forth in Section 10.05 so long as the
other conditions in Article X have been satisfied (other than those conditions that are to be satisfied by actions
taken at the Closing, so long as such conditions are capable of being satisfied at the Closing);

 

(c)            by
the Company, if:

 

(i)            there
has been a material breach by Buyer, Parent or Merger Sub of any covenant, representation or warranty contained in this Agreement
that has prevented or would prevent the satisfaction of any condition set forth in Article XI and (A) the Company
has provided written notice to Buyer of such material breach and its intent to terminate this Agreement pursuant to this Section 13.01(c)(i);
and (B) Buyer, Parent or Merger Sub, as applicable, has not cured such material breach within twenty Business Days (or by
the End Date, if sooner) after receiving written notice thereof from the Company; provided, however, that the
Company shall not be entitled to terminate this Agreement pursuant to this Section 13.01(c)(i) if there has been
a material breach by the Company or Blocker Seller that has prevented or would prevent satisfaction of any condition set forth
in Article X;

 

    69

     

    

 

(ii)            (A) all
the conditions set forth in Article X (other than those conditions (1) the failure of which to be satisfied is
caused by a breach by Buyer, Parent or Merger Sub of their respective obligations under this Agreement or (2) that are to
be satisfied by actions taken at the Closing, so long as such conditions are capable of being satisfied at the Closing) have been
satisfied or waived, (B) the Company has delivered a written notice (a “Closing Failure Notice”) to Buyer
confirming that (x) all the conditions set forth in Article XI (other than those conditions which by their nature
are to be satisfied at the Closing, but subject to the satisfaction or, if permissible, waiver of such conditions at the Closing)
have been satisfied or that the Company is willing to waive any such conditions that remain unsatisfied, and (y) the Company
and Blocker Seller are each ready, willing and able to perform their respective obligations to effect the Closing on such date
of notice if the Buyer Parties and Merger Sub perform their respective obligations hereunder to consummate the Closing, and (C) the
Buyer Parties and Merger Sub fail to consummate the Closing within three Business Days following the date of the delivery of the
Closing Failure Notice; or

 

(iii)          the
Transactions have not been consummated by the End Date; provided, however, the Company shall not be entitled to
terminate this Agreement pursuant to this Section 13.01(c)(iii) if the Company’s or Blocker Seller’s
breach of this Agreement has substantially contributed to the failure of the Transactions to occur by the End Date, or has prevented
the consummation of Transactions; or

 

(d)           by
either Buyer or the Company, if any Governmental Authority shall have enacted, promulgated, issued, entered or enforced any injunction,
judgment, order or ruling permanently enjoining, restraining or prohibiting the Transactions, which injunction, judgment, order
or ruling shall have become final and non-appealable; provided, however, that the right to terminate this Agreement
under this Section 13.01(d) shall not be available to any Party whose failure to fulfill any obligation or condition
under this Agreement has been the cause of, or resulted in, such injunction, judgment, order or ruling.

 

13.02       Termination
Fee.

 

(a)           If
(i) the Company terminates this Agreement pursuant to Section 13.01(c)(i) or Section 13.01(c)(ii) or
(ii) Buyer or Parent terminates this Agreement at a time when the Company could have terminated this Agreement pursuant to
Section 13.01(c)(i) or Section 13.01(c)(ii), then the Buyer Parties shall pay to the Representative
(for further distribution to Blocker Seller and/or the Unitholders) a cash payment of $30,000,000.00 (the “Termination
Fee”), it being understood that in no event shall the Buyer Parties be required to pay the Termination Fee on more than
one occasion. Each of the Parties agree that (x) the Termination Fee constitutes liquidated damages and is not a penalty,
(y) the liabilities and damages that may be incurred or suffered by the Company, Blocker Seller or Unitholders in circumstances
where the Termination Fee is payable are impossible or very difficult to accurately estimate, and (z) the Termination Fee
is a reasonable estimate of the anticipated or actual harm that might be suffered by the Company, Blocker Seller or Unitholders
in these circumstances. The Termination Fee shall be payable in immediately available funds by wire transfer no later than two
Business Days after such termination.

 

(b)           Notwithstanding
anything to the contrary in this Agreement, (i) the Representative’s right to receive payment of the Termination Fee
pursuant to this Section 13.02 and any expenses that may become payable under Section 15.20 shall be the
sole and exclusive remedy of the Company, Blocker Seller or Unitholders or any of their respective Affiliates against the Buyer
Parties, Merger Sub or any of their Affiliates or any of their respective stockholders, partners, or members or any Debt Financing
Source for any and all losses that may be suffered based upon, resulting from or arising out of the termination of this Agreement
in accordance with the first sentence of Section 13.02(a), and (ii) upon payment in full of the Termination Fee
and any expenses that may become payable under Section 15.20 to the Representative, none of the Buyer Parties, Merger
Sub or any of their Affiliates or any of their respective stockholders, partners, or members or any Debt Financing Source shall
have any further liability or obligation relating to or arising out of Buyer’s, Parent’s or Merger Sub’s failure
to consummate the Transactions; provided that nothing in this Section 13.02(b) shall limit the right of
the Company, its Subsidiaries and their respective Affiliates (x) to bring or maintain any Action for injunction, specific
performance or other equitable relief as provided in Section 15.10 prior to the termination of this Agreement or (y) to
bring or maintain any Action proceeding against the Buyer Parties arising out of or in connection with any breach of the Confidentiality
Agreement. In no event shall this Section 13.02 be construed to mean that receipt of the Financing is a condition
to the Buyer Parties’ or Merger Sub’s obligations hereunder.

 

    70

     

    

 

(c)           Each
of the Parties acknowledges that the agreements contained in this Section 13.02 are an integral part of the transactions
contemplated by this Agreement, and that without these agreements, the other Parties would not enter into this Agreement.

 

13.03       Effect
of Termination. If any Party validly terminates this Agreement pursuant to Section 13.01, all rights and obligations
of the Parties hereunder shall terminate without any liability of any Party to any other Party, except that the provisions of
this Article XIII and Article XV (other than Section 15.10) and the Confidentiality Agreement
shall survive the termination of this Agreement; provided that, except as set forth in Section 13.02(b), no
termination of this Agreement shall in any way limit any claim by a Party that another Party willfully and intentionally breached
the terms of this Agreement prior to or in connection with such termination, nor shall such termination limit the right of such
non-breaching Party to seek all other remedies available to it at law or equity; provided, further, that a failure
of Parent, Buyer or Merger Sub to consummate the Transactions at a time when all of the conditions to closing set forth in Article X
have been satisfied or waived shall be deemed to be an willful and intentional breach of this Agreement.

 

Article XIV

SURVIVAL OF REPRESENTATIONS AND WARRANTIES; INDEMNITY

 

14.01       Survival.
Each of the representations and warranties (other than the representations and warranties set forth in Sections 4.12, 5.11
and 6.27, which shall survive the Closing indefinitely), and each of the covenants and agreements that contemplate
or require performance prior to the Closing, in each case, set forth in this Agreement or any other Transaction Document, or in
any certificate delivered hereunder or thereunder, shall terminate at and as of the Closing. Without limiting the foregoing, except
as set forth in Section 14.02, the sole and exclusive recourse of Parent, Buyer, Merger Sub and their Affiliates for
any breach of any such representations and warranties shall be against the R&W Policy. Each covenant and agreement set forth
in this Agreement or any other Transaction Document, or in any certificate delivered hereunder or thereunder that contemplates
or requires performance at or after the Closing shall expressly survive the Closing in accordance with its terms until fully performed
or satisfied or, if no performance is specified, indefinitely (with the parties hereto agreeing to contractually lengthen any
applicable statutes of limitation).

 

14.02       Indemnification.

 

(a)           Survival.
Notwithstanding anything in this Agreement to the contrary, the Indemnity Matters shall survive the Closing and shall remain in
full force and effect until the date that is the eighteen month anniversary of the Closing Date and the Specific Matters shall
survive the Closing and shall remain in full force and effect until the date that is the twelve month anniversary of the Closing
Date (as applicable, the “Expiration Date”), at which time the Indemnity Matters and the Specific Matters,
as applicable, shall expire. Notwithstanding the foregoing, any claims asserted in good faith with reasonable specificity (to
the extent known at such time) and in writing by notice from Buyer or Parent to the Representative prior to the applicable Expiration
Date shall not thereafter be barred by the expiration of the Surviving Matter and such claims shall survive until finally resolved.

 

    71

     

    

 

(b)           Indemnification.
Subject to the other terms and conditions of this Article XIV, and solely from amounts in the Indemnity Escrow Account
or the Specific Escrow Account, the Buyer Parties and Surviving Company shall be indemnified against, and shall be held harmless
from and against, any and all losses, damages, liabilities, deficiencies, actions, judgments, interest, awards, penalties, fines,
costs or expenses of whatever kind, including reasonable attorneys’ fees, the cost of enforcing any right to indemnification
hereunder, and the cost of pursuing any insurance providers (but excluding consequential, exemplary and punitive damages) (collectively,
 “Losses”) incurred or sustained by, or imposed upon, Buyer, Parent or the Surviving Company based upon, arising
out of, with respect to or by reason of (i) any of the matters identified on Exhibit L (collectively, the “Indemnity
Matters”); and (ii) any of the matters identified on Exhibit M (collectively, the “Specific
Matters” and, together with the Indemnity Matters, collectively, the “Surviving Matters”).

 

(c)           Certain
Limitations. The indemnification provided for in Section 14.02(b) shall be subject to the following limitations
and any limitations set forth on Exhibit M:

 

(i)            Buyer,
Parent and Surviving Company acknowledge and agree that Buyer, Parent and Surviving Company shall first recover any Losses with
respect to the Surviving Matters from the R&W Policy and the Alternative Arrangements (if the policy provides coverage for
such a claim) then, only to the extent that the amount of such Losses has not been satisfied by recovery under the R&W Policy
and the Alternative Arrangements, directly from amounts in the Indemnity Escrow Account (in the case of the Indemnity Matters)
or the Specific Escrow Account (in the case of the Specific Matters). In no event may Buyer, Parent or Surviving Company actually
recover amounts from the Indemnity Escrow Account or the Specific Escrow Account, as applicable, the R&W Policy and any other
third party in an aggregate amount in excess of its Losses with respect to such claim, and in the event that Buyer, Parent or
Surviving Company has actually recovered amounts in excess of its Losses for a claim, any such excess recovery shall be promptly,
and in any event within 30 days after such payment is received, paid over to the Representative (to the extent such amount has
been paid out of the Indemnity Escrow Account or the Specific Escrow Account). The Buyer Parties and Surviving Company further
acknowledge and agree that the provisions of this Section 14.02(c) shall apply regardless of whether (a) Buyer,
Parent or Surviving Company obtains at or following the Closing or maintains following the Closing the R&W Policy or (b) the
R&W Policy is revoked, cancelled or modified in any manner after issuance through no fault of, or contribution by the Representative.
With respect to any Losses for which the Buyer Parties or Surviving Company is entitled to indemnification under Section 14.02(b),
the Buyer Parties and Surviving Company shall (and, if applicable, shall cause its Affiliates to) use reasonable best efforts
to seek recovery for Losses under the R&W Policy and any other insurance policy for any Losses covered by such policy (“Alternative
Arrangements”) with respect to such Loss; provided, however, that Buyer, Parent and their Affiliates shall
have no obligation to initiate any litigation or arbitration in connection with seeking such recovery. The amount of any Losses
for which the Buyer Parties or Surviving Company is entitled to indemnification under Section 14.02(b) shall
be net of any amounts actually received under the Alternative Arrangements. Buyer, Parent and Surviving Company acknowledge and
agree that in the event a claim under the R&W Policy with respect to the Surviving Matters is denied and Buyer’s, Parent’s
or Surviving Company’s grossly negligent actions (or inaction) is the primary cause of such denial, Buyer, Parent and Surviving
Company shall not be entitled to indemnity pursuant to this Agreement to the extent Blocker Seller and the Designated Unitholders
are prejudiced thereby.

 

(ii)           The
aggregate amount of Losses that the Buyer Parties and the Surviving Company shall be entitled to be indemnified with respect to
under Section 14.02(b)(i) shall not exceed the amount in the Indemnity Escrow Account. The aggregate amount of
Losses that the Buyer Parties and the Surviving Company shall be entitled to be indemnified with respect to under Section 14.02(b)(ii) shall
not exceed the amount in the Specific Escrow Account. Notwithstanding anything in this Agreement to the contrary, (x) the
sole and exclusive source of recovery for any claim for indemnification pursuant to Section 14.02(b)(i) shall
be the amounts remaining in then Indemnity Escrow Account from time to time, (y) the sole and exclusive source of recovery
for any claim for indemnification pursuant to Section 14.02(b)(ii) shall be the amounts remaining in the Specific
Escrow Account from time to time and (z) with respect any claim for indemnification pursuant to Section 14.02(b),
there shall be no recovery against or from any of the Designated Unitholders, Blocker Seller or any other Person directly.

 

    72

     

    

 

(iii)          Blocker
Seller and Unitholders acknowledge and agree that the denial of any claim by the Buyer Parties under the R&W Policy shall
not be construed as, or used as evidence that, the Buyer Parties or Surviving Company is not entitled to indemnification under
this Article XIV.

 

(iv)          The
amount of any Losses subject to indemnification under this Article XIV shall be calculated net of any Tax Benefit
inuring to the Buyer Parties, the Surviving Company or any of their Affiliates on account of such Losses. If a Tax Benefit is
realized by the Buyer Parties, the Surviving Company or any of their Affiliates after an indemnification payment is made to it,
then the Buyer Parties shall promptly pay to the Representative (on behalf of Blocker Seller and the Designated Unitholders) the
amount of such Tax Benefit at such time or times as and to the extent that such Tax Benefit is actually realized. For purposes
hereof, “Tax Benefit” shall mean any cash refund of Taxes paid or reduction in the amount of Taxes which otherwise
would have been paid in cash.

 

(d)           Indemnification
Procedures.

 

(i)            Control
of Surviving Matters. The Representative shall have the right to participate in, and by giving written notice to Buyer (1) within
90 days of the Closing Date or (2) at any time that the Representative determines in good faith that the Buyer has failed
or is failing to defend any Surviving Matter, to assume control of the defense of any Surviving Matter at the Representative’s
expense and by the Representative’s own counsel, and the Buyer Parties and the Surviving Company shall cooperate in good
faith in such defense; provided, that the Representative shall not have the right to assume control of the defense of any
such Surviving Matter that seeks an injunction or other equitable relief against the Representative. In the event that the Representative
assumes the defense of any Surviving Matter, subject to Section 14.02(d)(ii), it shall have the right to take such
action as it deems necessary to avoid, dispute, defend, appeal or make counterclaims pertaining to any such Surviving Matter in
the name and on behalf of the Buyer Parties and the Surviving Company. In the event that the Representative assumes the defense
of any Surviving Matter, the Buyer Parties shall have the right to participate in the defense of such Surviving Matter with counsel
selected by it that is reasonably acceptable to the Representative, subject to the Representative’s right to control the
defense thereof. The fees and disbursements of such counsel shall be borne by the Buyer Parties or Surviving Company, provided,
that if in the reasonable opinion of counsel to the Buyer Parties or Surviving Company, (A) there are legal defenses available
to the Buyer Parties or Surviving Company that are materially different from or additional to those available to the Representative;
or (B) there exists a material conflict of interest between the Representative and the Buyer Parties or Surviving Company
that cannot be waived, the Representative shall be liable for the reasonable fees and expenses of one counsel to the Buyer Parties
or Surviving Company in each jurisdiction for which the Buyer Parties or Surviving Company reasonably determines counsel is required.
The party controlling such defense of any Surviving Matter shall keep the other party reasonably apprised of the status of, and
any material developments with respect to, such Surviving Matter. If the Representative elects not to assume control of the defense
of any Surviving Matter, fails to notify Buyer, Parent or Surviving Company in writing of its election to defend as provided in
this Agreement within 90 days of the Closing Date, or fails to diligently prosecute the defense of any Surviving Matter, Buyer,
Parent or Surviving Company may, subject to Section 14.02(d)(ii), assume control of the defense of such Surviving
Matter and, subject to the other limitations in this Agreement, seek indemnification for any and all Losses based upon, arising
from or relating to such Surviving Matter. If the Representative does not assume the defense of any Surviving Matter, then the
Buyer Parties and the Surviving Company shall engage (i) the legal counsel that was engaged by the Company prior to the Closing
with respect to such Surviving Matter or (ii) any other counsel that is reasonably acceptable to the Representative. The
rights under this Section 14.02(d)(i) to participate in and/or control the defense or settlement of any Surviving
Matter shall be exercised on behalf of Blocker Seller and the Unitholders only by the Representative.

 

    73

     

    

 

(ii)           Cooperation.
The Representative, on the one hand, and the Buyer Parties and Surviving Company, on the other hand, shall cooperate with each
other in all reasonable respects in connection with the defense of any Surviving Matter, including making available records relating
to such Surviving Matter and furnishing, without expense (other than reimbursement of actual out-of-pocket expenses) to the defending
party, management employees of the non-defending party as may be reasonably necessary for the preparation of the defense of such
Surviving Matter. The Parties will use their reasonable best efforts to resolve the Surviving Matters as promptly as practicable.

 

(iii)          Settlement
of Surviving Matters. Notwithstanding any other provision of this Agreement, the Representative shall not enter into settlement
of any Surviving Matter without the prior written consent of Buyer, Parent or Surviving Company, as applicable, except as provided
in this Section 14.02(d)(iii). If a firm offer is made to settle a Surviving Matter without leading to liability or
the creation of a financial or other obligation on the part of the Buyer Parties or Surviving Company and provides for the unconditional
release of each of the Buyer Parties from all liabilities and obligations in connection with such Surviving Matter and the Representative
desires to accept and agree to such offer, the Representative shall give written notice to that effect to the Buyer. If the Buyer
fails to consent to such firm offer within ten days after its receipt of such notice, the Buyer Parties or Surviving Company may
continue to contest or defend such Surviving Matter and in such event, the maximum liability of the Representative as to such
Surviving Matter shall not exceed the amount of such settlement offer. If the Buyer Parties or Surviving Company, as applicable,
fails to consent to such firm offer and also fails to assume defense of such Surviving Matter, the Representative may settle the
Surviving Matter upon the terms set forth in such firm offer to settle such Surviving Matter. If Buyer, Parent or Surviving Company,
as applicable, has assumed or otherwise controls the defense of such Surviving Matter, it shall not agree to any settlement without
the prior written consent of the Representative (which consent shall not be unreasonably withheld or delayed).

 

14.03       Release
of Indemnity Escrow Account

 

. On the date that
is the eighteen month anniversary of the Closing Date, Buyer and the Representative shall cause the Escrow Agent to release to
the Representative (or, at the direction of the Representative, to the Paying Agent) (for the benefit of Blocker Seller and the
Designated Unitholders) the then-remaining amounts held by the Escrow Agent in the Indemnity Escrow Account in excess of
the aggregate amount of all Losses specified in any then-unresolved claims for indemnification made pursuant to the terms of this
Agreement and the Escrow Agreement; provided, that following the resolution of any such claim for indemnification, Buyer
and the Representative shall promptly and jointly instruct the Escrow Agent to release to the Representative (or, at the direction
of the Representative, to the Paying Agent) (for the benefit of Blocker Seller and the Designated Unitholders) any amounts that
would otherwise have been released by the Escrow Agent to the Representative pursuant to this Section 14.03 and which
were retained in the Indemnity Escrow Account pending resolution of such claim (other than amounts to be paid to the in satisfaction
of the now resolved claim for indemnification).

 

    74

     

    

 

14.04       Release
of Specific Escrow Account. On the date that is the twelve month anniversary of the Closing Date, Buyer and the Representative
shall cause the Escrow Agent to release to the Representative (or, at the direction of the Representative, to the Paying Agent)
(for the benefit of Blocker Seller and the Designated Unitholders) the then-remaining amounts held by the Escrow Agent in
the Specific Escrow Account in excess of the aggregate amount of all Losses specified in any then-unresolved claims for indemnification
made pursuant to the terms of this Agreement and the Escrow Agreement; provided, that following the resolution of any such
claim for indemnification, Buyer and the Representative shall promptly and jointly instruct the Escrow Agent to release to the
Representative (or, at the direction of the Representative, to the Paying Agent) (for the benefit of Blocker Seller and the Designated
Unitholders) any amounts that would otherwise have been released by the Escrow Agent to the Representative pursuant to this Section 14.04
and which were retained in the Specific Escrow Account pending resolution of such claim (other than amounts to be paid to
the in satisfaction of the now resolved claim for indemnification).

 

14.05       Exclusive
Remedy. Each of the Parties acknowledges and agrees that from and after the Closing, the indemnification provisions
in this Article XIV shall be the sole and exclusive remedy of the Buyer Parties, Merger Sub, the Surviving Company
and their respective Affiliates with respect to the transactions contemplated by this Agreement and all other documents or agreements
contemplated hereby (except for (i) disputes under Section 3.03, which disputes will be resolved in accordance
with the dispute resolution mechanism set forth in Section 3.03, (ii) the Letters of Transmittal and (iii) claims
against any Party for Fraud committed by such Party), provided that nothing herein shall prevent a party from seeking or obtaining
an injunction or other equitable remedy in accordance with Section 15.10. The Parties agree that the limits imposed
on each Party’s remedies with respect to this Agreement, the other agreements contemplated hereby and the transactions contemplated
hereby and thereby were specifically bargained for between sophisticated parties and were specifically taken into account in the
determination of the amounts to be paid to Blocker Seller and the Unitholders hereunder.

 

Article XV

GENERAL PROVISIONS

 

15.01       Notices.
All notices, demands and other communications to be given or delivered under or by reason of the provisions of this Agreement
shall be in writing and shall be deemed to have been given when personally delivered, one day after deposit with Federal Express
or similar overnight courier service, upon transmission by electronic mail if successfully transmitted during normal business
hours and, if not, the next Business Day after successful transmission or three days after being mailed by first class mail, return
receipt requested. Notices, demands and communications to Parent, Buyer, the Representative, Blocker Seller and the Company shall,
unless another address is specified in writing, be sent to the addresses indicated below:

 

(a)           if
to Buyer, Parent, Merger Sub and/or the Surviving Company (after the Effective Time) to:

 

AdaptHealth LLC

220 West Germantown Pike, Suite 250

Plymouth Meeting, PA 19462

Attention: Luke McGee and Chris Joyce

Email: lmcgree@adapthealth.com and cjoyce@adapthealth.com

 

with a copy (which notice shall not constitute notice) to:

 

    75

     

    

 

Polsinelli PC

555 Fayetteville Street, Suite 720

Raleigh, NC 27601

Attention: Barry Alexander

Email: barry.alexander@polsinelli.com

 

(b)           if
to the Company (prior to the Effective Time) to:

 

Solara Holdings, LLC

c/o Linden Capital Partners

150 North Riverside Plaza, Suite 5100

Chicago, IL 60606

Attention: Brian Miller and Michael Bernard

Email: bmiller@lindenllc.com and mbernard@lindenllc.com

 

with a copy (which notice shall not constitute notice) to:

 

Kirkland & Ellis LLP

300 North LaSalle Street

Chicago, IL 60654

Attention: Robert A. Wilson, P.C. and Daniel A. Guerin, P.C.

Email: robert.wilson@kirkland.com and daniel.guerin@kirkland.com

 

(c)           if
to Blocker Seller or Representative to:

 

LCP Solara Blocker Seller, LLC

c/o Linden Capital Partners

150 North Riverside Plaza, Suite 5100

Chicago, IL 60606

Attention: Brian Miller and Michael Bernard

Email: bmiller@lindenllc.com and mbernard@lindenllc.com

 

with a copy (which notice shall not constitute notice) to:

 

Kirkland & Ellis LLP

300 North LaSalle Street

Chicago, IL 60654

Attention: Robert A. Wilson, P.C. and Daniel A. Guerin, P.C.

Email: robert.wilson@kirkland.com and daniel.guerin@kirkland.com

 

15.02       Entire
Agreement. This Agreement (including the Exhibits and Schedules attached hereto), the Certificate of Merger, the Escrow Agreement,
the Paying Agent Agreement, the Letters of Transmittal, and the certificates of the Parties delivered pursuant to Section 3.02
(collectively, the “Transaction Documents”) contain the entire understanding of the Parties in respect
of their subject matter and supersede all prior agreements and understandings (oral or written) between the Parties with
respect to such subject matter, other than the Confidentiality Agreement. The Exhibits and Schedules constitute a part hereof
as though set forth in full above.

 

15.03       Expenses.
Except as otherwise provided herein, each Party shall pay its own fees and expenses, including its own counsel fees, incurred
in connection with this Agreement, except that Buyer will pay all costs of obtaining the R&W Policy, including all premiums,
underwriting fees and related brokers fees.

 

    76

     

    

 

15.04            Amendment;
Waiver. Except as otherwise provided in Section 15.21, this Agreement may not be modified, amended, supplemented,
cancelled or discharged, except by written instrument executed by Buyer and the Representative. No failure to exercise, and no
delay in exercising, any right, power or privilege under this Agreement shall operate as a waiver, nor shall any single or partial
exercise of any right, power or privilege hereunder preclude the exercise of any other right, power or privilege. No waiver of
any breach of any provision shall be deemed to be a waiver of any preceding or succeeding breach of the same or any other provision,
nor shall any waiver be implied from any course of dealing between the Parties. No extension of time for performance of any obligations
or other acts hereunder or under any other Transaction Document shall be deemed to be an extension of the time for performance
of any other obligations or any other acts.

 

15.05            Binding
Effect; Assignment. The rights and obligations of this Agreement shall bind and inure to the benefit of the Parties and their
respective successors and assigns. Nothing expressed or implied herein shall be construed to give any other Person any legal or
equitable rights hereunder, except that (a) the former and current officers, directors, employees and agents of Blocker,
the Company and its Subsidiaries are express third party beneficiaries of Section 8.02, (b) Non-Party Affiliates
are expressly intended as third-party beneficiaries of Section 15.18 and (c) the Debt Financing Sources are expressly
intended as third-party beneficiaries of Sections 13.02(b), 15.04, 15.05, 15.08 and 15.21.
Except as expressly provided herein, the rights and obligations of this Agreement may not be assigned by any Party without the
prior written consent of the other Parties. Buyer and Merger Sub may, without the consent of any other Party, assign their rights
hereunder for collateral security purposes to any lender providing financing to Buyer.

 

15.06            Counterparts.
This Agreement may be executed in any number of counterparts, each of which shall be an original but all of which together shall
constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Agreement, including
by electronic mail transmission of a “.pdf” or any electronic signature complying with the U.S. federal ESIGN Act
of 2000 (e.g., www.docusign.com) or other similar data file shall be effective as delivery of a manually executed counterpart
to this Agreement.

 

15.07            Interpretation;
Schedules. When a reference is made in this Agreement to an article, section, paragraph, clause, schedule or exhibit, such
reference shall be deemed to be to an article, section, paragraph, clause, schedule or exhibit of this Agreement unless otherwise
indicated. Whenever the words “include,” “includes” or “including” are used in this Agreement,
they shall be deemed to be followed by the words “without limitation.” Words of one gender shall be held to include
the other gender. The word “or” shall not be exclusive. The words “herein,” “hereof,” “hereunder”
or “hereby” and similar terms are to be deemed to refer to this Agreement as a whole and not to any specific section.
The headings contained herein and on the Schedules are for reference purposes only and shall not affect in any way the meaning
or interpretation of this Agreement or the Schedules. Unless otherwise specified herein, references to any statute, listing rule,
rule, standard, regulation or other law include a reference to the corresponding rules and regulations and each of them as
amended, modified, supplemented, consolidated, replaced or rewritten from time to time. References to any section of any statute,
listing rule, rule, standard, regulation or other law include any successor to such section. References to any Contract (including
this Agreement) or organizational document are to the Contract or organizational document as amended, modified, supplemented
or replaced from time to time, unless otherwise stated, and any description of any Contract, plan, instrument, document or other
item set forth on a Schedule is a summary only and is qualified in its entirety by the terms of such Contract, plan, instrument,
document or other item. References to any Person include such Person’s predecessors or successors, whether by merger, consolidation,
amalgamation, reorganization or otherwise, and permitted assigns. Any information set forth in one section of the Schedules will
be deemed to apply to other sections of the Schedules to the extent its relevance to such other section is reasonably apparent
from the face of such disclosure (notwithstanding the omission of a reference or cross-reference thereto). The specification of
any dollar amount in the representations and warranties contained in this Agreement or the inclusion of any specific item in the
Schedules hereto is not intended to imply that such amounts, or higher or lower amounts, or the items so included, or other items
not included, are or are not required to be disclosed, and no Party shall use the fact of the setting of such amounts or the fact
of the inclusion of any such item in any dispute or controversy with any Party as to whether any obligation, item or matter not
described herein or included in a Schedule is or is not required to be disclosed (including whether such amounts or items
are required to be disclosed as material) or that the amounts, or higher or lower amounts, or the items so included, or other
items not included, are within or outside the ordinary course of business. No information set forth in the Schedules will be deemed
to broaden in any way the scope of the Parties’ representations and warranties. The information contained in the Schedules
hereto is disclosed solely for the purposes of this Agreement, and no information contained therein shall be deemed to be an admission
by any Party to any third party of any matter whatsoever, including of any violation of Law or breach of any agreement.

 

    77

     

    

 

15.08            Governing
Law; Interpretation. Except as otherwise provided in Section 15.21, this Agreement shall be interpreted and construed
in accordance with the internal laws of the State of Delaware. Any and all claims, controversies, causes of action and Proceedings
arising out of or relating to this Agreement, whether sounding in contract, tort, or statute, shall be governed by the internal
laws of the State of Delaware, without giving effect to any conflict-of-laws or other rule that would result in the application
of the laws of a different jurisdiction.

 

15.09            Forum
Selection; Consent to Jurisdiction; Waiver of Jury Trial.

 

(a)            Any
Proceeding against Parent, Buyer, Merger Sub, the Company, any of the Unitholders, Blocker Seller, the Surviving Company or the
Representative arising out of, relating to, or with respect to, this Agreement or the Transactions shall be brought exclusively
in the state or federal courts located in New Castle County in the State of Delaware (the “Designated Courts”),
and the Parties hereto accept the exclusive jurisdiction of the Designated Courts for the purpose of any such Proceeding. Each
Party hereby irrevocably waives, to the fullest extent permitted by Law, any objection which it may now or hereafter have to the
laying of venue of any such Proceeding in any Designated Court and hereby further irrevocably waives any claim that any such Proceeding
brought in the Designated Courts has been brought in an inconvenient forum. Each Party agrees that service of any process, summons,
notice or document sent in accordance with Section 15.01 shall be effective service of process in any such Proceeding.

 

(b)            EACH
PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY THAT MAY ARISE OUT OF, OR WITH RESPECT TO, THIS AGREEMENT OR THE TRANSACTIONS
IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES,
TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION, DIRECTLY
OR INDIRECTLY, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO
REPRESENTATIVE, AGENT OR ATTORNEY OR ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN
THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (II) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS
OF THIS WAIVER, (III) EACH PARTY MAKES THIS WAIVER VOLUNTARILY AND (IV) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS
AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS OF THIS SECTION 15.09(b). EITHER PARTY MAY FILE
AN ORIGINAL COUNTERPART OR A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES TO THE
WAIVER OF THEIR RIGHT TO TRIAL BY JURY.

 

    78

     

    

 

15.10            Specific
Performance.

 

(a)           Each
of the Parties agrees that irreparable harm would occur if any of the provisions of this Agreement are not performed in accordance
with their specific terms and that monetary damages would not provide adequate remedy in such event. Accordingly, in addition
to any other remedy to which a non-breaching Party may be entitled at Law, a non-breaching Party shall be entitled to injunctive
relief without the posting of any bond to prevent breaches of this Agreement and to specifically enforce the terms and provisions
hereof. Each Party further waives any defense that a remedy at Law would be adequate in any action or Proceeding for specific
performance or injunctive relief hereunder. In the event that any Party seeks an injunction or injunctions to prevent breaches
of this Agreement or to enforce specifically the terms and provisions of this Agreement, such Party shall not be required to provide
any bond or other security in connection with any such injunction or other judgment. Notwithstanding the foregoing to the contrary,
Buyer’s payment of the Termination Fee in accordance with the terms of Section 13.02 and reimbursement of expenses
in accordance with Section 15.20 is Buyer’s sole liability and the exclusive remedy for the Company, Blocker
Seller and the Unitholders for termination by the Company in accordance with the first sentence of Section 13.02(a).

 

(b)           Notwithstanding
anything in Section 15.10(a) to the contrary, in the event that (i) all of the conditions set forth in Article X
(other than those conditions that are to be satisfied by actions taken at the Closing, so long as such conditions are capable
of being satisfied at the Closing) have been satisfied or waived by Buyer, (ii) the Company has delivered to Parent or Buyer
a Closing Failure Notice, (iii) the Equity Financing has been funded or will be funded subject to the Closing, and (iv) the
Debt Financing has been funded or will be funded subject to the Closing, then the Company shall be entitled to specific performance
of Parent’s, Buyer’s and Merger Sub’s obligations to consummate the Closing. The Company and the Representative
may pursue both a grant of specific performance in accordance with (and subject to the limitations set forth in) this Section 15.10
and the payment of the Termination Fee pursuant to Section 13.02; provided that, under no circumstances
will the Company, the Representative or their respective Affiliates be entitled to receive both (x) a grant of specific performance
of Parent’s, Buyer’s and Merger Sub’s obligation to consummate the Closing and (y) payment of the Termination
Fee.

 

15.11      Arm’s
Length Negotiations; Drafting. Each Party expressly represents and warrants to the other Parties that before executing this
Agreement, such Party has fully informed itself of the terms, contents, conditions and effects of this Agreement, such Party has
relied solely and completely upon its own judgment in executing this Agreement and such Party has had the opportunity to seek
and has obtained the advice of counsel before executing this Agreement, which is the result of arm’s length negotiations
conducted by and among the Parties and their respective counsel. This Agreement shall be deemed drafted jointly by the Parties
and nothing shall be construed against one Party or another as the drafting Party.

 

15.12       Time.
With regard to all dates and time periods set forth or referred to in this Agreement, time is of the essence.

 

15.13       Made
Available. The phrase “made available to Buyer” or similar phrases as used in this Agreement shall mean that the
subject documents were either posted to the virtual data room maintained by the Company or its representatives or delivered to
Buyer or its accountants, attorneys or other agents.

 

    79

     

    

 

15.14       Confidentiality;
Publicity. No press release or public announcement related to this Agreement or the Transactions or, prior to the Closing,
any other announcement or communication (other than by the Company or its Subsidiaries or any of their respective officers, employees
and agents in the ordinary course of business) to the employees, customers, suppliers or other business relations of the
Company or its Subsidiaries shall be issued or made without the joint approval of Buyer and the Representative, unless required
by Law (in the reasonable opinion of counsel) in which case Buyer and the Representative shall have the right to review and
comment on such press release or announcement prior to publication; provided that Blocker Seller and its respective Affiliates
shall be entitled to communicate with their respective investors relating to this Agreement and the Transactions; provided
further no Party shall be required to mention or otherwise use the name of another Party or its Affiliates (other than the
Company or its Subsidiaries) in such press release or public announcement and such omission shall not be used as a basis
for withholding approval of such press release or public announcement.

 

15.15            Designation
of the Representative.

 

(a)           Designation.
Blocker Seller is hereby designated to serve as the representative of the Unitholders and Blocker Seller (in its capacity as such,
the “Representative”) with respect to the matters expressly set forth in this Agreement and the other
Transaction Documents to be performed by the Representative.

 

(b)           Authority.
By executing a Letter of Transmittal (or, in the case of Blocker Seller, this Agreement), each Unitholder and Blocker Seller hereby
irrevocably appoints the Representative as such Person’s agent, proxy and attorney-in-fact for all purposes of this Agreement,
the Escrow Agreement, the Paying Agent Agreement and any other agreement entered into in connection herewith (including the full
power and authority on such Person’s behalf) (i) to consummate the Transactions, (ii) to pay expenses incurred
by such Person or the Representative in connection with the Transactions, including the negotiation and performance of the Transaction
Documents (whether incurred on or after the date hereof), (iii) to calculate any amounts payable to such Person pursuant
to any Transaction Document, (iv) to execute such further agreements or instruments of assignment as Buyer shall reasonably
request or which the Representative shall consider necessary or proper to effectuate the Transactions, all of which shall have
the effect of binding such Person as if such Person had personally executed such agreement or instrument, (v) to resolve
any adjustments or issues relating to any component of the Closing Cash Payment, (vi) to receive notices and other deliverables
hereunder on behalf of such Person, (vii) to execute and deliver on behalf of such Person any amendment or waiver to any
Transaction Document, (viii) to take all other actions to be taken by or on behalf of such Person in connection with the
Transactions, (ix) to dispute, compromise, settle and pay any claims made in connection with this Agreement or the Transactions
and (x) to do each and every act and exercise any and all rights which such Person is permitted or required to do or exercise
under the Transaction Documents. Such agency, proxy and attorney-in-fact and all authority granted hereunder are coupled with
an interest, are therefore irrevocable without the consent of the Representative and shall survive the death, incapacity, bankruptcy,
dissolution or liquidation of such Person. If, after the execution of this Agreement, any Unitholder or Blocker Seller dies, dissolves
or liquidates or becomes incapacitated or incompetent, then the Representative is nevertheless authorized, empowered and directed
to act in accordance with this Agreement as if that death, dissolution, liquidation, incapacity or incompetency had not occurred
and regardless of notice thereof. All decisions and actions by the Representative shall be binding upon all of the Unitholders
and Blocker Seller, and none of Blocker Seller or any Unitholder shall have the right to object, dissent, protest or otherwise
contest the same.

 

(c)           Representative
Holdback. The Representative Holdback shall be withheld and paid directly to an account maintained by the Representative as
a fund for the fees and expenses of the Representative incurred in its capacity as such, with any balance of the Representative
Holdback not utilized for such purposes to be returned to Blocker Seller and the Unitholders in accordance with their Unitholder
Percentages. In the event that the Representative Holdback is insufficient to satisfy the fees and expenses of the Representative
incurred in its capacity as such, the Representative shall be entitled to recover any such expenses from any portion of the Adjustment
Escrow Funds, the Indemnity Escrow Funds and the Specific Escrow Funds to be distributed to Blocker Seller and the Unitholders.
The Representative shall also be entitled to recover any remaining expenses directly from Blocker Seller and the Unitholders,
and the Representative shall not have any obligation to personally advance funds in connection with the performance of any duties
under this Agreement.

 

    80

     

    

 

(d)           Authority;
Indemnification. Parent and Buyer shall be entitled to rely on any action taken by the Representative, pursuant to Section 15.15(b) (each,
an “Authorized Action”), and each Authorized Action shall be binding on Blocker Seller and each Unitholder
as fully as if such Person had taken such Authorized Action. Parent and Buyer each agree that the Representative, as the Representative,
shall have no liability to Parent or Buyer for any Authorized Action, except to the extent that such Authorized Action is found
by a final order of a court of competent jurisdiction to have constituted actual fraud. Blocker Seller and each Unitholder severally
in accordance to its Unitholder Percentage, and not jointly or jointly and severally, will indemnify, reimburse and hold harmless
the Representative against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by the
Representative in connection with any Proceeding to which the Representative is made a party by reason of the fact that the Representative
is or was acting as the Representative pursuant to the terms of this Agreement.

 

(e)           Duties
of the Representative. The Representative shall have only the duties expressly stated in the Transaction Documents, and shall
have no other duty, express or implied. The Representative is not, by virtue of serving as Representative, a fiduciary of Blocker
Seller, any Unitholder or any other Person. The Representative, in its capacity as such, has no personal responsibility or liability
for any representation, warranty or covenant of the Company or any other Person. The Representative shall not be required to make
any inquiry concerning either the performance or observance of any of the terms, provisions or conditions of this Agreement.

 

(f)           Exculpation.
The Representative shall not be liable to Blocker Seller or any Unitholder for any action taken or omitted by it or any agent
employed by it under any Transaction Document, except to the extent that such action or omission is found by a final order of
a court of competent jurisdiction to have constituted actual fraud. The Representative shall not be liable to Blocker Seller or
any Unitholder for any apportionment or distribution of the Transaction Consideration except to the extent that such apportionment
or distribution is found by a final order of a court of competent jurisdiction to have constituted actual fraud. Neither the Representative
nor any agent employed by it shall incur any liability to Blocker Seller or any Unitholder relating to the performance of its
other duties hereunder, except to the extent that the Representative is found by a final order of a court of competent jurisdiction
to have committed actual fraud in connection therewith.

 

    81

     

    

 

15.16       Acknowledgements.
The Buyer Parties, on their own behalf and on behalf of their respective Affiliates, acknowledge and agree that: (a) the
representations and warranties of the Company expressly set forth in Article VI and the representations and warranties
of Blocker Seller expressly set forth in Article V constitute the sole and exclusive representations and warranties
made to the Buyer Parties and their respective Affiliates or any other Person with respect to the Company and its Subsidiaries,
the Unitholders, Blocker Seller, Blocker and their respective Affiliates in connection with the Transactions; (b) except
for the representations and warranties of the Company expressly set forth in Article VI and the representations and
warranties of Blocker Seller expressly set forth in Article V, none of the Company or its Subsidiaries, the Unitholders,
Blocker Seller, Blocker, any their respective Affiliates, nor any other Person makes, or has made, any other express or implied
representation or warranty with respect to the Company and its Subsidiaries, the Unitholders, Blocker Seller, Blocker and their
respective Affiliates in connection with the Transactions and that any other representations and warranties of any kind or nature,
express or implied, are specifically disclaimed by the Company and its Subsidiaries, the Unitholders, Blocker, Blocker Seller
and their respective Affiliates and shall not form the basis of any claim against Company and its Subsidiaries, the Unitholders,
Blocker, Blocker Seller, any of their respective Affiliates or any other Person; and (c) in connection with the Transactions,
the Buyer Parties and their respective Affiliates are relying solely upon the representations and warranties of the Company expressly
set forth in Article VI and the representations and warranties of Blocker Seller expressly set forth in Article V
and are not relying, and have not relied, upon any information (including the completeness or accuracy thereof) other than
the representations and warranties of the Company expressly set forth in Article VI and the representations and warranties
of Blocker Seller expressly set forth in Article V, including any information relating to the future or historical
business, condition (financial or otherwise), results of operations, prospects, assets or liabilities of the Company and its Subsidiaries,
including with respect to any projections, forecasts, estimates, plans or budgets of future revenues, expenses or expenditures,
or future results of operations, or any other information, document or material provided to or made available to Parent, Buyer,
their respective Affiliates or representatives or Parent’s or Buyer’s lenders or other financing sources or their
respective Affiliates or representatives, in each case, whether in certain “data rooms,” information memorandum, management
presentations or in any other form, including meetings, calls or correspondence with management of the Company and its Subsidiaries
or Blocker or their respective Affiliates or representatives and whether delivered to or made available prior to or after the
date hereof. In furtherance of the foregoing, the Buyer Parties, on their own behalf and on behalf of their respective Affiliates,
acknowledge that the Buyer Parties and their respective Affiliates have conducted, to their satisfaction, an independent investigation
of the financial condition and position, results of operations, assets, liabilities, properties and projected operations of Blocker
and the Company and its Subsidiaries prior to making their determination to proceed with the Transactions and have completed such
investigations of Blocker and the Company and its Subsidiaries as they deem necessary and appropriate, and have received all of
the information that they have requested from the Company and its Subsidiaries and Blocker in connection with the execution and
delivery of this Agreement and the other Transaction Documents and the consummation of the Transactions. In connection with Parent’s,
Buyer’s and their respective Affiliates’ investigation of Blocker and the Company and its Subsidiaries, the Buyer
Parties and their respective Affiliates have received certain projections, including projected statements of operating revenues
and income from operations of the Company and its Subsidiaries, and certain business plan information. The Buyer Parties, on their
own behalf and on behalf of their respective Affiliates, acknowledges that there are uncertainties inherent in attempting to make
such estimates, projections and other forecasts and plans, that the Buyer Parties and their respective Affiliates are familiar
with such uncertainties and that the Buyer Parties and their respective Affiliates are taking full responsibility for making their
own evaluation of the adequacy and accuracy of all estimates, projections and other forecasts and plans so furnished to it, including
the reasonableness of the assumptions underlying such estimates, projections and forecasts.

 

15.17            Company
Representation. Parent and Buyer, for themselves and on behalf of their respective Subsidiaries (including Merger Sub) and
their respective directors, equityholders, members, partners, officers, employees and Affiliates, hereby agree that, in the event
that a dispute arises after the Closing between Parent, Buyer, Blocker, the Surviving Company and/or its Subsidiaries, on the
one hand, and the Representative, Blocker Seller or any Unitholder, on the other hand, Kirkland & Ellis LLP may represent
the Representative, Blocker Seller or such Unitholder in such dispute, even though the interests of the Representative, Blocker
Seller or such Unitholder may be directly adverse to Parent, Buyer, Blocker, the Surviving Company and/or its Subsidiaries and
even though Kirkland & Ellis LLP may have represented Blocker, the Company and/or its Subsidiaries in a matter substantially
related to such dispute. Parent, Buyer and Merger Sub further agree that, as to all communications among Kirkland & Ellis
LLP, the Representative, the Company, and of its Subsidiaries and any of their respective Affiliates that relate in any way to
the Transactions, the attorney-client privilege and the expectation of client confidence belongs to the Representative and shall
not pass to or be claimed by Parent, Buyer, Blocker, the Surviving Company or any of their Subsidiaries. Notwithstanding the foregoing,
in the event that a dispute arises between Parent, Buyer, Blocker, the Surviving Company or any of their Subsidiaries and a third
party (other than a party to any Transaction Document or any Affiliate of any such party) after the Closing, Blocker, the Surviving
Company and its Subsidiaries may assert the attorney-client privilege to prevent disclosure of confidential communications by
Kirkland & Ellis LLP to such third party; provided, however, that neither Blocker nor the Surviving Company or its Subsidiaries
may waive such privilege without the prior written consent of the Representative. In addition, all of the client files and records
in the possession of Kirkland & Ellis LLP related to the Transactions will be property of (and be controlled by) the
Representative and neither Blocker nor the Surviving Company or any of its Subsidiaries shall be entitled to retain copies of,
or have access to, any such records.

 

    82

     

    

 

15.18       Non-Recourse
Parties. All claims or causes of action (whether in contract or in tort, in law or in equity) that may be based upon, arise
out of or relate to this Agreement or the other Transaction Documents, or the negotiation, execution or performance of this Agreement
or the other Transaction Documents (including any representation or warranty made in or in connection with this Agreement or the
other Transaction Documents or as an inducement to enter into this Agreement or the other Transaction Documents), may be made
only against the entities that are expressly identified as parties hereto and thereto, as applicable. No Person who is not a named
party to this Agreement or the other Transaction Documents, including any past, present or future director, officer, employee,
incorporator, member, partner, stockholder, Affiliate, agent, Debt Financing Source, attorney or representative of any named party
to this Agreement or the other Transaction Documents (“Non-Party Affiliates”), shall have any liability (whether
in contract or in tort, in law or in equity, or based upon any theory that seeks to impose liability of an entity party against
its owners or affiliates) for any obligations or liabilities arising under, in connection with or related to this Agreement or
such other Transaction Document (as the case may be) or for any claim based on, in respect of, or by reason of this Agreement
or such other Transaction Document (as the case may be) or the negotiation or execution hereof or thereof; and each party hereto
waives and releases all such liabilities, claims and obligations against any such Non-Party Affiliates. Non-Party Affiliates are
expressly intended as third party beneficiaries of this Section 15.18.

 

15.19       Guaranty
of Obligations of Buyer. Parent hereby irrevocably and unconditionally guarantees the full and complete performance of all
obligations (including all performance and payment obligations) of Buyer under this Agreement and the other Transaction Documents,
and acknowledges that a breach of this Agreement or any Transaction Document by Buyer shall be deemed to be a breach of this Agreement
or such Transaction Document by Parent. Parent agrees to (a) take all actions necessary to cause Buyer to perform all of
its obligations, covenants and agreements under this Agreement and the other Transaction Documents and (b) not circumvent
the provisions of this Agreement by disposing of, or otherwise transferring, all or any portion of its equity interests in Buyer.

 

15.20       Prevailing
Party. Other than with respect to disputes arising pursuant to Section 3.03, in any dispute arising out of or
related to this Agreement, any of the Exhibits or Schedules hereto, or any agreement, document, instrument or certificate contemplated
hereby, or any transactions contemplated hereby or thereby, the applicable adjudicating body shall award to the prevailing party,
if any, the costs and attorneys’ fees reasonably incurred by the prevailing party in connection with the dispute and the
enforcement of its rights under this Agreement, any of the Exhibits or Schedules hereto, any agreement, document, instrument or
certificate contemplated hereby or any transactions contemplated hereby or thereby, and, if the adjudicating body determines a
party to be the prevailing party under circumstances where the prevailing party won on some but not all of the claims and counterclaims,
the adjudicating body may award the prevailing party an appropriate percentage of the costs and attorneys’ fees reasonably
incurred by the prevailing party in connection with the adjudication and the enforcement of its rights under this Agreement, any
of the Exhibits or Schedules hereto, any agreement, document, instrument or certificate contemplated hereby or any transaction
contemplated hereby or thereby.

 

    83

     

    

 

15.21       Debt
Financing Arrangements. Notwithstanding anything to the contrary contained in this Agreement: (a) each of Blocker Seller,
Representative and the Company agrees that it will not bring or support any Person, or permit any of its Affiliates to bring or
support any Person, in any action, suit, proceeding, cause of action, claim, cross-claim or third-party claim of any kind or description,
whether in law or in equity, whether in contract or in tort or otherwise, against any Person that has committed or subsequently
commits to provide or otherwise enters into any agreements in connection with providing debt financing to the Buyer Parties, Merger
Sub or any of their respective Affiliates (the “Debt Financing Sources,” which defined term for the purposes
of this provision shall include their respective former, current and future Affiliates, equityholders, members, partners, controlling
persons, officers, directors, employees, agents, advisors and representatives involved in such debt financing) in any way relating
to this Agreement or any of the transactions contemplated by this Agreement, including, but not limited to, any dispute arising
out of or relating in any way to the Debt Commitment Letter, any related Fee Letter or the performance thereof or the financings
contemplated thereby, in any forum other than the federal and New York State courts located in the Borough of Manhattan within
the City of New York; (b) each of the Parties hereto agrees that, except as specifically set forth in the Debt Commitment
Letter, all claims or causes of action (whether at law, in equity, in contract, in tort or otherwise) against any of the Debt
Financing Sources in any way relating to the Debt Commitment Letter, any related Fee Letter or the performance thereof or the
financings contemplated thereby, shall be exclusively governed by, and construed in accordance with, the internal laws of the
State of New York, without giving effect to principles or rules of conflict of laws to the extent such principles or rules would
require or permit the application of law of another jurisdiction; and (c) EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND
UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION (WHETHER AT LAW OR IN
EQUITY, IN CONTRACT, IN TORT OR OTHERWISE) DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING IN ANY WAY TO THE DEBT
COMMITMENT LETTER, ANY RELATED FEE LETTER OR THE PERFORMANCE THEREOF OR THE DEBT FINANCING CONTEMPLATED THEREBY. Notwithstanding
anything to the contrary contained in this Agreement, (i) Blocker Seller, Representative and the Company and their respective
subsidiaries, Affiliates, directors, officers, employees, agents, partners, managers, members or stockholders shall not have any
rights or claims against any Debt Financing Source in any way relating to this Agreement or any of the transactions contemplated
by this Agreement, or in respect of any oral representations made or alleged to have been made in connection herewith or therewith,
including any dispute arising out of or relating in any way to the Debt Commitment Letter, any related Fee Letter or the performance
thereof or the financings contemplated thereby, whether at law or in equity, in contract, in tort or otherwise and (ii) no
Debt Financing Source shall have any liability (whether in contract, in tort or otherwise) to Blocker Seller, Representative,
the Company or any of their respective subsidiaries, Affiliates, directors, officers, employees, agents, partners, managers, members
or stockholders for any obligations or liabilities of any party hereto under this Agreement or for any claim based on, in respect
of, or by reason of, the transactions contemplated hereby and thereby or in respect of any oral representations made or alleged
to have been made in connection herewith or therewith, including any dispute arising out of or relating in any way to the Debt
Commitment Letter, any related Fee Letter or the performance thereof or the financings contemplated thereby, whether at law or
in equity, in contract, in tort or otherwise. Notwithstanding anything to the contrary contained in this Agreement, the Debt Financing
Sources are intended third-party beneficiaries of, and shall be entitled to the protections of, this Section 15.21
and Sections 13.02(b), 15.04, 15.05, 15.08 and 15.18 to the same extent as if the Debt Financing
Sources were parties to this Agreement. This Section 15.21 and Sections 13.02(b), 15.04, 15.05,
15.08 and 15.18 (and any related definitions) may not be amended, modified or supplemented, or any of its provisions
waived, in each case, in a manner that is materially adverse to the Debt Financing Sources, without the written consent of the
Debt Financing Sources.

 

[SIGNATURES APPEAR ON THE FOLLOWING
PAGE]

 

    84

     

    

 

IN WITNESS WHEREOF,
the Parties hereto have caused this Agreement to be duly executed and delivered as of the day and year first above written.

 

	 	BUYER:
	 	 
	 	ADAPTHEALTH LLC
	 	 
	 	By: 	/s/ Luke McGee
	 	Name: Luke McGee
	 	Title: Chief Executive Officer
	 	 
	 	PARENT:
	 	 
	 	ADAPTHEALTH CORP.
	 	 
	 	By:	 /s/ Luke McGee
	 	Name: Luke McGee
	 	Title: Chief Executive Officer
	 	 
	 	MERGER SUB:
	 	 
	 	ELEANOR MERGER SUB, LLC
	 	 
	 	By: 	/s/ Luke McGee
	 	Name: Luke McGee
	 	Title: Chief Executive Officer

 

Signature Page to Stock Purchase
Agreement and Agreement and Plan of Merger

 

    

     

    

 

 

	 	COMPANY:
	 	 
	 	SOLARA HOLDINGS, LLC
	 	 
	 	By:	/s/ Stephen Foreman
	 	Name: Stephen Foreman
	 	Title: Chief Executive Officer

 

Signature Page to Stock Purchase
Agreement and Agreement and Plan of Merger

 

    

     

    

	 	 
	 	BLOCKER SELLER AND REPRESENTATIVE:
	 	 
	 	LCP SOLARA BLOCKER SELLER,
    LLC
	 	 
	 	By:	/s/ Michael Bernard
	 	Name: Michael Bernard
	 	Title: President, Secretary
    and Treasurer

 

Signature Page to Stock Purchase
Agreement and Agreement and Plan of Merger

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]